WO2011146121A1 - Novel dna-binding proteins and uses thereof - Google Patents
Novel dna-binding proteins and uses thereof Download PDFInfo
- Publication number
- WO2011146121A1 WO2011146121A1 PCT/US2011/000885 US2011000885W WO2011146121A1 WO 2011146121 A1 WO2011146121 A1 WO 2011146121A1 US 2011000885 W US2011000885 W US 2011000885W WO 2011146121 A1 WO2011146121 A1 WO 2011146121A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tale
- domain
- dna
- sequence
- cell
- Prior art date
Links
- 102000052510 DNA-Binding Proteins Human genes 0.000 title description 15
- 108700020911 DNA-Binding Proteins Proteins 0.000 title description 12
- 238000000034 method Methods 0.000 claims abstract description 156
- 230000004568 DNA-binding Effects 0.000 claims abstract description 126
- 230000014509 gene expression Effects 0.000 claims abstract description 99
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 82
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 69
- 229920001184 polypeptide Polymers 0.000 claims abstract description 66
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 51
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 51
- 239000002157 polynucleotide Substances 0.000 claims abstract description 51
- 108090000623 proteins and genes Proteins 0.000 claims description 455
- 210000004027 cell Anatomy 0.000 claims description 302
- 102000004169 proteins and genes Human genes 0.000 claims description 240
- 238000003776 cleavage reaction Methods 0.000 claims description 171
- 230000007017 scission Effects 0.000 claims description 170
- 102000037865 fusion proteins Human genes 0.000 claims description 130
- 108020001507 fusion proteins Proteins 0.000 claims description 130
- 101710163270 Nuclease Proteins 0.000 claims description 114
- 150000007523 nucleic acids Chemical class 0.000 claims description 106
- 102000039446 nucleic acids Human genes 0.000 claims description 101
- 108020004707 nucleic acids Proteins 0.000 claims description 101
- 150000001413 amino acids Chemical class 0.000 claims description 69
- 230000004913 activation Effects 0.000 claims description 53
- 230000006780 non-homologous end joining Effects 0.000 claims description 36
- 238000012217 deletion Methods 0.000 claims description 29
- 230000037430 deletion Effects 0.000 claims description 29
- 239000012634 fragment Substances 0.000 claims description 23
- 230000001404 mediated effect Effects 0.000 claims description 23
- 238000002744 homologous recombination Methods 0.000 claims description 15
- 230000006801 homologous recombination Effects 0.000 claims description 15
- 108010042407 Endonucleases Proteins 0.000 claims description 13
- 230000002779 inactivation Effects 0.000 claims description 10
- 102000004533 Endonucleases Human genes 0.000 claims description 6
- 210000004102 animal cell Anatomy 0.000 claims description 6
- 108091006106 transcriptional activators Proteins 0.000 claims description 6
- 241000251468 Actinopterygii Species 0.000 claims description 5
- 108091006107 transcriptional repressors Proteins 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 210000005253 yeast cell Anatomy 0.000 claims description 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 102100025169 Max-binding protein MNT Human genes 0.000 claims 1
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 abstract description 31
- 235000018102 proteins Nutrition 0.000 description 232
- 108020004414 DNA Proteins 0.000 description 155
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 136
- 230000004927 fusion Effects 0.000 description 119
- 238000010459 TALEN Methods 0.000 description 118
- 230000027455 binding Effects 0.000 description 93
- 230000000694 effects Effects 0.000 description 93
- 241000196324 Embryophyta Species 0.000 description 90
- 239000013598 vector Substances 0.000 description 82
- 210000004899 c-terminal region Anatomy 0.000 description 74
- 235000001014 amino acid Nutrition 0.000 description 71
- 230000032965 negative regulation of cell volume Effects 0.000 description 70
- 229940024606 amino acid Drugs 0.000 description 69
- 238000003556 assay Methods 0.000 description 69
- 239000002773 nucleotide Substances 0.000 description 67
- 125000003729 nucleotide group Chemical group 0.000 description 61
- 239000000203 mixture Substances 0.000 description 53
- 241001465754 Metazoa Species 0.000 description 50
- 102100029268 Neurotrophin-3 Human genes 0.000 description 50
- 101000634196 Homo sapiens Neurotrophin-3 Proteins 0.000 description 49
- 230000006870 function Effects 0.000 description 46
- 238000013456 study Methods 0.000 description 37
- 230000010354 integration Effects 0.000 description 34
- 241000700159 Rattus Species 0.000 description 33
- 239000013612 plasmid Substances 0.000 description 33
- 230000035772 mutation Effects 0.000 description 32
- 230000001105 regulatory effect Effects 0.000 description 32
- 108700008625 Reporter Genes Proteins 0.000 description 31
- 238000002474 experimental method Methods 0.000 description 31
- 210000004962 mammalian cell Anatomy 0.000 description 31
- 210000000130 stem cell Anatomy 0.000 description 31
- 108091034117 Oligonucleotide Proteins 0.000 description 30
- 108091028043 Nucleic acid sequence Proteins 0.000 description 27
- 108020004999 messenger RNA Proteins 0.000 description 27
- 239000000047 product Substances 0.000 description 26
- 102000040945 Transcription factor Human genes 0.000 description 23
- 108091023040 Transcription factor Proteins 0.000 description 23
- 230000009261 transgenic effect Effects 0.000 description 23
- 108010077544 Chromatin Proteins 0.000 description 22
- 125000003275 alpha amino acid group Chemical group 0.000 description 22
- 210000003483 chromatin Anatomy 0.000 description 22
- 210000002257 embryonic structure Anatomy 0.000 description 22
- 230000008685 targeting Effects 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 21
- 239000005090 green fluorescent protein Substances 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 21
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 20
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 20
- 238000012546 transfer Methods 0.000 description 20
- 230000003612 virological effect Effects 0.000 description 20
- 230000005782 double-strand break Effects 0.000 description 19
- 238000001415 gene therapy Methods 0.000 description 19
- 102000004190 Enzymes Human genes 0.000 description 18
- 108090000790 Enzymes Proteins 0.000 description 18
- 108700019146 Transgenes Proteins 0.000 description 18
- 238000013461 design Methods 0.000 description 18
- 238000000338 in vitro Methods 0.000 description 18
- 238000001727 in vivo Methods 0.000 description 18
- 238000003780 insertion Methods 0.000 description 18
- 230000037431 insertion Effects 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 18
- 238000010362 genome editing Methods 0.000 description 17
- -1 IL2Ry Proteins 0.000 description 16
- 241000589634 Xanthomonas Species 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 238000002965 ELISA Methods 0.000 description 15
- 239000013604 expression vector Substances 0.000 description 15
- 108091008146 restriction endonucleases Proteins 0.000 description 15
- 230000002103 transcriptional effect Effects 0.000 description 15
- 108091026890 Coding region Proteins 0.000 description 14
- 230000004048 modification Effects 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 239000013603 viral vector Substances 0.000 description 14
- 108091093088 Amplicon Proteins 0.000 description 13
- 108010061833 Integrases Proteins 0.000 description 13
- 238000013459 approach Methods 0.000 description 13
- 230000033228 biological regulation Effects 0.000 description 13
- 210000001671 embryonic stem cell Anatomy 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 238000012163 sequencing technique Methods 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 230000007018 DNA scission Effects 0.000 description 12
- 241000702421 Dependoparvovirus Species 0.000 description 12
- 102000018120 Recombinases Human genes 0.000 description 12
- 108010091086 Recombinases Proteins 0.000 description 12
- 101710185494 Zinc finger protein Proteins 0.000 description 12
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 12
- 230000004075 alteration Effects 0.000 description 12
- 230000002759 chromosomal effect Effects 0.000 description 12
- 238000010367 cloning Methods 0.000 description 12
- 239000000499 gel Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 230000003993 interaction Effects 0.000 description 12
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 12
- 230000008439 repair process Effects 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 11
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 11
- 241000700605 Viruses Species 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 11
- 230000006798 recombination Effects 0.000 description 11
- 238000005215 recombination Methods 0.000 description 11
- 230000001177 retroviral effect Effects 0.000 description 11
- 150000003384 small molecules Chemical class 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 238000001890 transfection Methods 0.000 description 11
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 10
- 108060001084 Luciferase Proteins 0.000 description 10
- 239000005089 Luciferase Substances 0.000 description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
- 241000232299 Ralstonia Species 0.000 description 10
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 10
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 10
- 240000008042 Zea mays Species 0.000 description 10
- 239000012190 activator Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 10
- 239000006166 lysate Substances 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 241000701161 unidentified adenovirus Species 0.000 description 10
- 108700028369 Alleles Proteins 0.000 description 9
- 102000053602 DNA Human genes 0.000 description 9
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 description 9
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 9
- 102100035620 Protein phosphatase 1 regulatory subunit 12C Human genes 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 9
- 210000000349 chromosome Anatomy 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 239000000539 dimer Substances 0.000 description 9
- 230000012743 protein tagging Effects 0.000 description 9
- 229910052725 zinc Inorganic materials 0.000 description 9
- 239000011701 zinc Substances 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 8
- 102100034349 Integrase Human genes 0.000 description 8
- 108090000742 Neurotrophin 3 Proteins 0.000 description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 238000012239 gene modification Methods 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 210000001161 mammalian embryo Anatomy 0.000 description 8
- 229950010131 puromycin Drugs 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 238000011144 upstream manufacturing Methods 0.000 description 8
- 102100031780 Endonuclease Human genes 0.000 description 7
- 235000010469 Glycine max Nutrition 0.000 description 7
- 244000068988 Glycine max Species 0.000 description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
- 241000254158 Lampyridae Species 0.000 description 7
- 108700040121 Protein Methyltransferases Proteins 0.000 description 7
- 102000055027 Protein Methyltransferases Human genes 0.000 description 7
- 108010020764 Transposases Proteins 0.000 description 7
- 102000008579 Transposases Human genes 0.000 description 7
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 238000004520 electroporation Methods 0.000 description 7
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 238000004806 packaging method and process Methods 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- 102000014914 Carrier Proteins Human genes 0.000 description 6
- 102000012330 Integrases Human genes 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 6
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 6
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 6
- 108091027967 Small hairpin RNA Proteins 0.000 description 6
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 6
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 6
- 108091008324 binding proteins Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 230000009368 gene silencing by RNA Effects 0.000 description 6
- 239000000833 heterodimer Substances 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 235000009973 maize Nutrition 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 6
- 108020001580 protein domains Proteins 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 125000006850 spacer group Chemical group 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 241000195493 Cryptophyta Species 0.000 description 5
- 108010016626 Dipeptides Proteins 0.000 description 5
- 108090000331 Firefly luciferases Proteins 0.000 description 5
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 5
- 101000595674 Homo sapiens Pituitary homeobox 3 Proteins 0.000 description 5
- 206010029113 Neovascularisation Diseases 0.000 description 5
- 239000005642 Oleic acid Substances 0.000 description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 102100035100 Transcription factor p65 Human genes 0.000 description 5
- 238000000137 annealing Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- RIOXQFHNBCKOKP-UHFFFAOYSA-N benomyl Chemical compound C1=CC=C2N(C(=O)NCCCC)C(NC(=O)OC)=NC2=C1 RIOXQFHNBCKOKP-UHFFFAOYSA-N 0.000 description 5
- MITFXPHMIHQXPI-UHFFFAOYSA-N benzoxaprofen Natural products N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000002538 fungal effect Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 5
- 238000000520 microinjection Methods 0.000 description 5
- 239000003607 modifier Substances 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 238000002271 resection Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 241001430294 unidentified retrovirus Species 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 229930024421 Adenine Natural products 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 230000033616 DNA repair Effects 0.000 description 4
- 241000219146 Gossypium Species 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 101150036143 NTF3 gene Proteins 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- 241000589771 Ralstonia solanacearum Species 0.000 description 4
- 108010052090 Renilla Luciferases Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 229960000643 adenine Drugs 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 210000002459 blastocyst Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 4
- 229960005542 ethidium bromide Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000005714 functional activity Effects 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 238000000099 in vitro assay Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000001638 lipofection Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 230000009452 underexpressoin Effects 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 239000013607 AAV vector Substances 0.000 description 3
- 241000589158 Agrobacterium Species 0.000 description 3
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 240000002791 Brassica napus Species 0.000 description 3
- 101150017501 CCR5 gene Proteins 0.000 description 3
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 3
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 3
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- 241000450599 DNA viruses Species 0.000 description 3
- 101710096438 DNA-binding protein Proteins 0.000 description 3
- 108091060211 Expressed sequence tag Proteins 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 101100446349 Glycine max FAD2-1 gene Proteins 0.000 description 3
- 244000020551 Helianthus annuus Species 0.000 description 3
- 235000003222 Helianthus annuus Nutrition 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 240000008415 Lactuca sativa Species 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 241000209510 Liliopsida Species 0.000 description 3
- 108091036060 Linker DNA Proteins 0.000 description 3
- 241000227653 Lycopersicon Species 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 108091061960 Naked DNA Proteins 0.000 description 3
- 108700019961 Neoplasm Genes Proteins 0.000 description 3
- 102000048850 Neoplasm Genes Human genes 0.000 description 3
- 102000011931 Nucleoproteins Human genes 0.000 description 3
- 108010061100 Nucleoproteins Proteins 0.000 description 3
- 108010047956 Nucleosomes Proteins 0.000 description 3
- 241000209094 Oryza Species 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 3
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 3
- 102100036088 Pituitary homeobox 3 Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 244000062793 Sorghum vulgare Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 238000013357 binding ELISA Methods 0.000 description 3
- 239000002551 biofuel Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 108091092356 cellular DNA Proteins 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000009274 differential gene expression Effects 0.000 description 3
- 238000006471 dimerization reaction Methods 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 241001233957 eudicotyledons Species 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- 108091070501 miRNA Proteins 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 210000001665 muscle stem cell Anatomy 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 210000004897 n-terminal region Anatomy 0.000 description 3
- 210000001623 nucleosome Anatomy 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000030648 nucleus localization Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000037432 silent mutation Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
- 229940113082 thymine Drugs 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 239000013638 trimer Substances 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- 108010013043 Acetylesterase Proteins 0.000 description 2
- 102100033647 Activity-regulated cytoskeleton-associated protein Human genes 0.000 description 2
- 101001030716 Arabidopsis thaliana Histone deacetylase HDT1 Proteins 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 244000075850 Avena orientalis Species 0.000 description 2
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 2
- 235000002566 Capsicum Nutrition 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 208000035240 Disease Resistance Diseases 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 101150016855 FAD2-1 gene Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 108091027305 Heteroduplex Proteins 0.000 description 2
- 108010036115 Histone Methyltransferases Proteins 0.000 description 2
- 102000011787 Histone Methyltransferases Human genes 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 2
- 101000687346 Homo sapiens PR domain zinc finger protein 2 Proteins 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 235000003228 Lactuca sativa Nutrition 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- 241000220225 Malus Species 0.000 description 2
- 240000004658 Medicago sativa Species 0.000 description 2
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 2
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102100024885 PR domain zinc finger protein 2 Human genes 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- 241000220324 Pyrus Species 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 241000209056 Secale Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 235000021536 Sugar beet Nutrition 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 101710183280 Topoisomerase Proteins 0.000 description 2
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 241000520892 Xanthomonas axonopodis Species 0.000 description 2
- 241000589636 Xanthomonas campestris Species 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 210000003763 chloroplast Anatomy 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000004345 fruit ripening Effects 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 210000002149 gonad Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000012405 in silico analysis Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 239000012212 insulator Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000002966 oligonucleotide array Methods 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 102000021127 protein binding proteins Human genes 0.000 description 2
- 108091011138 protein binding proteins Proteins 0.000 description 2
- 210000001938 protoplast Anatomy 0.000 description 2
- 230000014493 regulation of gene expression Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 102000028561 sterol response element binding proteins Human genes 0.000 description 2
- 108091009326 sterol response element binding proteins Proteins 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 230000037426 transcriptional repression Effects 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- JTTIOYHBNXDJOD-UHFFFAOYSA-N 2,4,6-triaminopyrimidine Chemical compound NC1=CC(N)=NC(N)=N1 JTTIOYHBNXDJOD-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108010020183 3-phosphoshikimate 1-carboxyvinyltransferase Proteins 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 102100021266 Alpha-(1,6)-fucosyltransferase Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 235000003840 Amygdalus nana Nutrition 0.000 description 1
- 244000296825 Amygdalus nana Species 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 101100517192 Arabidopsis thaliana NRPD1 gene Proteins 0.000 description 1
- 101100038200 Arabidopsis thaliana RPD1 gene Proteins 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
- 235000005781 Avena Nutrition 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000206761 Bacillariophyta Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108010018763 Biotin carboxylase Proteins 0.000 description 1
- 241001536303 Botryococcus braunii Species 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 235000011331 Brassica Nutrition 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 244000188595 Brassica sinapistrum Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 101100290380 Caenorhabditis elegans cel-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 102100028892 Cardiotrophin-1 Human genes 0.000 description 1
- 102000004018 Caspase 6 Human genes 0.000 description 1
- 108090000425 Caspase 6 Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 241001515826 Cassava vein mosaic virus Species 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 241000722206 Chrysotila carterae Species 0.000 description 1
- 241000219109 Citrullus Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 240000004270 Colocasia esculenta var. antiquorum Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000723607 Comovirus Species 0.000 description 1
- 241000218631 Coniferophyta Species 0.000 description 1
- 240000000491 Corchorus aestuans Species 0.000 description 1
- 235000011777 Corchorus aestuans Nutrition 0.000 description 1
- 235000010862 Corchorus capsularis Nutrition 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 241000219122 Cucurbita Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 101710155335 DELLA protein SLR1 Proteins 0.000 description 1
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 1
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 description 1
- 102100024810 DNA (cytosine-5)-methyltransferase 3B Human genes 0.000 description 1
- 101710123222 DNA (cytosine-5)-methyltransferase 3B Proteins 0.000 description 1
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000008836 DNA modification Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 241000208175 Daucus Species 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 235000002723 Dioscorea alata Nutrition 0.000 description 1
- 235000007056 Dioscorea composita Nutrition 0.000 description 1
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 description 1
- 235000005362 Dioscorea floribunda Nutrition 0.000 description 1
- 235000004868 Dioscorea macrostachya Nutrition 0.000 description 1
- 235000005361 Dioscorea nummularia Nutrition 0.000 description 1
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000195632 Dunaliella tertiolecta Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 235000001950 Elaeis guineensis Nutrition 0.000 description 1
- 244000127993 Elaeis melanococca Species 0.000 description 1
- 241000224431 Entamoeba Species 0.000 description 1
- 101100049549 Enterobacteria phage P4 sid gene Proteins 0.000 description 1
- 101000889905 Enterobacteria phage RB3 Intron-associated endonuclease 3 Proteins 0.000 description 1
- 101000889904 Enterobacteria phage T4 Defective intron-associated endonuclease 3 Proteins 0.000 description 1
- 101000889899 Enterobacteria phage T4 Intron-associated endonuclease 2 Proteins 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 101800001467 Envelope glycoprotein E2 Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000132521 Erigeron Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 102100034543 Fatty acid desaturase 3 Human genes 0.000 description 1
- 108010087894 Fatty acid desaturases Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 230000010558 Gene Alterations Effects 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 108700023224 Glucose-1-phosphate adenylyltransferases Proteins 0.000 description 1
- 101100446350 Glycine max FAD2-2 gene Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 235000009438 Gossypium Nutrition 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 108010002459 HIV Integrase Proteins 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 108010049606 Hepatocyte Nuclear Factors Proteins 0.000 description 1
- 102000008088 Hepatocyte Nuclear Factors Human genes 0.000 description 1
- 102100022846 Histone acetyltransferase KAT2B Human genes 0.000 description 1
- 108090000246 Histone acetyltransferases Proteins 0.000 description 1
- 102000003893 Histone acetyltransferases Human genes 0.000 description 1
- 101000819490 Homo sapiens Alpha-(1,6)-fucosyltransferase Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101100438883 Homo sapiens CCR5 gene Proteins 0.000 description 1
- 101000916283 Homo sapiens Cardiotrophin-1 Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000931098 Homo sapiens DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101001047006 Homo sapiens Histone acetyltransferase KAT2B Proteins 0.000 description 1
- 101000615495 Homo sapiens Methyl-CpG-binding domain protein 3 Proteins 0.000 description 1
- 101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 description 1
- 101100137155 Homo sapiens POU5F1 gene Proteins 0.000 description 1
- 101001109800 Homo sapiens Pro-neuregulin-1, membrane-bound isoform Proteins 0.000 description 1
- 101000702560 Homo sapiens Probable global transcription activator SNF2L1 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000702544 Homo sapiens SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5 Proteins 0.000 description 1
- 101000802101 Homo sapiens mRNA decay activator protein ZFP36L2 Proteins 0.000 description 1
- 241000209219 Hordeum Species 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
- 102000044753 ISWI Human genes 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 235000006350 Ipomoea batatas var. batatas Nutrition 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 241000208822 Lactuca Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000209082 Lolium Species 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 235000002262 Lycopersicon Nutrition 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000589195 Mesorhizobium loti Species 0.000 description 1
- 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 description 1
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 description 1
- 102100021291 Methyl-CpG-binding domain protein 3 Human genes 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000009869 Neu-Laxova syndrome Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102100028267 Neutral amino acid transporter B(0) Human genes 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 108010008964 Non-Histone Chromosomal Proteins Proteins 0.000 description 1
- 102000006570 Non-Histone Chromosomal Proteins Human genes 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 241001233986 Orychophragmus Species 0.000 description 1
- 101100046877 Oryza sativa subsp. japonica TRAB1 gene Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 102100036220 PC4 and SFRS1-interacting protein Human genes 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000218196 Persea Species 0.000 description 1
- 101100440941 Petroselinum crispum CPRF1 gene Proteins 0.000 description 1
- 240000007377 Petunia x hybrida Species 0.000 description 1
- 241000219833 Phaseolus Species 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 240000008334 Pisonia alba Species 0.000 description 1
- 241000219843 Pisum Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 108700001094 Plant Genes Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 241000183024 Populus tremula Species 0.000 description 1
- 241000709992 Potato virus X Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100025803 Progesterone receptor Human genes 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 235000011432 Prunus Nutrition 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 101150065817 ROM2 gene Proteins 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000220259 Raphanus Species 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101710200251 Recombinase cre Proteins 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000589187 Rhizobium sp. Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101001025539 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Homothallic switching endonuclease Proteins 0.000 description 1
- 101100473190 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPN1 gene Proteins 0.000 description 1
- 101100042631 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SIN3 gene Proteins 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000207763 Solanum Species 0.000 description 1
- 235000002634 Solanum Nutrition 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 108010039811 Starch synthase Proteins 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 102000007451 Steroid Receptors Human genes 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 108010043934 Sucrose synthase Proteins 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- 241000723873 Tobacco mosaic virus Species 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 241000196252 Ulva Species 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000219977 Vigna Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 241000209149 Zea Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 108700021044 acyl-ACP thioesterase Proteins 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 244000193174 agave Species 0.000 description 1
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000000005 bacterial plant pathogen Species 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 108010040093 cellulose synthase Proteins 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 108091006090 chromatin-associated proteins Proteins 0.000 description 1
- 101150034144 ci gene Proteins 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 244000038559 crop plants Species 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012786 cultivation procedure Methods 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 108010005155 delta-12 fatty acid desaturase Proteins 0.000 description 1
- 108010011713 delta-15 desaturase Proteins 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 230000000447 dimerizing effect Effects 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
- 230000001909 effect on DNA Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 210000002304 esc Anatomy 0.000 description 1
- 239000006277 exogenous ligand Substances 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012246 gene addition Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000004034 genetic regulation Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000010196 hermaphroditism Effects 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 102000055650 human NRG1 Human genes 0.000 description 1
- 102000057714 human NTF3 Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 108010064894 hydroperoxide lyase Proteins 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011850 initial investigation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 108010093345 lens epithelium-derived growth factor Proteins 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 102100034703 mRNA decay activator protein ZFP36L2 Human genes 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000005739 manihot Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000000897 modulatory effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 238000009401 outcrossing Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000012247 phenotypical assay Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000003032 phytopathogenic effect Effects 0.000 description 1
- 108090000102 pigment epithelium-derived factor Proteins 0.000 description 1
- 230000008121 plant development Effects 0.000 description 1
- 244000000003 plant pathogen Species 0.000 description 1
- 230000037039 plant physiology Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 208000028172 protozoa infectious disease Diseases 0.000 description 1
- 235000014774 prunus Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 108091035233 repetitive DNA sequence Proteins 0.000 description 1
- 102000053632 repetitive DNA sequence Human genes 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 102000023888 sequence-specific DNA binding proteins Human genes 0.000 description 1
- 108091008420 sequence-specific DNA binding proteins Proteins 0.000 description 1
- 238000012883 sequential measurement Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
- 229910010271 silicon carbide Inorganic materials 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 235000020354 squash Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000003160 two-hybrid assay Methods 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
- C12N15/8213—Targeted insertion of genes into the plant genome by homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12Y301/21004—Type II site-specific deoxyribonuclease (3.1.21.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
Definitions
- the present invention provides methods for genetic modification and regulation of expression status of endogenous genes and other genomic loci using engineered DNA binding proteins.
- Gene expression is normally controlled through alterations in the function of sequence specific DNA binding proteins called transcription factors. They act to influence the efficiency of formation or function of a transcription initiation complex at the promoter. Transcription factors can act in a positive fashion (activation) or in a negative fashion (repression).
- Transcription factor function can be constitutive (always "on") or conditional.
- Conditional function can be imparted on a transcription factor by a variety of means, but the majority of these regulatory mechanisms depend of the sequestering of the factor in the cytoplasm and the inducible release and subsequent nuclear translocation, DNA binding and activation (or repression).
- transcription factors that function this way include progesterone receptors, sterol response element binding proteins (SREBPs) and NF-kappa B.
- SREBPs sterol response element binding proteins
- NF-kappa B There are examples of transcription factors that respond to phosphorylation or small molecule ligands by altering their ability to bind their cognate DNA recognition sequence (Hou et al., Science 256:1701 (1994); Gossen & Bujard, Proc.
- ZFPs zinc finger proteins
- Targeted alteration of genome sequences is the targeted alteration of genome sequences.
- Such targeted cleavage events can be used, for example, to induce targeted mutagenesis, induce targeted deletions of cellular DNA sequences, and facilitate targeted recombination at a predetermined chromosomal locus.
- United States Patent Publications 20030232410; 20050208489; 20050026157; 20050064474; 20060188987; 2008015996, and International Publication WO 2007/014275 the disclosures of which are incorporated by reference in their entireties for all purposes. See, also, Santiago et al. (2008) Proc Natl Acad Sci USA 105:5809-5814; Perez et al. (2008) Nat Biotechnol 26:808-816 (2008).
- the cleavage event is induced using one or more pairs of custom-designed zinc finger nucleases that dimerize upon binding DNA to form a catalytically active nuclease complex.
- specificity has been further increased by using one or more pairs of zinc finger nucleases that include engineered cleavage half- domains that cleave double-stranded DNA only upon formation of a heterodimer. See, e.g., U.S. Patent Publication No. 20080131962, incorporated by reference herein in its entirety.
- the double-stranded breaks (DSBs) created by artificial nucleases have been used, for example, to induce targeted mutagenesis, induce targeted deletions of cellular DNA sequences, and facilitate targeted recombination at a predetermined chromosomal locus.
- DSBs double-stranded breaks
- the ability to generate a DSB at a target genomic location allows for genomic editing of any genome.
- homologous recombination requires the presence of a homologous sequence as a template (known as a "donor") to guide the cellular repair process and the results of the repair are error-free and predictable.
- a template or "donor" sequence for homologous recombination
- the cell typically attempts to repair the DSB via the error-prone process of NHEJ.
- T3S type III secretion
- TALE transcription activator-like effectors
- TAL-effectors transcription activator-like effectors
- TALEs contain a centralized repeat domain that mediates DNA recognition, with each repeat unit containing approximately 33-35 amino acids specifying one target base. TALEs also contain nuclear localization sequences and several acidic transcriptional activation domains (for a review see Schornack S, et al (2006) J Plant Physiol 163(3): 256-272). In addition, in the
- Ralstonia solanacearum two genes designated brgl 1 and hpxl7 have been found that are homologous to the AvrBs3 family of Xanthomonas in the R.
- solanacearum biovar 1 strain GMI1000 and in the biovar 4 strain RSI 000 See Heuer et al (2007) Appl and Envir Micro 73(13): 4379-4384.
- These genes are 98.9% identical in nucleotide sequence to each other but differ by a deletion of 1,575 bp in the repeat domain of hpxl7.
- both gene products have less than 40% sequence identity with AvrBs3 family proteins of Xanthomonas.
- DNA-binding specificity of these TALEs depends on the sequences found in the tandem TALE repeat units.
- the repeated sequence comprises approximately 33-35 amino acids and the repeats are typically 91-100% homologous with each other (Bonas et al, ibid).
- These two adjacent amino acids are referred to as the Repeat Variable Diresidue (RVD).
- TALEs DNA recognition units
- C cytosine
- NG binds to T
- NI to A NI to A
- NN binds to G or A
- NG binds to T.
- These specificity-determining TALE repeat units have been assembled into proteins with new combinations of the natural TALE repeat units and altered numbers of repeats, to make variant TALE proteins.
- these variants When in their native architecture, these variants are able to interact with new sequences and activate the expression of a reporter gene in plant cells (Boch et al, ibid.). However, these proteins maintain the native (full-length) TALE protein architecture and only the number and identity of the TALE repeat units within the construct were varied.
- Entire or nearly entire TALE proteins have also been fused to a nuclease domain from the Fokl protein to create a TALE-nuclease fusion protein
- TALEN TALEN
- Such constructs could also modify endogenous genes in yeast cells to quantifiable levels and could modify endogenous genes in mammalian and plant cells to detectable, but unquantifiable levels when appropriate sequence amplification schemes are employed. See, Li et al. (201 lb) Nucleic Acids Res. epub doi: 10.1093/nar/gkrl88; Cermak et a/.(201 1) Nucleic Acids Res.
- the present invention thus provides for methods of targeted manipulation of expression state or sequence of endogenous loci.
- the methods of the invention use DNA-binding proteins comprising one or more TALE- repeat units fused to functional protein domains (collectively "TALE-fusions"), to form engineered transcription factors, engineered nucleases (“TALENs”), recombinases, transposases, integrases, methylases, enzymatic domains and reporters.
- TALE-fusions DNA-binding proteins comprising one or more TALE- repeat units fused to functional protein domains
- TALENs engineered nucleases
- the polypeptide includes the at least one TALE repeat unit linked to additional TALE protein sequences, for efficient and specific function at endogenous target DNA.
- polypeptides comprising one or more ⁇ e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20 or more) TALE repeat and/or half-repeat units.
- the polypeptide typically includes an N-cap sequence (polypeptide) of any length that supports DNA-binding function of the TALE repeat(s) or functional activity of the TALE fusion protein.
- the polypeptide may also include a C-cap sequence (polypeptide), for example a C-cap sequence of less than approximately 250 amino acids (C+230 C-cap; from residue C-20 to residue C+230).
- At least one of the TALE repeat units of the TALE polypeptides as described herein include repeat variable di-residue (RVD) regions that are atypical.
- the TALE repeat unit may be a wild-type domain isolated from Xanthomonas, Ralstonia or another related bacteria and/or may be engineered in some manner (e.g., may be non-naturally occurring).
- at least one TALE repeat unit is engineered (e.g., non-naturally occurring, atypical, codon optimized, combinations thereof, etc.).
- one or more amino acids in the TALE repeat domain are altered such that the domain binds to a selected target sequence (typically different from the target sequence bound by a naturally occurring TALE DNA binding domain).
- at least one TALE repeat unit is modified at some or all of the amino acids at positions 4, 11, 12, 13 or 32 within the TALE repeat unit.
- at least one TALE repeat unit is modified at 1 or more of the amino acids at positions 2, 3, 4, 11, 12, 13, 21, 23, 24, 25, 26, 27, 28, 30, 31, 32, 33, 34, or 35 within one TALE repeat unit.
- the nucleic acid encoding the TALE repeat is modified such that the DNA sequence is altered but the amino acid sequence is not.
- the DNA modification is for the purposes of codon
- At least one TALE repeat unit is altered by
- TALE proteins comprising several modified TALE repeat units are provided. Combinations of naturally occurring and non-naturally occurring TALE repeat units are also provided.
- the TALE protein (wild-type or engineered) further comprises N-cap and optionally the C-cap sequences for efficient and specific function at endogenous target DNA.
- the N-cap comprises residues N+l to N+136 (see Figure IB for a description of the residue numbering scheme), or any fragment thereof.
- the C-cap comprises residues C-20 to C+28, C-20 to C+39, C-20 to C+55, or C-20 to C+63 or any fragments of the full length TALE C-terminus thereof.
- the polypeptide comprising the TALE repeat domain, as well as an N-cap and optional C-cap sequences further comprises a regulatory or functional domain, for example, a transcriptional activator, transcriptional repressor, nuclease, recombinase, transposase, integrase, methylase or the like.
- Polynucleotides encoding these proteins are also provided as are pharmaceutical compositions.
- the invention includes host cells, cell lines and transgenic organisms (e.g., plants, fungi, animals) comprising these proteins/polynucleotides and/or modified by these proteins (e.g., genomic modification that is passed onto the progeny).
- exemplary cells and cell lines include animal cells (e.g., mammalian, including human, cells such as stem cells), plant cells, bacterial cells, protozoan cells, fish cells, or fungal cells.
- the cell is a mammalian cell. Methods of making and using these proteins and/or polynucleotides are also provided.
- fusion proteins comprising one or more engineered TALE repeat units, an N-cap, and an optional C-cap sequence, operatively linked to one or more heterologous polypeptide domains, for example functional (regulatory) domains.
- Libraries comprising modules of TALE repeats are provided as are optional structured or flexible linkers for connecting the engineered TALE repeats to the functional protein domain of interest.
- the functional protein domain e.g., transcriptional activator, repressor, or nuclease
- the present invention also provides a method for identifying suitable target sequences (sites) for engineered TALE fusion proteins.
- a target site identified has an increased number of guanine nucleotides ("G") as compared to a natural TALE target sequence.
- the target does not require flanking thymidine nucleotides ("T"), as typical in naturally occurring TALE proteins.
- the RVDs selected for use in the engineered TALE protein contains one or more NK
- RVDs for the recognition of G nucleotides in the target sequence.
- novel (non-naturally occurring) RVDs differing from those found in nature, which are capable of recognizing nucleotide bases.
- Non-limiting examples of atypical or non-naturally occurring RVDs include RVDs as shown in Table 3 OA, for example, VG and IA to recognize T, RG to recognize A and T, and AA to recognize A, C, and T are provided.
- RVDs capable of interacting equally with all nucleotide bases e.g. A, C, T, and G. Additional RVDs useful in the compositions and methods described herein are shown in Table 27.
- the gap spacing is constrained to 12-13 base pairs, while in other embodiments, the engineered TALEN is designed to cleave DNA targets comprising a gap spacing of between 12 to 21 base pairs.
- the TALEN heterodimer is designed to cleave a sequence comprising a gap of between 1 and 34 nucleotides between each monomer binding site.
- the TALEN is constrained to cleave a target with a 12 or 13 base pair gap by utilizing a TALEN architecture comprising the +28 C-terminal truncation (C+28 C-cap).
- the designed TALEN is made to cleave a target nucleic acid comprising a 12 to 21 base pair gap spacing using a TALEN architecture comprising the +63 C-terminal truncation, which increases the likelihood of being able to identify a suitable TALEN target site due to the flexibility in gap spacing requirements.
- the TALEN has an engineered Rl/2 repeat such that the Rl/2 repeat is capable of targeting nucleotide bases other than T.
- the present invention provides a vector for an engineered
- TALE DNA binding domain fusion wherein the vector comprises the TALE N-cap and C-cap sequences flanking the TALE repeat sequences as well as locations to allow for the cloning of multiple TALE repeat units, linker sequences, promoters, selectable markers,
- TALENs polyadenylation signal sites, functional protein domains and the like. Also provided by the invention herein is a method for the construction of a modular archive library including at least one TALE- repeat unit (e.g., engineered) for ready assembly of specific TALE DNA binding domain domains and fusion proteins comprising these domains (e.g., TALENs).
- TALE- repeat unit e.g., engineered
- the present invention provides a method of modulating the expression of an endogenous cellular gene in a cell, the method comprising the step of: contacting a first target site in the endogenous cellular gene with a first engineered TALE fused to a functional domain (e.g., transcriptional modulator domain), thereby modulating expression of the endogenous cellular gene.
- a functional domain e.g., transcriptional modulator domain
- the present invention provides a method of modulating expression of an endogenous cellular gene in a cell, the method comprising the step of: contacting a target site in the endogenous cellular gene with a fusion TALE protein wherein the TALE comprises an engineered TALE repeat domain such that the TALE has specificity for a desired sequence.
- the modulatory effect is to activate the expression of the endogenous gene.
- the expression of the endogenous gene is inhibited.
- activation or repression of the endogenous gene is modulated by the binding of a TALE fusion protein such that an endogenous activator or repressor cannot bind to the regulator regions of the gene of interest.
- the step of contacting further comprises contacting a second target site in an endogenous cellular gene with a second engineered TALE fusion protein, thereby modulating expression of the second endogenous cellular gene.
- the first and second target sites are adjacent.
- the first and second target sites are in different genes, for example to modulate expression of two or more genes using TALE-transcription factors.
- the first and second target sites are in the same gene, for example when a pair of TALEN fusion proteins is used to cleave in the same gene.
- the first and second target sites are separated by any of base pairs ("gap size"), for example, 1 to 20 (or any number therebetween) or even more base pairs.
- the step of contacting further comprises contacting more than two target sites.
- two sets of target sites are contacted by two pairs of TALENs, and are used to create a specific deletion or insertion at the two sets of targets.
- the first TALE protein is a fusion protein comprising a regulatory or functional domain. In another embodiment, the first TALE protein is a fusion protein comprising at least two regulatory or functional domains. In another embodiment, the first and second TALE proteins are fusion proteins, each comprising a regulatory domain. In another embodiment, the first and second TALE proteins are fusion proteins, each comprising at least two regulatory domains. The one or more functional domains may be fused to either (or both) ends of the TALE protein. Any of the TALE fusions proteins can be provided as polynucleotides encoding these proteins.
- the invention provides compositions for C-caps linking a nuclease domain to a TALE repeat domain as described herein, wherein the resulting fusion protein exhibits highly active nuclease function.
- the C-cap comprises ⁇ peptide sequence from native TALE C-terminal flanking sequence.
- the C-cap comprises peptide sequence from a TALE repeat domain.
- the C-cap comprises sequences not derived from TALE proteins.
- C-caps may also exhibit a chimeric structure, for example comprising peptide sequences from native TALE C-terminal flanking sequence and/or TALE repeat domains and/or non-TALE polypeptides.
- the regulatory or functional domain may be selected from the group consisting of a transcriptional repressor, a transcriptional activator, a nuclease domain, a DNA methyl transferase, a protein
- the functional domain is an epigenetic regulator.
- the fusion protein would comprise an epigenetic regulator such as, by non-limiting example, a histone methyltransferase, DNA methyltransferase, or histone deacetylase. See for example, co-owned United States patent 7,785,792.
- the TALE fusion protein comprises a TALE-repeat domain fused to a nuclease domain (a "TALEN").
- TALEN nuclease domain
- the TALE repeat domain is further fused to an N-cap sequence and, optionally, a C-cap sequence.
- the nuclease domain is connected to either the amino terminus of the N-cap or carboxy terminus of the C-cap via linker peptide sequences that provide efficient catalytic function of the nuclease domain.
- the nuclease domain may be naturally occurring or may be engineered or non-naturally occurring.
- the nuclease domain is derived from a Type IIS nuclease (e.g.
- the TALE DNA binding domain is operably linked to a Bfi I nuclease domain.
- the Fokl domain is a single chain nuclease domain, comprising two cleavage half domains, and in others it is a Fokl cleavage half domain.
- a single TALEN protein is used by itself to induce a double strand break in a target DNA, while in others, the TALEN is used as part of a pair of nucleases.
- the pair comprises two TALENs comprising Fokl half domains, wherein the pairing of the Fokl half domains is required to achieve DNA cleavage, while in other cases the TALEN protein is used in combination with a zinc-finger nuclease wherein pairing of the two Fokl cleavage domains is required to achieve DNA cleavage.
- the TALE DNA binding domain is fused to a zinc finger to make a zin finger/TALE hybrid DNA binding domain.
- the hybrid DNA binding domain is able to skip interacting with internal stretches of DNA bases within the DNA target binding site.
- the Fokl domains are able to form homodimers, and in other instances, heterodimerization of two non-identical Fokl cleavage domains from each member of the TALEN pair is required for targeted cleavage activity. In these heterodimeric TALEN pairs, two Fokl domains of the same type are not able to productively homodimerize. In other embodiments, a TALEN pair is used wherein one Fokl cleavage domain is inactive such that pairing may occur, but the target DNA is nicked to produce a cut on one strand of the DNA molecule rather than cleaving both strands.
- the TALE fusion protein may be encoded by a TALE fusion protein nucleic acid.
- the sequence encoding the TALE fusion protein is operably linked to a promoter.
- the methods of modulating endogenous gene expression or genomic modification further comprises the step of first administering the nucleic acid encoding the TALE protein to the cell.
- the TALE-fusion protein may be expressed from an expression vector such as a retroviral expression vector, an adenoviral expression vector, a DNA plasmid expression vector, or an AAV expression vector.
- the expression vector is a lentiviral vector, and in some of these embodiments, the lentiviral vector is integrase-defective.
- TALENs e.g., TALEN pairs
- any desired target locus e.g., endogenous gene
- Non-limiting examples include TALENs specific for NTF3, VEGF, CCR5, IL2Ry, BAX, BAK, FUT8, GR, DHFR, CXCR4, GS, Rosa26, AAVS1 (RPP1R12C), MHC genes, PITX3, ben-1, Pou5Fl (OCT4), Cl, RPDl, etc.
- the TALE-repeat domains as described herein may bind to a target site that is upstream of, or adjacent to, a transcription initiation site of the endogenous cellular gene.
- the target site may be adjacent to an RNA polymerase pause site downstream of a transcription initiation site of the endogenous cellular gene.
- the TALE fusion protein e.g., a TALEN
- a method for cleaving one or more genes of interest in a cell comprising: (a) introducing, into the cell, one or more one or more TALEN protein(s) (or polynucleotides encoding the TALENs) that bind to a target site in the one or more genes under conditions such that the TALEN protein(s) is (are) expressed and the one or more genes are cleaved.
- TALEN protein(s) or polynucleotides encoding the TALENs
- two or more TALEN proteins are introduced, one, some or all can be introduced as polynucleotides or as polypeptides.
- said gene cleavage results in the functional disruption of the targeted gene.
- Cleavage of the targeted DNA may be followed by NHEJ wherein small insertions or deletions (indels) are inserted at the site of cleavage. These indels then cause functional disruption through introduction of non-specific mutations at the cleavage location.
- a method for introducing an exogenous sequence into the genome of a cell comprising the steps of: (a) introducing, into the cell, one or more TALEN protein(s) (or polynucleotides encoding the TALEN protein(s)) that bind to a target site in a target gene under conditions such that the TALEN protein(s) is (are) expressed and the one or more target sites within the genes are cleaved; and (b) contacting the cell with an exogenous polynucleotide; such that cleavage of the DNA target si te(s) stimulates integration of the exogenous polynucleotide into the genome by homologous recombination.
- the exogenous TALEN protein(s) or polynucleotides encoding the TALEN protein(s) that bind to a target site in a target gene under conditions such that the TALEN protein(s) is (are) expressed and the one or more target sites within the genes are clea
- the exogenous polynucleotide is integrated physically into the genome.
- the exogenous polynucleotide is integrated into the genome by copying of the exogenous sequence into the host cell genome via specialized nucleic acid replication processes associated with homology-directed repair (HDR) of the double strand break.
- integration into the genome occurs through non-homology dependent targeted integration (e.g. "end-capture”).
- the exogenous polynucleotide comprises a recombinase recognition site (e.g. loxP or FLP) for recognition by a cognate recombinase (e.g. Cre or FRT, respectively).
- the exogenous sequence is integrated into the genome of a small animal (e.g. rabbit or rodent such as mouse, rat, etc.).
- the TALE-fusion protein comprises a transposase
- TALE polypeptides are used.
- the TALE-fusion protein comprises a tranposase or integrase and is used for the development of a CHO-cell specific transposase/integrase system.
- the TALE- fusion protein comprises a
- the TALE-repeat domain has been engineered to recognize a specifically desired target sequence.
- the TALE-repeat domain is fused to a subunit of a protein complex that functions to effect epigenetic modification of the genome or of chromatin.
- TALE-fusion further comprises a reporter or selection marker wherein the TALE-repeat domain has been engineered to recognize a specifically desired target sequence.
- the reporter is a fluorescent marker, while in other aspects, the reporter is an enzyme.
- compositions comprising one or more of the TALE-fusion proteins.
- the composition comprises one or more TALE- fusion proteins in combination with a pharmaceutically acceptable excipient.
- the composition comprises a polynucleotide encoding the TALE fusion protein.
- Some embodiments comprise a composition comprising a DNA molecule encoding a TALEN.
- the composition comprises a RNA molecule encoding a TALEN.
- Some compositions further comprise a nucleic acid donor molecule.
- the polynucleotide may be, for example, mRNA.
- a TALE-fusion protein expression vector comprising a polynucleotide, encoding one or more TALE-fusion proteins described herein, operably linked to a promoter (e.g., constitutive, inducible, tissue-specific or the like).
- a promoter e.g., constitutive, inducible, tissue-specific or the like.
- a host cell comprising one or more
- the host cell further comprises one or more zinc finger proteins and/or ZFP encoding vectors.
- the host cell may be stably transformed or transiently transfected or a combination thereof with one or more of these protein expression vectors.
- the one or more protein expression vectors express one or fusion proteins in the host cell.
- the host cell may further comprise an exogenous polynucleotide donor sequence.
- any prokaryotic or eukaryotic host cells can be employed, including, but not limited to, bacterial, plant, fish, yeast, algae, insect, worm or mammalian cells.
- the host cell is a plant cell.
- the host cell is part of a plant tissue such as the vegetative parts of the plant, storage organs, fruit, flower and/or seed tissues.
- the host cell is an algae cell.
- the host cell is a fibroblast.
- the host cell may comprise a stem cell, for example an embryonic stem cell.
- the stem cell may be a mammalian stem cell, for example, a hematopoietic stem cell, a mesenchymal stem cell, an embryonic stem cell, a neuronal stem cell, a muscle stem cell, a liver stem cell, a skin stem cell, an induced pluripotent stem cell and/or combinations thereof.
- the stem cell is a human induced pluripotent stem cells (hiPSC) or a human embryonic stem cell (hESC).
- the host cell can comprise an embryo cell, for example one or more mouse, rat, rabbit or other mammal cell embryos.
- stem cells or embryo cells are used in the development of transgenic animals, including for example animals with TALE-mediated genomic modifications that are integrated into the germline such that the mutations are heritable.
- these transgenic animals are used for research purposes, i.e. mice, rats, rabbits; while in other aspects, the transgenic animals are livestock animals, i.e. cows, chickens, pigs, sheep etc.
- the transgenic animals are those used for therapeutic purposes, i.e. goats, cows, chickens, pigs; and in other aspects, the transgenic animals are companion animals, i.e. cats, dogs, horses, birds or fish.
- a target is chosen based upon its similarity to target sites used by typical, naturally occurring TALE proteins.
- a target is selected that is not utilized by typical, naturally occurring TALE proteins because the engineered TALE proteins have been altered in such a way as to make them able to interact with an atypical, target sequence.
- this alteration involves the selection of atypical (non-naturally occurring or rare) RVD sequences.
- the atypical RVD used is a 'NK' RVD for the recognition of a G residue in the desired target sequence.
- targets are selected that contain non-natural ratios of nucleic acid bases because the engineered TALE proteins have been altered in such a way as to make them able to interact with a non-natural ratio of nucleic acid bases.
- the ratio of bases in the desired target sequence comprises an unusual number of G residues.
- the ratio of bases in the desired target sequence comprises an unusual number of atypical di-nucleotides, tri-nucleotides or tetra- nucleotides.
- RVDs able to interact with all nucleotides to provide the user a greater flexibility in choosing target sequences.
- the invention provides compositions and methods for in vivo genomic manipulation.
- mRNAs encoding TALENs may be injected into gonads, ovum or embryos for introducing specific DSBs as desired.
- donor nucleotides are co-delivered with the TALEN mRNAs to cause specific targeted integration in the organism.
- kits comprising the TALE- domain proteins (and fusion proteins comprising these TALE-repeat proteins) of the invention.
- kits may be used to facilitate genomic manipulation by the user and so can provide a TALEN, for example, that will cleave a desired target or a safe harbor locus within a genome.
- the TALEN may be provided either as nucleic acid (e.g. DNA or RNA) or may be provided as protein.
- the protein may be formulated to increase stability, or may be provided in a dried form.
- the kits are used for diagnostic purposes.
- the TALE- fusion included in the kit is a transcriptional regulator.
- the TALE- fusion comprises a reporter.
- FIG. 1 A shows a schematic of the domain structure of a TALE protein (not drawn to scale).
- 'N' and 'C indicate the amino and carboxy termini, respectively.
- the TALE repeat domain, N-cap and C-cap are labeled and the residue numbering scheme for the N-cap and C-cap in this protein are indicated.
- R0 represents the 34 amino acids preceding the first tandem TALE repeat that may share some structural homology with the TALE repeat units and that may specify thymine in a DNA target sequence.
- Ri /2 denotes the C-terminal TALE "half-repeat," which is a 20 residue peptide sequence (with residues numbered from C -20 to C -1) with homology to the first 20 residues of a typical TALE repeat.
- NLS is the nuclear localization sequence.
- AD is the acidic activation domain.
- Figure IB SEQ ID NO:135) shows the primary sequence of a cloned natural TALE protein (hereinafter referred to as "TALE13”) that was isolated with a cloning scheme designed to delete the N-terminal 1-152 amino acid residues.
- N-cap and C-cap are indicated by a thick black line below the sequence; positions N+l and N+l 36 in the N-cap and positions C+l and C+278 in the C-cap are indicated.
- the half repeat is the first 20 residues of the C-cap and ends immediately prior to the position indicated as "C+l". Underlined residues in the TALE repeats and half repeat indicate amino acids (RVDs) that specify the DNA nucleotide contacted by the repeat during target binding.
- Figure 2 panels A and B, show the reporter construct for use with the predicted target of TALE 13 (TR13).
- Figure 2A (SEQ ID NO: 136) shows a schematic of the reporter vector indicating the cloning sites used for inserting 1-4 TR13 targets into the vector. The region in italics is the promoter region for the luciferase gene.
- Figure 2B (SEQ ID NO: 137) shows the linker sequence used containing two TR13 targets.
- FIG 3 panels A and B, show a schematic of the reporter construct containing 0-4 TR13 targets ( Figure 3 A) and synergistic reporter gene activation by
- TALE13-VP16 fusion protein (TR13-VP16, TALE 13 linked with an activation domain from VP 16) on the luciferase reporter constructs containing 1 to 4 multiple TR13 targets, indicated as R13xl to R13x4, respectively ( Figure 3B).
- pGL3 is the control reporter vector lacking any TR13 target elements.
- FIG 4A is a schematic of the TALE proteins, with or without the addition of VP 16 domain, as well as the reporter constructs used in the study.
- R13x2 indicates the construct where two of the TALE13 (TR13) targets are inserted while R15x2 indicates the construct where two of the TALE 15 (TR15) targets are inserted.
- Figure 4B shows the reporter gene activation by TALE protein with the VP 16 fusion but not by the TALE protein itself.
- the natural transcriptional activation domain present in the TALE protein was not functional in mammalian cells in this assay.
- TALE 13 and TALE 15 are indicated as TR13 and TR15 respectively.
- TR13-VP16 and TR15-VP16 are similar to TR13 and TR15 with the additional VP16 activation domain fused to their C-terminus.
- FIG. 5 A shows a schematic of the reporter constructs where the target sequences are placed either proximal (R13x4) or distal (R13x4D) to the SV40 promoter.
- Figure 5B shows the reporter gene activation by the indicated TALEs.
- nR13V-dl45C refers to an expression construct containing the SV40 nuclear localization sequence, the TR13 sequence with 145 amino acid residues deleted from the C-terminus (yielding a C+133 C-cap) and the VP16 activation domain
- R13-VP16 refers to an expression construct containing TALE 13 sequence and the VP 16 activation domain.
- the C-terminal 145 amino acids of the full length TALEs are not required for the reporter gene activation, and (ii) the reporter gene activation is greatest when the target sequences are placed proximal to the promoter sequence.
- Figure 6, panels A and B are graphs depicting the reporter gene (luciferase) activation using a TALE fusion.
- Figure 6A depicts the activation of a reporter gene using a fusion protein comprising the engineered TALE 18 protein (R23570 here; referred to as NT- L in later figures).
- the reporter construct contains 2 copies of the engineered TALE18 targets upstream from the luciferase gene. Activation of this reporter is observed only with R23570V, which contains the 17.5 engineered repeat sequences (17 full TALE repeats and one half repeat), the N- and C-terminal sequences (N-cap and C-cap) flanking the tandem TALE repeats of TR13, and the VP16 activation domain.
- nR23570S-dNC contains the SV40 NLS (n), the 17.5 engineered TALE repeat sequences, fused to a single p65 activation domain (S), but is lacking the N- and C- terminal sequences (N-cap and C-cap) from TALE (dNC).
- the nR23570SS-dNC is the same as nR23570S-dNC except that it has two p65 domains.
- the R0-VP16 construct is the same as R23570 but lacks the tandem TALE repeats. 'Mock' shows the results for an experiment lacking an expression construct.
- Figure 6B depicts the activation of an endogenous gene in its chromosomal environment by a fusion protein comprising the engineered (non-naturally occurring) TALE 18 domain.
- the engineered TALE 18 (R23570V), which is designed to target to the NTF3 gene, can lead to a substantial increase in the endogenous NTF3 mRNA level. Under the same conditions, the expression of NTF3 mRNA is not affected by either R0-VP16 or GFP. R23570V and R0-VP16 are described as above.
- Figure 7, panels A to D depict additional exemplary NTF3-specific TALE transcription factor fusions.
- Figure 7A depicts a diagram of the exemplary proteins and their target in the NTF3 promoter (SEQ ID NO: 138). The two TALE transcription factor variants were linked to the VP 16 activation domain and expressed in HEK293 cells. The sequence at the bottom shows the promoter-proximal region of human NTF3. Underlined bases indicate the target site for the NT-L TALE repeat domain. The hooked arrow shows the start site of NTF3 transcription.
- Figure 7B shows relative NTF3 mRNA levels in HEK293 cells expressing either the top or lower protein sketched in figure 7A.
- eGFP indicates cells transfected with a control plasmid that expresses enhanced GFP. Measurements were performed in quadruplicate and error bars indicate standard deviations.
- Figure 7C depicts levels of NTF3 protein secreted from HEK293 cells expressing either the top or lower proteins sketched in 7A. Measurements were performed in duplicate using an ELIS A assay, and error bars indicate standard deviations.
- Neg. indicates cells transfected with an empty vector control.
- Figure 7D shows the RVDs (top row of letters), expected binding site (second row of letters) and SELEX-derived base frequency matrix for NT-L (graph at bottom).
- the most frequently selected base matches the target locus sequence.
- Figure 8 panels A and B are graphs depicting the DNA binding ability, as assayed by ELIS A, of a series of N- and C-terminal truncations of various engineered TALE DNA binding domains.
- Figure 8 A depicts the data for an NT3 -specific TALE DNA binding domain comprising 9.5 TALE repeats
- Figure 8B depicts the data for a VEGF-specific TALE DNA binding domain comprising 9.5 TALE repeats.
- both proteins showed an apparent decrease in relative DNA binding affinity under the conditions of this assay when the protein was truncated on the N-terminus further than the N +134 position. Additionally, both proteins showed an apparent decrease in relative DNA binding affinity under the conditions of this assay when the C-terminus was truncated past amino acid C+54.
- FIG. 9 panels A and B, depict the DNA binding activity, as assayed by
- FIG. 9A the data for the NTF3-specific TALE DNA binding domain is shown, but in this case, when the N-terminal truncations were being tested, the C-terminus was maintained at the C+54 position. For the C-terminal truncations, the N-terminal amino acid was the N+134 position.
- Figure 9B the data for the VEGF-specific TALE DNA binding domains is shown. As shown, the N- and C-terminal ends were maintained as described above for Figure 9A.
- Figure 10 shows dissection of TALE functional domains involved for activity.
- R13V-dl45C has a C+133 C-cap
- R13V-dl82C has a C+95 C-cap
- R13V-dC has a C+22 C-cap
- nR13V-dN has a N+8 N-cap
- nR13V-d223N has an N+52 N-cap
- nR13V-d240 has an N+34 N-cap.
- FIG 11, panels A and B depict nuclease activity of TALE 13 linked to two copies of the Fokl domain in K562 cells.
- Figure 11 A depicts a schematic of a single stranded annealing based reporter assay (SSA) for detecting the nuclease activity in mammalian cells.
- the reporter construct (SSA-R13) in this assay contained the TALE13 target, sandwiched by the N-terminal (GF) and C-terminal part (FP) of the GFP coding sequence.
- the plasmid SSA-R13 by itself cannot drive the GFP expression, but the cleavage of the R13 target promotes homologous recombination between the N-terminal (GF) and C-terminal (FP) part of the GFP to form a functional GFP.
- the nuclease activity of TALEN protein was assessed by analyzing the percentage of the GFP positive cells.
- Figure 1 IB demonstrates nuclease activity by a TALEN protein.
- the GFP positive cells generated from SSA-R13 reporter construct increased significantly using a TALEN (R13dl82C-scFokI; C+95 C-cap), compared to a control experiment lacking the nuclease plasmid (mock).
- R13dl82C-scFokI is the same as R13V-dl82C described above except that two copies of Fokl domain, linked by 12 copies of GGGGS sequences between the Fokl domains, is used to replace the VP 16 activation domain.
- Figure 12 depicts an ethidium bromide gel showing nuclease activity of the
- TALE- 13 effector domain-FokI cleavage half-domain fusions in vitro.
- the columns show data for four TALE domain nuclease cleavage proteins: the nuclease fusion with a N+137, C+28 configuration using either the L2 or L8 linker (see Example 7); the nuclease fusion with the N+137, C+39 configuration, using the L2 linker; and the N+137, C+63 fusion with the L2 linker.
- the gap spacings between the two target sites are shown beneath the wells where the number indicates the number of bp between the targets. "S” indicates a single target site for only one half of the pair.
- Pmll indicates cleavage with a standard restriction enzyme and blank indicates the results when the experiment was carried out without the nuclease encoding plasmid.
- Figure 13 is a graph depicting the DNA cleavage obtained by the indicated
- TALE13-FokI cleavage half domain fusions "Dimer Gap” indicates the number of bp between the two target sites, and "Percent DNA Cleavage” indicates how much DNA was cleaved in the reaction. The results indicate that virtually 100 percent DNA cleavage is achievable in these reaction conditions with the three of the four nucleases tested..
- Figure 14 depicts an ethidium bromide-stained gel showing nuclease activity of the TALE domain-FokI half cleavage domain fusions.
- the N-terminus was varied while the C-terminus was maintained with the C +63 configuration.
- the Pmll and Blank controls are the same as for Figure 12.
- the N-terminal truncations tested in this experiment were N+137, N+134, N+130 and N+l 19.
- the different DNA target sites are indicated as in Figure 12 except that the label is above the cognate lane rather than below it.
- Activity of the nucleases is diminished when the N-terminus is shorter than approximately +134 to +137.
- the amount of DNA loaded in each lane for the 5 bp gap and 8 bp gap targets was uneven so it is difficult to determine if the lower bands in these lanes represent DNA cleavage products or background bands due to inefficient PCR at the inverted repeats.
- Figure 15 panels A and B, depict TALEN activity in K562 cells.
- FIG. 15A depicts the target sequence used in the reporter plasmid for the NTF3 targeting TALE pairs which also includes binding sites for a pair of CCR5-specific ZFNs (8267/8196).
- Figure 15B is a graph depicting the results of the SSA nuclease assay where (- )NT3 R18 C28L8 (light gray bars; C+28 C-cap, L8 linker) depicts data observed when only one member of the NTF3-specific pair was present while (+)NT3 R18 C28L8 (dark gray bars) depicts the results when both members of the pair were present.
- "8267EL8196KK” indicates the results using the CCR5 -specific ZFN pair.
- Figure 16 depicts the results of a Cel-I SurveyorTM mismatch assay
- TALENs The samples, numbered 1-30 are as described in the text. (+) denotes addition of the Cel-I enzyme, (-) denotes the assay without any added enzyme. A band of approximately 226 bp is apparent in most of the samples, indicating a mismatch induced by cleavage of the endogenous NTF3 target by the nuclease, followed by non-homologous end joining which introduces areas of mismatch with the wild type sequence, "gfp" indicates the control where cells were transfected with a GFP encoding plasmid only. The percent NHEJ activity quantitated on the gel is indicated in each sample containing the Cel-I enzyme. The gel demonstrates that the pairs induced targeted locus disruption at up to 8.66% of total alleles in some samples at this endogenous locus in a mammalian cell.
- FIG. 17 panels A through C, depict the activity of NTF3-specific
- FIG. 17A shows the SELEX specificity data for the engineered TALEN protein designated NT-R which is the engineered partner made for the NT-L
- FIG. 17B shows a gel of the results of a Cel-I assay using four NTF3-specific TALEN pairs in K562 cells where the culture conditions were either at 30°C or 37°C. As can be seen from the data presented, the most active pair demonstrated gene modification levels of 3% at 37°C and 9% under cold-shock conditions (30°C) (Doyon et al. (2010) Nat Methods 8(l):74-9. Epub 2010 Dec 5 and U.S. Application No. 12/800,599). 84 amplicons from the PCR pool from the cold-shock study were then sequenced, and seven mutated alleles were identified, which are shown in Figure 17C (SEQ ID NO:343-350). As can be seen, small indels are observed.
- Figure 18, panels A and B depict the sequencing results observed following endogenous cleavage of the NTF3 locus in K562 cells using TALENs.
- Figure 18A depicts the chromosomal sequence (SEQ ID NO:139-140) and the boxes delineate the binding sites for the two TALENs.
- Figure 18B depicts a compilation of sequencing results of the NTF3 locus from cells treated with the different NTF3 TALEN pairs described in Example 8 aligned with the wild-type (“wt") sequence (SEQ ID NO: 141 -175).
- Figure 19 depicts the results of a targeted integration event at an endogenous gene via a DSB induced by the NTF3-specific TALENs.
- Oligonucleotides for capture in the DSB were synthesized to contain overhangs corresponding to all possible sequences within the space between the TALEN binding sites. PCR was done using a set of primers that primed off of the inserted oligonucleotide and a region outside the putative cut site.
- Eight (8) different pairs of NTF3-specific TALENs were tested wherein the pairs are labeled A-H. The legend shows a portion of the gel demonstrating how the lanes are read.
- Figure 20A shows part of the NTF3 target locus (top duplex, SEQ ID ⁇ NO:351) and one of the oligonucleotide duplexes used for this study (bottom duplex, SEQ ID NO:352). Binding sites for NT-L+28 and NT-R+63 are underlined in the top sequence. The cleavage overhang that will most efficiently capture the duplex (5' CTGG) is also
- Figure 20B shows part of the NTF3 target locus (top duplex, SEQ ID NO:353) and the second oligonucleotide duplex used for this study (bottom sequences, SEQ ED NO:354). Binding sites for NT-L+28 and NT-R+63 are underlined in the top sequence. The cleavage overhang that will most efficiently capture this second duplex (5' TGGT) is also shown.
- Figure 20C (SEQ ID NO:355-357) shows results following expression of NT-L+28 and NT-R+63 in K562 cells in the presence of the oligonucleotide duplex shown in Figure 20A.
- junctions between successfully integrated duplex and genomic DNA were then amplified using one primer that anneals within the duplex and one primer that anneals to the native NTF3 locus.
- the resulting amplicons were cloned and sequenced.
- the "expected" sequence at top indicates the sequence that would result from a perfect ligation of
- FIG. 20D shows results from experiments as shown in Figure 20C except that the oligonucleotide duplex shown in Figure 20B was used, which has a 4 bp overhang that is shifted by one base relative to the duplex shown in Figure 20 A.
- the lowest four lines provide junction sequences obtained from this study. As shown, four distinct sequences were identified, which each exhibit short deletions consistent with resection prior to NHEJ-mediated repair.
- Figure 21 depicts several of the potential secondary DNA structures predicted to form in the natural TALE repeat domain during PCR amplification that can disrupt efficient amplification of the template.
- Analysis of the DNA sequence of the TALE -repeat protein was done using Mfold (M. Zuker Nucleic Acids Res. 31(13):3406-15, (2003)). 800 base pairs of the nucleic acid sequence were analyzed starting at the 5' end of the nucleic acid encoding the first full TALE repeat sequence. The sequence analyzed contained
- Figure 22 depicts pictoral results of in silico analysis of 1963 TALE repeats from Xanthomonas bacteria displaying the conserved amino acids at each position in the 34 amino acid repeat unit.
- Letter size is inversely related to observed diversity at any given position: larger letters indicate less tolerance of diversity while smaller letters indicate the alternate amino acids that can be observed at a given location. Different shades of color represent different chemical classes of the amino acids.
- RVDs were: 28.8% HD; 20.6% NI, 15.1% NN; 13.2% NG; 8.5% NS; 5.5% HG; and 5.5% NG* (where the asterisk indicates the RVD was observed in a 33- residue TALE repeat instead of the more typical 34-residue repeat). 15 other RVD sequences were observed in this sample, but these all had frequencies below 1 %.
- Figure 23 depicts a schematic of the method used to tandemly link PCR amplicons of selected TALE repeat modules and ligate them into a vector backbone to create the desired TALE fusion protein. Specific primers are listed in Example 1 1. Also depicted is the vector backbone into which the assembled TALE fusion is cloned.
- the fusion partner domain is a FokI nuclease catalytic domain to allow production of one member of a TALEN pair.
- Figure 24, panels A and B depict the use of TALENs to drive homology- based transfer of a short segment of heterology encoding a RFLP into the endogenous CCR5 locus.
- Figure 24A shows a schematic for the assay, and depicts the location of the PCR primers used and the Bgl I site.
- Figure 24B depicts a gel showing insertion of a 46 bp donor sequence into a DSB introduced by a CCR5-specific TALEN pair.
- the donor sequence contains a unique BglI restriction site, so upon PCR amplification of the target site and then digestion of the PCR product with BglI, sequences that have been cleaved by the TALEN pair and have had insertion of the 46 bp donor sequence will have two BglI cleavage products, as indicated in the Figure.
- FIG 25, panels A and B, are graphs depicting the cleavage efficacy of
- Figure 25 A depicts the activity of a panel of CCR5-specific TALEN pair with a +28/+28 pairing (C+28 C-cap on both TALENs) while Figure 25B depicts the activity of a panel CCR5-specific TALEN pair comprising a +63/+63 pairing (C+63 C-cap on both TALENs).
- the activity of the +28/+28 pair is more tightly constrained to a 12 or 13 bp gap spacing between the two target sequences while the +63/+63 pair exhibits activity across a gap spacing range of 12-23 bp.
- Figure 26 is a graph depicting the endogenous activity of a CCR5-specific
- TALEN pair with different length C-cap sequences or stated another way, different sequences linking the array of full TALE repeats to the nuclease domain.
- C terminal truncations were made across the C-terminal sequence to yield C-caps from C-2 to C+278.
- These constructs were tested for TALEN activity in K562 cells against an endogenous target with an 18 bp gap spacing where the cells were incubated at either 37°C (light squares) or cold shock conditions (30°C, dark diamonds). The activity was highly dependent on the identity of the sequence used to connect the array of full TALE repeats with the Fokl cleavage domain.
- Figure 27 depicts the specificity of an exemplary TALEN chosen for RVD analysis.
- the TALEN was designed to bind to the 11 base target sequence 5'- TTGAC AATCCT-3 ' (SEQ ID NO: 178). Shown are the DNA binding results determine by ELISA analysis when this target is altered at position 6, such that the identity of the target at positions 5-7 is either CAA (designed target), CGA, TCG or TTG.
- Figure 28 is a graphical display of the ELISA affinities measured for all the
- RVDs tested The data are shown in a 20x20 grid where the first amino acid of the RVD (position 12) is indicated on the vertical left of the grid and the second amino acid of the RVD (position 13) is indicated horizontally above the grid.
- the size of the letters A, C, G, and T in each grid is scaled based on the square root of the normalized ELISA signal for the CAA site, CCA site, and CGA site and CTA site respectively.
- Many RVDs have improved DNA binding properties with respect to the naturally occurring HD, NI, NG, NS, NN, IG, HG, and NK RVDs.
- the four RVDs that are the most frequently found in nature (HD, NG, NI, and NN) are boxed for reference. For these four RVDs, the preferred base by ELISA matched expected preferred base.
- Figure 29 are gels depicting the results of measurements of activity of
- FIGS. 1-10 are gels depicting the measurement of TALEN activity using
- TALENs that have TALE repeat units comprising either fully atypical RVDs (Fully
- repeat domains where all the repeat units of one type or specificity have been substituted e.g. all repeat units with RVDs that specify 'T' etc.
- atypical RVDs Type Substitutions
- TALENs where only one repeat unit with the array has been substituted with an atypical RVD-comprising repeat unit
- Activity assays were carried out either at 37 degrees or under cold shock conditions (30 degrees), and quantitation of any measurable NHEJ activity is indicated on the lanes.
- Figure 31 is a series of gels depicting the presence of NHEJ events in rat pups born following TALEN treatment of rat embryos. Genomic DNA was isolated from the pups and PCR was performed on the region surrounding the nuclease target site. The product was then examined for NHEJ induced mismatches using the T7 endonuclease. The arrow indicates the band that is produced from the presence of a mismatch. 7 of 66 pups examined (11%) were positive for an NHEJ event.
- TALE-repeat domains can be engineered to recognize a desired endogenous DNA sequence and that fusing functional domains to such engineered TALE-repeat domains can be used to modify the functional state, or the actual genomic DNA sequence of an endogenous cellular locus, including a gene, that is present in its native chromatin environment.
- the present invention thus provides TALE- fusion DNA binding proteins that have been engineered to specifically recognize, with high efficacy, endogenous cellular loci including genes.
- the TALE-fusions of the invention can be used to regulate endogenous gene expression, both through activation and repression of endogenous gene transcription.
- the TALE-fusions can also be linked to other regulatory or functional domains, for example nucleases, transposases or methylases, to modify endogenous chromosomal sequences.
- compositions described herein allow for novel human and mammalian therapeutic applications, e.g., treatment of genetic diseases, cancer, fungal, protozoal, bacterial, and viral infection, ischemia, vascular disease, arthritis, immunological disorders, etc., as well as providing for functional genomics assays, and generating engineered cell lines for research and drug screening, and means for developing plants with altered phenotypes, including but not limited to, increased disease resistance, and altering fruit ripening characteristics, sugar and oil composition, yield, and color.
- two or more TALE-fusions can be administered to any cell, recognizing either the same target endogenous cellular gene, or different target endogenous cellular genes.
- the TALE-fusion protein is linked to at least one or more regulatory domains, described below.
- regulatory or functional domains include transcription factor repressor or activator domains such as KRAB and VP 16, co-repressor and co-activator domains, DNA methyl transferases, histone acetyltransferases, histone deacetylases, and DNA cleavage domains such as the cleavage domain from the endonuclease Fokl.
- compositions and methods including fusion proteins comprising one or more TALE -repeat units, an N-cap and, optionally, a C-cap fused to nuclease domains useful for genomic editing (e.g., cleaving of genes; alteration of genes, for example by cleavage followed by insertion (physical insertion or insertion via homology- directed repair) of an exogenous sequence and/or cleavage followed by NHEJ; partial or complete inactivation of one or more genes; generation of alleles with altered functional states of endogenous genes, insertion of regulatory elements; etc.) and alterations of the genome which are carried into the germline.
- genomic editing e.g., cleaving of genes; alteration of genes, for example by cleavage followed by insertion (physical insertion or insertion via homology- directed repair) of an exogenous sequence and/or cleavage followed by NHEJ; partial or complete inactivation of one or more genes; generation of alleles with altered functional states of endogenous genes
- compositions for example to edit (alter) one or more genes in a target cell.
- methods of making and using these compositions provide highly efficient methods for targeted gene alteration (e.g., knock-in) and/or knockout (partial or complete) of one or more genes and/or for randomized mutation of the sequence of any target allele, and, therefore, allow for the generation of animal models of human diseases.
- compositions (C-caps) for linking a nuclease domain to a TALE repeat array that provide highly active nuclease function.
- the C-cap comprises peptide sequence from a native TALE C-terminal flanking sequence.
- the C-cap comprises peptide sequence from a TALE repeat domain.
- the C-cap comprises non-TALE sequences.
- C-caps may also exhibit a chimeric structure, containing peptide sequences from native TALE C-terminal flanking sequence and/or TALE repeat domains and/or neither of these sources.
- TALENs can also be engineered to allow the insertion of a donor of interest into a safe harbor locus such as AAVS1 (see co-owned US Patent Publication 20080299580) or CCR5 (see co-owned United States Patent Publication 20080159996).
- the donor can comprise a gene of interest or can encode an RNA of interest such as an shRNA, RNAi or miRNA.
- engineered TALE-fusion proteins e.g., transcriptional activators, transcriptional repressors and nucleases
- TALE-fusion proteins e.g., transcriptional activators, transcriptional repressors and nucleases
- tet-regulated systems and the RU-486 system see, e.g., Gossen & Bujard, Proc Natl Acad Sci 89:5547 (1992); Oligino et al, Gene Ther. 5:491-496 (1998); Wang et al, Gene Ther. 4:432-441 (1997); Neering et al, Blood 88:1 147-1 155 (1996); and Rendahl et al, Nat. Biotechnol. 16:757-761 (1998)).
- TALE- fusion activators and repressors impart small molecule control on the expression of the TALE- fusion activators and repressors and thus impart small molecule control on the target gene(s) of interest.
- This beneficial feature could be used in cell culture models, in gene therapy, and in transgenic animals and plants.
- compositions disclosed herein employ, unless otherwise indicated, conventional techniques in molecular biology, biochemistry, chromatin structure and analysis, computational chemistry, cell culture, recombinant DNA and related fields as are within the skill of the art.
- nucleic acid refers to a deoxyribonucleotide or ribonucleotide polymer, in linear or circular conformation, and in either single- or double-stranded form.
- polynucleotide refers to a deoxyribonucleotide or ribonucleotide polymer, in linear or circular conformation, and in either single- or double-stranded form.
- these terms are not to be construed as limiting with respect to the length of a polymer.
- the terms can encompass known analogues of natural nucleotides, as well as nucleotides that are modified in the base, sugar and/or phosphate moieties (e.g., phosphorothioate backbones).
- an analogue of a particular nucleotide has the same base-pairing specificity; i.e., an analogue of A will base-pair with T.
- polypeptide peptide
- protein protein
- amino acid polymers in which one or more amino acids are chemical analogues or modified derivatives of a corresponding naturally- occurring amino acids.
- Binding refers to a sequence-specific, non-covalent interaction between macromolecules (e.g., between a protein and a nucleic acid). Not all components of a
- binding interaction need be sequence-specific (e.g., contacts with phosphate residues in a
- a "binding protein” is a protein that is able to bind non-covalently to another molecule.
- a binding protein can bind to, for example, a DNA molecule (a DNA-binding protein), an RNA molecule (an RNA-binding protein) and/or a protein molecule (a protein-binding protein).
- a DNA-binding protein a DNA-binding protein
- an RNA-binding protein an RNA-binding protein
- a protein-binding protein it can bind to itself (to form homodimers, homotrimers, etc.) and/or it can bind to one or more molecules of a different protein or proteins.
- a binding protein can have more than one type of binding activity. For example, zinc-finger proteins have DNA-binding, RNA-binding and protein-binding activity.
- a "TALE-repeat domain” (also “repeat array”) is a sequence that is involved in the binding of the TALE to its cognate target DNA sequence and that comprises one o more TALE “repeat units.”
- a single “repeat unit” (also referred to as a “repeat”) is typically 33-35 amino acids in length and exhibits at least some sequence homology with other TALE repeat sequences within a naturally occurring TALE protein.
- a TALE repeat unit as described herein is generally of the form (X) 1 to 11 -(X RVD ) 2 -(X) 20 -22 (SEQ ID NO:399) where X RVD (positions 12 and 13) exhibit hypervariability in naturally occurring TALE proteins.
- Altering the identity of the amino acids at positions 12 and 13 can alter the preference for the identity of the DNA nucleotide (or pair of complementary nucleotides in double-stranded DNA) with which the repeat unit interacts.
- An "atypical" RVD is an RVD sequence (positions 12 and 13) that occurs infrequently or never in nature, for example, in less than 5% of naturally occurring TALE proteins, preferably in less than 2% of naturally occurring TALE proteins and even more preferably less than 1% of naturally occurring TALE proteins.
- An atypical RVD can be non-naturally occurring.
- N-cap polypeptide and N-terminal sequence are used to refer to an amino acid sequence (polypetide) that flanks the N-terminal portion of the TALE repeat domain.
- the N-cap sequence can be of any length (including no amino acids), so long as the TALE-repeat domain(s) function to bind DNA.
- an N-cap sequence may be involved in supplying proper structural stabilization for the TALE repeat domain and/or nonspecific contacts with DNA.
- An N- cap sequence may be naturally occurring or non-naturally occurring, for example it may be derived from the N-terminal region of any full length TALE protein.
- the N-cap sequence is preferably a fragment (truncation) of a polypeptide found in full-length TALE proteins, for example any truncation of a N-terminal region flanking the TALE repeat domain in a naturally occurring TALE protein that is sufficient to support DNA-binding function of the TALE-repeat domain or provide support for TALE fusion protein activity.
- each TALE-repeat unit comprises a typical RVD and/or when the C-cap comprises a full-length naturally occurring C- terminal region of a TALE protein, the N-cap sequence does not comprise a full-length N-terminal region of a naturally occurring TALE protein.
- this sequence is not necessarily involved in DNA recognition, but may enhance efficient and specific function at endogenous target DNA or efficient activity of the TALE fusion protein.
- the portion of the N- cap sequence closest to the N-terminal portion of the TALE repeat domain may bear some homology to a TALE repeat unit and is referred to as the "R0 repeat.”
- the preferred nucleotide to the position immediately 5' of the target site is thymidine (T). It may be that the R0 repeat portion of the N-cap prefers to interact with a T (or the A base-paired to the T in double- stranded DNA) adjacent to the target sequence specified by the TALE repeats. Shown below is one example of an R0 sequence:
- C-cap or "C-terminal region” refers to optionally present amino acid sequences (polypeptides) that may be flanking the C-terminal portion of the TALE repeat domain.
- the C-cap can also comprise any part of a terminal C-terminal TALE repeat, including 0 residues, truncations of a TALE repeat or a full TALE repeat.
- the first 20 residues of the C-terminal region are typically homologous to the first 20 residues of a TALE repeat unit and may contain an RVD sequence capable of specifying the preference of nucleotides 3' of the DNA sequence specified by the TALE repeat domain.
- this portion of the C-terminal region homologous to the first 20 residues of a TALE repeat is also referred to as the "half repeat.”
- the numbering scheme of residues in the C-terminal region reflects this typical partial homology where the number scheme starts at C-20, increments to C-19, C-18, C-17, C-16, C-15, C-14, C-13, C-12, C-l 1, C-10, C-9, C-8, C-7, C-6, C-5, C-4, C-3, C-2, C-l, increments to C+l, and then increments to C+2, C+3, etc. towards the C-terminus of the polypeptide.
- a C+28 C-cap refers to the sequence from residue C-20 to residue C+28 (inclusive) and thus has a length of 48 residues.
- the C-cap sequences may be naturally occurring (e.g., fragments of naturally occurring proteins) or non-naturally occurring (e.g., a fragment of a naturally occurring protein comprising one or more amino acid deletions, substitutions and/or additions), or any other natural or non-natural sequence with the ability to act as a C cap.
- the C-terminal region is not absolutely required for the DNA-binding function of the TALE repeat domain(s), but, in some embodiments, a C-cap may interact with DNA and also may enhance the activity of functional domains, for example in a fusion protein comprising a nuclease at the C-terminal to the TALE repeat domain.
- a "zinc-finger DNA binding protein” (or binding domain) is a protein, or a domain within a larger protein, that binds DNA in a sequence-specific manner through one or more zinc- fingers, which are regions of amino acid sequence within the binding domain whose structure is stabilized through coordination of a zinc ion.
- the term zinc-finger DNA binding protein is often abbreviated as zinc-finger protein or ZFP.
- a "selected" zinc-finger protein or protein comprising a TALE- repeat domain is a protein whose production results primarily from an empirical process such as phage display, interaction trap or hybrid selection. See e.g., US 5,789,538; US 5,925,523; US 6,007,988; US 6,013,453; US 6,200,759; WO 95/19431 ; WO 96/06166; WO 98/53057; WO 98/54311 ; WO 00/27878; WO 01/60970 WO 01/88197 and WO 02/099084.
- sequence refers to a nucleotide sequence of any length, which can be
- DNA or RNA can be linear, circular or branched and can be either single-stranded or double stranded.
- donor sequence refers to a nucleotide sequence that is inserted into a genome.
- a donor sequence can be of any length, for example between 2 and 10,000 nucleotides in length (or any integer value therebetween or thereabove), preferably between about 100 and 1 ,000 nucleotides in length (or any integer therebetween), more preferably between about 200 and 500 nucleotides in length.
- a "homologous, non-identical sequence” refers to a first sequence which shares a degree of sequence identity with a second sequence, but whose sequence is not identical to that of the second sequence.
- a polynucleotide comprising the wild-type sequence of a mutant gene is homologous and non-identical to the sequence of the mutant gene.
- the degree of homology between the two sequences is sufficient to allow homologous recombination therebetween, utilizing normal cellular mechanisms.
- Two homologous non-identical sequences can be any length and their degree of non-homology can be as small as a single nucleotide (e.g., for correction of a genomic point mutation by targeted homologous recombination) or as large as 10 or more kilobases (e.g., for insertion of a gene at a predetermined ectopic site in a chromosome).
- Two polynucleotides comprising the homologous non-identical sequences need not be the same length.
- an exogenous polynucleotide i.e., donor polynucleotide
- an exogenous polynucleotide i.e., donor polynucleotide of between 20 and 10,000 nucleotides or nucleotide pairs can be used.
- nucleic acid and amino acid sequence identity are known in the art. Typically, such techniques include determining the nucleotide sequence of the mRNA for a gene and/or determining the amino acid sequence encoded thereby, and comparing these sequences to a second nucleotide or amino acid sequence. Genomic sequences can also be determined and compared in this fashion. In general, identity refers to an exact nucleotide-to- nucleotide or amino acid-to-amino acid correspondence of two polynucleotides or polypeptide sequences, respectively. Two or more sequences (polynucleotide or amino acid) can be compared by determining their percent identity. The percent identity of two sequences, whether nucleic acid or amino acid sequences, is the number of exact matches between two aligned sequences divided by the length of the shorter sequences and multiplied by 100.
- the degree of sequence similarity between polynucleotides can be determined by hybridization of polynucleotides under conditions that allow formation of stable duplexes between homologous regions, followed by digestion with single-stranded-specific nuclease(s), and size determination of the digested fragments.
- Two nucleic acid, or two polypeptide sequences are substantially homologous to each other when the sequences exhibit at least about 70%-75%, preferably 80%-82%, more preferably 85%-90%, even more preferably 92%, still more preferably 95%, and most preferably 98% sequence identity over a defined length of the molecules, as determined using the methods above.
- substantially homologous also refers to sequences showing complete identity to a specified DNA or
- DNA sequences that are substantially homologous can be identified in a Southern hybridization experiment under, for example, stringent conditions, as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Sambrook et al., supra; Nucleic Acid Hybridization: A Practical Approach, editors B.D. Hames and S.J. Higgins, (1985) Oxford; Washington, DC; I L Press).
- Recombination refers to a process of exchange of genetic information between two polynucleotides.
- HR homologous recombination
- This process requires nucleotide sequence homology, uses a "donor” molecule to template repair of a "target” molecule (i.e., the one that experienced the double-strand break), and is variously known as “non-crossover gene conversion” or “short tract gene conversion,” because it leads to the transfer of genetic information from the donor to the target.
- such transfer can involve mismatch correction of heteroduplex DNA that forms between the broken target and the donor, and/or "synthesis-dependent strand annealing," in which the donor is used to resynthesize genetic information that will become part of the target, and/or related processes.
- Such specialized HR often results in an alteration of the sequence of the target molecule such that part or all of the sequence of the donor polynucleotide is incorporated into the target polynucleotide.
- one or more targeted nucleases as described herein create a double-stranded break in the target sequence (e.g., cellular chromatin) at a predetermined site, and a "donor" polynucleotide, having homology to the nucleotide sequence in the region of the break, can be introduced into the cell.
- a "donor" polynucleotide having homology to the nucleotide sequence in the region of the break
- the presence of the double-stranded break has been shown to facilitate integration of the donor sequence.
- the donor sequence may be physically integrated or, alternatively, the donor polynucleotide is used as a template for repair of the break via homologous recombination, resulting in the introduction of all or part of the nucleotide sequence as in the donor into the cellular chromatin.
- a first sequence in cellular chromatin can be altered and, in certain embodiments, can be converted into a sequence present in a donor polynucleotide.
- the use of the terms "replace” or “replacement” can be understood to represent replacement of one nucleotide sequence by another, (i.e., replacement of a sequence in the informational sense), and does not necessarily require physical or chemical replacement of one polynucleotide by another.
- two DSBs are introduced by the targeted nucleases described herein, resulting in the deletion of the DNA in between the DSBs.
- the "donor" polynucleotides are inserted between these two DSBs.
- portions of the donor sequence that are homologous to sequences in the region of interest exhibit between about 80 to 99% (or any integer
- the homology between the donor and genomic sequence is higher than 99%, for example if only 1 nucleotide differs as between donor and genomic sequences of over 100 contiguous base pairs.
- a non-homologous portion of the donor sequence can contain sequences not present in the region of interest, such that new sequences are introduced into the region of interest.
- the non-homologous sequence is generally flanked by sequences of 50-1,000 base pairs (or any integral value therebetween) or any number of base pairs greater than 1,000, that are homologous or identical to sequences in the region of interest.
- the donor sequence is non-homologous to the first sequence, and is inserted into the genome by nonhomologous recombination mechanisms.
- additional TALE-fusion proteins fused to nuclease domains as well as additional pairs of TALE- (or zinc finger) nucleases can be used for additional double-stranded cleavage of additional target sites within the cell.
- Any of the methods described herein can be used for partial or complete inactivation of one or more target sequences in a cell by targeted integration of donor sequence that disrupts expression of the gene(s) of interest.
- Cell lines with partially or completely inactivated genes are also provided.
- the methods of targeted integration as described herein can also be used to integrate one or more exogenous sequences.
- the exogenous nucleic acid sequence can comprise, for example, one or more genes or cDNA molecules, or any type of coding or noncoding sequence, as well as one or more control elements (e.g., promoters).
- the exogenous nucleic acid sequence may produce one or more RNA molecules (e.g., small hairpin RNAs (shRNAs), inhibitory RNAs (RNAis), microRNAs (miRNAs), etc.).
- Cleavage can be initiated by a variety of methods including, but not limited to, enzymatic or chemical hydrolysis of a phosphodiester bond. Both single-stranded cleavage and double-stranded cleavage are possible, and double-stranded cleavage can occur as a result of two distinct single-stranded cleavage events. DNA cleavage can result in the production of either blunt ends or staggered ends. In certain embodiments, fusion
- polypeptides are used for targeted double-stranded DNA cleavage.
- a "cleavage half-domain” is a polypeptide sequence which, in conjunction with a second polypeptide (either identical or different) forms a complex having cleavage activity (preferably double-strand cleavage activity).
- first and second cleavage half-domains;" “+ and - cleavage half-domains” and “right and left cleavage half-domains” are used interchangeably to refer to pairs of cleavage half-domains that dimerize.
- An "engineered cleavage half-domain” is a cleavage half-domain that has been modified so as to form obligate heterodimers with another cleavage half-domain (e.g., another engineered cleavage half-domain). See, also, U.S. Patent Publication Nos.
- Chromatin is the nucleoprotein structure comprising the cellular genome.
- Cellular chromatin comprises nucleic acid, primarily DNA, and protein, including histones and non-histone chromosomal proteins.
- the majority of eukaryotic cellular chromatin exists in the form of nucleosomes, wherein a nucleosome core comprises approximately 150 base pairs of DNA associated with an octamer comprising two each of histones H2A, H2B, H3 and H4; and linker DNA (of variable length depending on the organism) extends between nucleosome cores.
- a molecule of histone HI is generally associated with the linker DNA.
- chromatin is meant to encompass all types of cellular nucleoprotein, both prokaryotic and eukaryotic.
- Cellular chromatin includes both chromosomal and episomal chromatin.
- a "chromosome,” is a chromatin complex comprising all or a portion of the genome of a cell.
- the genome of a cell is often characterized by its karyotype, which is the collection of all the chromosomes that comprise the genome of the cell.
- the genome of a cell can comprise one or more chromosomes.
- An "episome” is a replicating nucleic acid, nucleoprotein complex or other structure comprising a nucleic acid that is not part of the chromosomal karyotype of a cell.
- Examples of episomes include plasmids and certain viral genomes.
- a "target site” or “target sequence” is a nucleic acid sequence that defines a portion of a nucleic acid to which a binding molecule will bind, provided sufficient conditions for binding exist.
- the sequence 5'-GAATTC-3' is a target site for the Eco RI restriction endonuclease.
- Plant cells include, but are not limited to, cells of monocotyledonous
- Non-limiting examples of monocots include cereal plants such as maize, rice, barley, oats, wheat, sorghum, rye, sugarcane, pineapple, onion, banana, and coconut.
- Non-limiting examples of dicots include tobacco, tomato, sunflower, cotton, sugarbeet, potato, lettuce, melon, soybean, canola (rapeseed), and alfalfa.
- Plant cells may be from any part of the plant and/or from any stage of plant development.
- exogenous molecule is a molecule that is not normally present in a cell, but can be introduced into a cell by one or more genetic, biochemical or other methods.
- Normal presence in the cell is determined with respect to the particular developmental stage and environmental conditions of the cell.
- a molecule that is present only during embryonic development of muscle is an exogenous molecule with respect to an adult muscle cell.
- a molecule induced by heat shock is an exogenous molecule with respect to a non-heat-shocked cell.
- An exogenous molecule can comprise, for example, a functioning version of a malfunctioning endogenous molecule or a malfunctioning version of a normally-functioning endogenous molecule.
- An exogenous molecule can also be a molecule normally found in another species, for example, a human sequence introduced into an animal's genome.
- An exogenous molecule can be, among other things, a small molecule, such as is generated by a combinatorial chemistry process, or a macromolecule such as a protein, nucleic acid, carbohydrate, lipid, glycoprotein, lipoprotein, polysaccharide, any modified derivative of the above molecules, or any complex comprising one or more of the above molecules.
- Nucleic acids include DNA and RNA, can be single- or double-stranded; can be linear, branched or circular; and can be of any length. Nucleic acids include those capable of forming duplexes, as well as triplex-forming nucleic acids. See, for example, U.S. Patent Nos. 5,176,996 and 5,422,251.
- Proteins include, but are not limited to, DNA-binding proteins, transcription factors, chromatin remodeling factors, methylated DNA binding proteins, polymerases, methylases, demethylases, acetylases, deacetylases, kinases, phosphatases, integrases, recombinases, ligases, topoisomerases, gyrases and helicases.
- an exogenous molecule can be the same type of molecule as an endogenous molecule, e.g., an exogenous protein or nucleic acid.
- an exogenous nucleic acid can comprise an infecting viral genome, a plasmid or episome introduced into a cell, or a chromosome that is not normally present in the cell.
- Methods for the introduction of exogenous molecules into cells include, but are not limited to, lipid-mediated transfer (i.e., liposomes, including neutral and cationic lipids), electroporation, direct injection, cell fusion, particle bombardment, calcium phosphate co- precipitation, DEAE-dextran-mediated transfer and viral vector-mediated transfer.
- an "endogenous" molecule is one that is normally present in a particular cell at a particular developmental stage under particular environmental conditions.
- an endogenous nucleic acid can comprise a chromosome, the genome of a mitochondrion, chloroplast or other organelle, or a naturally-occurring episomal nucleic acid.
- Additional endogenous molecules can include proteins, for example, transcription factors and enzymes.
- a "fusion" molecule is a molecule in which two or more subunit molecules are linked, preferably covalently.
- the subunit molecules can be the same chemical type of molecule, or can be different chemical types of molecules.
- Examples of the first type of fusion molecule include, but are not limited to, fusion proteins (for example, a fusion between a TALE-repeat domain and a cleavage domain) and fusion nucleic acids (for example, a nucleic acid encoding the fusion protein described supra).
- Examples of the second type of fusion molecule include, but are not limited to, a fusion between a triplex - forming nucleic acid and a polypeptide, and a fusion between a minor groove binder and a nucleic acid.
- Fusion protein in a cell can result from delivery of the fusion protein to the cell or by delivery of a polynucleotide encoding the fusion protein to a cell, wherein the polynucleotide is transcribed, and the transcript is translated, to generate the fusion protein.
- Trans-splicing, polypeptide cleavage and polypeptide ligation can also be involved in expression of a protein in a cell. Methods for polynucleotide and polypeptide delivery to cells are presented elsewhere in this disclosure.
- Gene expression refers to the conversion of the information, contained in a gene, into a gene product.
- a gene product can be the direct transcriptional product of a gene (e.g., mRNA, tRNA, rRNA, antisense RNA, ribozyme, structural RNA, shRNA, RNAi, miRNA or any other type of RNA) or a protein produced by translation of a mRNA.
- Gene products also include RNAs which are modified, by processes such as capping,
- polyadenylation polyadenylation, methylation, and editing, and proteins modified by, for example, methylation, acetylation, phosphorylation, ubiquitination, ADP-ribosylation, myristilation, and glycosylation.
- Gap size refers to the nucleotides between the two TALE targets sites on the nucleic acid target. Gaps can be any size, including but not limited to between 1 and 100 base pairs, or 5 and 30 base pairs, preferably between 10 and 25 base pairs, and more preferably between 12 and 21 base pairs. Thus, a preferable gap size may be 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 base pairs.
- Modulation of gene expression refers to a change in the activity of a gene.
- Modulation of expression can include, but is not limited to, gene activation and gene repression.
- Genome editing e.g., cleavage, alteration, inactivation, donor integration, random mutation
- Gene inactivation refers to any reduction in gene expression as compared to a cell that does not include a modifier as described herein. Thus, gene inactivation may be partial or complete.
- a "region of interest" is any region of cellular chromatin, such as, for example, a gene or a non-coding sequence within or adjacent to a gene, in which it is desirable to bind an exogenous molecule. Binding can be for the purposes of targeted DNA cleavage and/or targeted recombination.
- a region of interest can be present in a
- a region of interest can be within the coding region of a gene, within transcribed non-coding regions such as, for example, leader sequences, trailer sequences or introns, or within non-transcribed regions, either upstream or downstream of the coding region.
- a region of interest can be as small as a single nucleotide pair or up to 2,000 nucleotide pairs in length, or any integral value of nucleotide pairs.
- operative linkage and "operatively linked” (or “operably linked”) are used interchangeably with reference to a juxtaposition of two or more components (such as sequence elements), in which the components are arranged such that both components function normally and allow the possibility that at least one of the components can mediate a function that is exerted upon at least one of the other components.
- a transcriptional regulatory sequence such as a promoter
- a transcriptional regulatory sequence is generally operatively linked in cis with a coding sequence, but need not be directly adjacent to it.
- an enhancer is a transcriptional regulatory sequence that is operatively linked to a coding sequence, even though they are not contiguous.
- the term "operatively linked" can refer to the fact that each of the components performs the same function in linkage to the other component as it would if it were not so linked.
- the TALE-repeat domain and the cleavage domain are in operative linkage if, in the fusion polypeptide, the TALE-repeat domain portion is able to bind its target site and/or its binding site, while the cleavage domain is able to cleave DNA in the vicinity of the target site.
- a "functional fragment" of a protein, polypeptide or nucleic acid is a protein, polypeptide or nucleic acid whose sequence is not identical to the full-length protein, polypeptide or nucleic acid, yet retains the same or has enhanced function as compared to the full-length protein, polypeptide or nucleic acid. Additionally, a functional fragment may have lesser function than the full-length protein, polypeptide or nucleic acid, but still have adequate function as defined by the user. A functional fragment can possess more, fewer, or the same number of residues as the corresponding native molecule, and/or can contain one or more amino acid or nucleotide substitutions.
- nucleic acid e.g., coding function, ability to hybridize to another nucleic acid
- DNA-binding function of a polypeptide can be determined, for example, by filter-binding, electrophoretic mobility-shift, or immunoprecipitation assays. DNA cleavage can be assayed by gel electrophoresis. See Ausubel et ah, supra.
- the ability of a protein to interact with another protein can be determined, for example, by co-immunoprecipitation, two-hybrid assays or complementation, both genetic and biochemical. See, for example, Fields et al (1989) Nature 340:245-246; U.S. Patent No. 5,585,245 and PCT WO 98/44350.
- TALE-repeat domains can be "engineered” to bind to a predetermined nucleotide sequence, for example via engineering (altering one or more amino acids) of the hypervariable diresidue region, for example positions 12 and/or 13 of a repeat unit within a TALE protein.
- the amino acids at positions 4, 1 1, and 32 may be engineered.
- atypical RVDs may be selected for use in an engineered TALE protein, enabling specification of a wider range of non-natural target sites.
- a NK RVD may be selected for use in recognizing a G nucleotide in the target sequence.
- amino acids in the repeat unit may be altered to change the characteristics (i.e.
- engineered TALE proteins are proteins that are non-naturally occurring.
- the genes encoding TALE repeat domains are engineered at the DNA level such that the codons specifying the TALE repeat amino acids are altered, but the specified amino acids are not (e.g., via known techniques of codon optimization).
- Non-limiting examples of engineered TALE proteins are those obtained by design and/or selection.
- a designed TALE protein is a protein not occurring in nature whose design/composition results principally from rational criteria. Rational criteria for design include application of substitution rules and
- a "selected" TALE- repeat domain is a non- naturally occurring or atypical domain whose production results primarily from an empirical process such as phage display, interaction trap or hybrid selection.
- a "multimerization domain” is a domain incorporated at the amino, carboxy or amino and carboxy terminal regions of a TALE-fusion protein. These domains allow for multimerization of multiple TALE-fusion protein units. Examples of multimerization domains include leucine zippers. Multimerization domains may also be regulated by small molecules wherein the multimerization domain assumes a proper conformation to allow for interaction with another multimerization domain only in the presence of a small molecule or external ligand. In this way, exogenous ligands can be used to regulate the activity of these domains.
- the target sites useful in the above methods can be subject to evaluation by other criteria or can be used directly for design or selection (if needed) and production of a TALE- fusion protein specific for such a site.
- a further criterion for evaluating potential target sites is their proximity to particular regions within a gene. Target sites can be selected that do not necessarily include or overlap segments of demonstrable biological significance with target genes, such as regulatory sequences. Other criteria for further evaluating target segments include the prior availability of TALE- fusion proteins binding to such segments or related segments, and/or ease of designing new TALE- fusion proteins to bind a given target segment.
- a TALE- fusion protein that binds to the segment can be provided by a variety of approaches. Once a TALE- fusion protein has been selected, designed, or otherwise provided to a given target segment, the TALE- fusion protein or the DNA encoding it are synthesized. Exemplary methods for synthesizing and expressing DNA encoding TALE-repeat domain-containing proteins are described below. The TALE- fusion protein or a polynucleotide encoding it can then be used for modulation of expression, or analysis of the target gene containing the target site to which the TALE- fusion protein binds.
- polypeptides described herein comprise one or more (e.g., 1, 2, 3, 4, 5, 6,
- TALE-repeat units 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or even more TALE-repeat units.
- TALE DNA binding domains comprising multiple TALE-repeat units, have been studied to determine the sequences responsible for specificity. Within one organism, the TALE repeats typically are highly conserved (except for the RVD) but may not be well conserved across different species.
- a TALE-repeat unit as found in the polypeptides described herein is generally of the form: X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 -X 10 -X 11 -(X RVD ) 2 -(X) 2 o -22 (SEQ ID NO:399), where X is any amino acid and X RVD (positions 12 and 13) involved in DNA binding.
- Non- limiting exemplary embodiments of such domains include: embodiments in which X 1 comprises a leucine (L), or methionine (M) residue; embodiments in which X comprises an alanine (A) residue or a valine (V) residue; embodiments in which (X) 20-22 comprises the sequence (Gly or Ser)-(X) 19-21 (SEQ ID NO:400); embodiments in which (X) 20-22 comprises the sequence (X) 3-4 -(Ala or Thr)-(X) 16-17 (SEQ ID NO:401); embodiments in which (X) 20-22 comprises the sequence (X) 4-5 -(Leu or Val)-(X) 15-16 (SEQ ID NO:402); ; and combinations of any of the above embodiments (e.g., X 1 comprises a leucine (L) or methionine (M) residue and X 10 comprises an alanine (A) residue; X 1 comprises L or M and (X)2o-22 comprises the sequence Gly/Ser-
- the TALE-repeat units of the compositions and methods described herein may be derived from any suitable TALE-protein.
- TALE proteins include TALE proteins derived from Ralstonia spp. or Xanthamonas spp..
- the DNA-binding domain comprises one or more one or more naturally occurring and/or engineered TALE-repeat units derived from the plant pathogen
- the DNA-binding domain comprises one or more naturally occurring and/or engineered TALE-repeat units derived from the plant pathogen Ralstonia solanacearum, or other TALE DNA binding domain from the TALE protein family.
- the TALE DNA binding domains as described herein can include (i) one or more TALE repeat units not found in nature; (ii) one or more naturally occurring TALE repeat units; (iii) one or more TALE repeat units with atypical RVDs; and combinations of (i), (ii) and/or (iii).
- a TALE DNA binding domain of the invention consists of completely non-naturally occurring or atypical repeat units.
- the TALE-repeat units naturally occurring or engineered
- Table 1 shows an alignment of exemplary repeat units within two TALE proteins. Each TALE repeat is shown on a separate line with the columns indicating the type of repeat, position of the start of that repeat, the name of the repeat, the residues at the hypervariable positions, and the entire repeat sequence.
- TALE DNA binding proteins have been identified and can be found in a standard GenBank search, including: AAB00675.1, (13.5 TALE repeats), AAB69865.1 (13.5 repeats), AAC43587.1 (17.5 repeats), AAD01494.1 (12.5 repeats), AAF98343.1 (25.5 repeats), AAG02079.2 (25.5 repeats), AAN01357.1 (8.5 repeats), AAO72098 (17.5 repeats), AAQ79773.2 (5.5 repeats), AAS46027.1 (28.5 repeats), AAS58127.2 (13.5 repeats), AAS58128.2 (17.5 repeats), AAS58129.3 (18.5 repeats), AAS58130.3(9.5 repeats),
- AAT46123.1 (22.5 repeats), AAT46124.1 (26.5 repeats), AAW59491.1 (5.5 repeats), AAW59492.1 (16.5 repeats), AAW59493.1 (19.5 repeats), AAW77510.1 (5.5 repeats), AAY43358 (21.5 repeats), AAY43359.1 (11.5 repeats), AAY43360.1 (14.5 repeats),
- TALE type proteins have also been found in the bacterium Ralstonia solanacearum and Table 2 lists a similar comparison of two examples of these DNA binding domains:
- TALE type proteins from Ralstonia include
- ABO27069.1 (10.5 repeats), ABO27070.1 (11.5 repeats), ABO27071.1 (7.5 repeats), ABO27072.1 (3.5 repeats), etc.
- the DNA-binding polypeptides comprising TALE-repeat domains as described herein may also include additional TALE polypeptide sequences, for example N- terminal (N-cap) sequences and, optionally, C-terminal (C-cap) sequences flanking the repeat domains.
- N-cap sequences may be naturally or non-naturally occurring sequences of any length sufficient to support the function (e.g., DNA-binding, cleavage, activation, etc.) of the DNA-binding polypeptide and fusion proteins comprising these TALE-repeat domain- containing DNA-binding polypeptides.
- the protein comprises an N- cap sequence comprising a fragment (truncation) of a region of a TALE protein N-terminal to the repeat domain (e.g., an N-cap sequence comprising at least 130 to 140 residues (e.g., 131, 132, 133, 134, 135, 136, 137, 138, 139 or 140 residues) of a TALE polypeptide N-terminal of the repeat domain).
- an N-cap sequence comprising a fragment (truncation) of a region of a TALE protein N-terminal to the repeat domain (e.g., an N-cap sequence comprising at least 130 to 140 residues (e.g., 131, 132, 133, 134, 135, 136, 137, 138, 139 or 140 residues) of a TALE polypeptide N-terminal of the repeat domain).
- the TALE-repeat domain polypeptides as described herein the protein comprises a C-cap sequence comprising a fragment (truncated) region of a TALE protein C-terminal to the repeat domain (e.g., an C-cap sequence comprising C-20 to C+28, C-20 to C+55, or C-20 to C+63).
- the C- cap sequence comprises a half-repeat (C-20 to C-l).
- the TALE DNA-binding polypeptides as described herein may include N-cap, C-cap sequences or both N-cap and C-cap sequences
- N-terminal and C-terminal sequences of the TALE repeats shown in Table 1 and 2 are shown below in Table 3.
- the TALE repeat sequences of Tables 1 and 2 are shown in bold.
- TALE fusions comprising the Fokl cleavage domain can also cleave DNA in living cells (see Christin et al, ibid, Li et al (201 la) and (201 lb) ibid, Cernak et al (2011) Nucl. Acid. Res.
- An engineered TALE protein and TALE fusion protein can have a novel binding specificity, compared to a naturally-occurring TALE protein.
- Engineering methods include, but are not limited to, rational design and various types of selection. Rational design includes, for example, using databases comprising nucleotide sequences for modules for single or multiple TALE repeats. Exemplary selection methods, including phage display and two-hybrid systems, are disclosed in US Patents 5,789,538; 5,925,523; 6,007,988;
- one or more TALE-repeat units of the DNA-binding protein comprise atypical RVDs.
- the repeat units often show little variability within the framework sequence (i.e. the residue(s) not involved in direct DNA contact (non-RVD residues). This lack of variability may be due to a number of factors including evolutionary relationships between individual TALE repeat unitsand protein folding requirements between adjacent repeats. Between differing phytopathogenicbacterial species however the framework sequences can vary.
- the TALE repeat sequences in the Xanthomonas campestris pv vesicatoria, the protein AvrBs3 has less than 40% homology with brgl 1 and hpxl 7 repeat units from Ralstonia solanacearum (see Heuer et a ⁇ (2007) Appl Environ Micro 73 (13): 4379-4384).
- the TALE repeat may be under stringent functional selection in each bacterium's natural environment, e.g., from the sequence of the genes in the host plant that the TALE regulates.
- variants in the TALE framework may be introduced by targeted or random mutagenesis by various methods know in the art, and the resultant TALE fusion proteins screened for optimal activity.
- Multi TALE repeat modules may also be useful not only for assembling the
- DNA binding domains comprising at least one TALE repeat unit
- mini-TALE multimers i.e. trimers, tetramers, pentamers etc.
- spanning linkers that also functioned as capping regions between the mini-TALE DNA binding domains would allow for base skipping and may result in higher DNA binding specificity.
- the use of linked mini-TALE DNA binding domains would relax the requirement for strict functional modularity at the level of individual TALE repeats and allows for the development of more complex and/or specific DNA recognition schemes wherein amino acids from adjacent motifs within a given module might be free to interact with each other for cooperative recognition of a desired DNA target sequence.
- Mini-TALE DNA binding domains could be linked and expressed using a suitable selection system (i.e. phage display) with randomized dipeptide motifs (or any other identified key positions) and selected based on their nucleic acid binding characteristics.
- a suitable selection system i.e. phage display
- multi-TALE repeat modules may be used to create an archive of repeat modules to allow for rapid construction of any specific desired TALE-fusion protein.
- DNA binding domains may also be produced. These fusions may also be further linked to a desired functional domain.
- TALE DNA binding domains and/or zinc finger domains may be linked together using any suitable linker sequences, including for example, linkers of 5 or more amino acids in length (e.g., TGEKP (SEQ ID NO:48), TGGQRP (SEQ ID NO:49), TGQKP (SEQ ID NO:50), and/or TGSQKP (SEQ ID NO:51)), although it is likely that sequences that can function as capping sequence (N-cap and C-cap sequences) would be required at the interface between the TALE repeat domain and the linker.
- linkers of 5 or more amino acids in length e.g., TGEKP (SEQ ID NO:48), TGGQRP (SEQ ID NO:49), TGQKP (SEQ ID NO:50), and/or TGSQKP (SEQ ID NO:51)
- linkers when linkers are used, linkers of five or more amino acids can be used in conjunction with the cap sequences to join the TALE DNA binding domains to a desired fusion partner domain. See, also, U.S. Patent Nos. 6,479,626; 6,903,185; and
- linkers between the TALE repeat domains and the fused functional protein domains can be constructed to be either flexible or positionally constrained to allow for the most efficient genomic modification. Linkers of varying lengths and compositions may be tested.
- Fusion proteins comprising DNA-binding proteins (e.g., TALE- fusion proteins) as described herein and a heterologous regulatory or functional domain (or functional fragment thereof) are also provided.
- Common domains include, e.g., transcription factor domains (activators, repressors, co-activators, co-repressors), nuclease domains, silencer domainss, oncogene domainss (e.g., myc, jun, fos, myb, max, mad, rel, ets, bcl, myb, mos family members etc.); DNA repair enzymes and their associated factors and modifiers; DNA rearrangement enzymes and their associated factors and modifiers; chromatin associated proteins and their modifiers (e.g.
- kinases e.g., methyltransferases, topoisomerases, helicases, ligases, kinases, phosphatases, polymerases, endonucleases
- DNA targeting enzymes such as transposons, integrases, recombinases and resolvases and their associated factors and modifiers, nuclear hormone receptors, nucleases (cleavage domains or half-domains) and ligand binding domains.
- Other fusion proteins may include reporter or selection markers. Examples of reporter domains include GFP, GUS and the like. Reporters with specific utility in plant cells include GUS.
- Suitable domains for achieving activation include the HSV VP 16 activation domain (see, e.g., Hagmann et al, J. Virol. 71, 5952-5962 (1997)) nuclear hormone receptors (see, e.g., Torchia et al, Curr. Opin. Cell. Biol. 10:373-383 (1998)); the p65 subunit of nuclear factor kappa B (Bitko & Bank, J. Virol. 72:5610-5618 (1998) and Doyle & Hunt, Neuroreport 8:2937-2942 (1997)); Liu et al, Cancer Gene Ther.
- HSV VP 16 activation domain see, e.g., Hagmann et al, J. Virol. 71, 5952-5962 (1997)
- nuclear hormone receptors see, e.g., Torchia et al, Curr. Opin. Cell. Biol. 10:373-383 (1998)
- chimeric functional domains such as VP64 (Beerli et al, (1998) Proc. Natl Acad. Sci. USA 95:14623-33), and degron (Molinari et al, (1999) EMBO J. 18, 6439-6447).
- Additional exemplary activation domains include, Oct 1, Oct-2A, Spl, AP-2, and CTF1 (Seipel et al, EMBO J. 11, 4961-4968 (1992) as well as p300, CBP, PCAF, SRC1 PvALF, AtHD2A and ERF-2. See, for example, Robyr et al. (2000) Mol. Endocrinol.
- Additional exemplary activation domains include, but are not limited to, OsGAI, HALF-1, CI, API, ARF-5,-6,-7, and -8, CPRF1, CPRF4, MYC-RP/GP, and TRAB1.
- OsGAI OsGAI
- HALF-1 CI
- API ARF-5,-6,-7
- -8 CPRF1, CPRF4, MYC-RP/GP
- TRAB1 exemplary activation domains
- a fusion protein (or a nucleic acid encoding same) between a DNA-binding domain as described herein and a functional domain
- an activation domain or a molecule that interacts with an activation domain is suitable as a functional domain.
- any molecule capable of recruiting an activating complex and/or activating activity (such as, for example, histone acetylation) to the target gene is useful as an activating domain of a fusion protein.
- Insulator domains, localization domains, and chromatin remodeling proteins such as ISWI-containing domains and/or methyl binding domain proteins suitable for use as functional domains in fusion molecules are described, for example, in co-owned U.S. Patent Applications
- Exemplary repression domains include, but are not limited to, KRAB A/B,
- KOX TGF-beta-inducible early gene (TIEG), v-erbA, SID, MBD2, MBD3, members of the DNMT family (e.g., DNMT1, DNMT3A, DNMT3B), Rb, and MeCP2.
- TIEG TGF-beta-inducible early gene
- MBD2, MBD3, members of the DNMT family e.g., DNMT1, DNMT3A, DNMT3B
- Rb MeCP2.
- Additional exemplary repression domains include, but are not limited to, ROM2 and AtHD2A. See, for example, Chem et al. (1996) Plant Cell 8:305-321 ; and Wu et al. (2000) Plant J. 22:19-27.
- the target site bound by the TALE- fusion protein is present in an accessible region of cellular chromatin.
- Accessible regions can be determined as described, for example, in co-owned International Publication WO 01/83732. If the target site is not present in an accessible region of cellular chromatin, one or more accessible regions can be generated as described in co-owned WO 01/83793. In additional
- the DNA-binding domain of a fusion molecule is capable of binding to cellular chromatin regardless of whether its target site is in an accessible region or not.
- such DNA-binding domains are capable of binding to linker DNA and or nucleosomal DNA.
- Examples of this type of "pioneer" DNA binding domain are found in certain steroid receptor and in hepatocyte nuclear factor 3 (HNF3). Cordingley et al. (1987) Cell 48:261-270; Pina et al. (1990) Cell 60:719-731 ; and Cirillo et al. (1998) EMBO J. 17:244-254.
- the fusion molecule may be formulated with a pharmaceutically acceptable carrier, as is known to those of skill in the art. See, for example, Remington's Pharmaceutical Sciences, 17th ed., 1985; and co-owned WO 00/42219.
- the functional component/domain of a fusion molecule can be selected from any of a variety of different components capable of influencing transcription of a gene once the fusion molecule binds to a target sequence via its DNA binding domain.
- the functional component can include, but is not limited to, various transcription factor domains, such as activators, repressors, co-activators, co-repressors, and silencers.
- Functional domains that are regulated by exogenous small molecules or ligands may also be selected.
- RheoSwitch® technology may be employed wherein a functional domain only assumes its active conformation in the presence of the external RheoChemTM ligand (see for example US 20090136465).
- the TALE-fusion protein may be operably linked to the regulatable functional domain wherein the resultant activity of the TALE- fusion protein is controlled by the external ligand.
- the TALE DNA-binding proteins, or fragments thereof are used as nucleases via fusion (N- and/or C-terminal to the TALE-repeat domain, N-cap and/or C-cap sequences) of a TALE DNA-binding domain to at least one nuclease (cleavage domain, cleavage half-domain).
- the cleavage domain portion of the fusion proteins disclosed herein can be obtained from any endonuclease or exonuclease.
- Exemplary endonucleases from which a cleavage domain can be derived include, but are not limited to, restriction endonucleases and homing endonucleases. See, for example, 2002-2003
- a cleavage half-domain can be derived from any nuclease or portion thereof, as set forth above, that requires dimerization for cleavage activity.
- two fusion proteins are required for cleavage if the fusion proteins comprise cleavage half- domains.
- a single protein comprising two cleavage half-domains can be used.
- the two cleavage half-domains can be derived from the same endonuclease (or functional fragments thereof), or each cleavage half-domain can be derived from a different
- the target sites for the two fusion proteins are preferably disposed, with respect to each other, such that binding of the two fusion proteins to their respective target sites places the cleavage half-domains in a spatial orientation to each other that allows the cleavage half-domains to form a functional cleavage domain, e.g., by dimerizing.
- the near edges of the target sites are separated by 5-8 nucleotides or by 15-18 nucleotides.
- any integral number of nucleotides or nucleotide pairs can intervene between two target sites ⁇ e.g. , from 2 to 50 nucleotide pairs or more).
- the site of cleavage lies between the target sites.
- Restriction endonucleases are present in many species and are capable of sequence-specific binding to DNA (at a recognition site), and cleaving DNA at or near the site of binding.
- Certain restriction enzymes ⁇ e.g., Type IIS) cleave DNA at sites removed from the recognition site and have separable binding and cleavage domains.
- the Type IIS enzyme Fok I catalyzes double-stranded cleavage of DNA, at 9 nucleotides from its recognition site on one strand and 13 nucleotides from its recognition site on the other. See, for example, US Patents 5,356,802; 5,436,150 and 5,487,994; as well as Li et al.
- fusion proteins comprise the cleavage domain (or cleavage half-domain) from at least one Type IIS restriction enzyme and one or more TALE DNA-binding domains, which may or may not be engineered.
- Exemplary Type IIS restriction enzymes whose cleavage domains are separable from the binding domain, include Fok I and Bfil (see Zaremba et al, (2004) J Mol Biol. 336(l):81-92). Fok enzyme is active as a dimer (see Bitinaite et al. (1998) Proc. Natl. Acad. Sci. USA 95: 10,570-10,575).
- two fusion proteins each comprising a Fokl cleavage half-domain, can be used to reconstitute a catalytically active cleavage domain.
- a single polypeptide molecule containing a TALE-repeat domain and two Fok I cleavage half-domains can also be used.
- Another preferred Type IIS restriction enzyme is Bfil (see Zaremba et al, (2004) J Mol Biol. 336(l):81-92). The cleavage domain of this enzyme may be separated from its DNA binding domain and operably linked to a TALE DNA binding domain to create a TALEN.
- a cleavage domain or cleavage half-domain can be any portion of a protein that retains cleavage activity, or that retains the ability to multimerize (e.g., dimerize) to form a functional cleavage domain.
- the cleavage domain comprises one or more engineered cleavage half-domain (also referred to as dimerization domain mutants) that minimize or prevent homodimerization, as described, for example, in U.S. Patent Publication Nos. 20050064474; 20060188987, 20080131962, 20090311787; 20090305346; 20110014616, and US Patent Application No. 12/931,660, the disclosures of all of which are incorporated by reference in their entireties herein.
- engineered cleavage half-domain also referred to as dimerization domain mutants
- Exemplary engineered cleavage half-domains oiFok I that form obligate heterodimers include a pair in which a first cleavage half-domain includes mutations at amino acid residues at positions 490 and 538 of Fok I and a second cleavage half-domain includes mutations at amino acid residues 486 and 499.
- Additional engineered cleavage half-domains of Fok I form an obligate heterodimers can also be used in the fusion proteins described herein.
- the first cleavage half- domain includes mutations at amino acid residues at positions 490 and 538 of Fok I and the second cleavage half-domain includes mutations at amino acid residues 486 and 499.
- a mutation at 490 replaces Glu (E) with Lys (K); the mutation at 538 replaces Iso (I) with Lys (K); the mutation at 486 replaced Gin (Q) with Glu (E); and the mutation at position 499 replaces Iso (I) with Lys (K).
- the engineered cleavage half-domains described herein were prepared by mutating positions 490 (E ⁇ K) and 538 (I ⁇ K) in one cleavage half-domain to produce an engineered cleavage half-domain designated "E490K:I538K” and by mutating positions 486 (Q ⁇ E) and 499 (I ⁇ L) in another cleavage half-domain to produce an engineered cleavage half-domain designated "Q486E:I499L".
- the engineered cleavage half-domains described herein are obligate heterodimer mutants in which aberrant cleavage is minimized or abolished. See, e.g.,
- the engineered cleavage half-domains described herein are obligate heterodimer mutants in which aberrant cleavage is minimized or abolished. See, e.g.,
- the engineered cleavage half-domain comprises mutations at positions 486, 499 and 496 (numbered relative to wild-type Fokl), for . instance mutations that replace the wild type Gin (Q) residue at position 486 with a Glu (E) residue, the wild type Iso (I) residue at position 499 with a Leu (L) residue and the wild-type Asn (N) residue at position 496 with an Asp (D) or Glu (E) residue (also referred to as a "ELD” and "ELE” domains, respectively).
- the engineered cleavage half-domain comprises mutations at positions 490, 538 and 537 (numbered relative to wild- type Fokl), for instance mutations that replace the wild type Glu (E) residue at position 490 with a Lys (K) residue, the wild type Iso (I) residue at position 538 with a Lys (K) residue, and the wild-type His (H) residue at position 537 with a Lys (K) residue or a Arg (R) residue (also referred to as "KKK” and "KKR” domains, respectively).
- the engineered cleavage half-domain comprises mutations at positions 490 and 537 (numbered relative to wild-type Fokl), for instance mutations that replace the wild type Glu (E) residue at position 490 with a Lys (K) residue and the wild-type His (H) residue at position 537 with a Lys (K) residue or a Arg (R) residue (also referred to as "KTK” and "KIR” domains, respectively).
- Fokl nuclease domain variants including mutations known as “Sharkey” or “Sharkey' (Sharkey prime)” mutations may be used (see Guo et al, (2010) J. Mol. Biol.
- Engineered cleavage half-domains described herein can be prepared using any suitable method, for example, by site-directed mutagenesis of wild-type cleavage half- domains (Fok I) as described in U.S. Patent Publication Nos. 20050064474, 20070134796; 20080131962.
- TALE-fusion polypeptides and nucleic acids can be made using routine techniques in the field of recombinant genetics. Basic texts disclosing the general methods of use in this invention include Sambrook et al., Molecular Cloning, A Laboratory Manual (2nd ed. 1989); Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990); and Current Protocols in Molecular Biology (Ausubel et al., eds., 1994)). In addition, essentially any nucleic acid can be custom ordered from any of a variety of commercial sources.
- peptides and antibodies can be custom ordered from any of a variety of antibodies
- Two alternative methods are typically used to create the coding sequences required to express newly designed DNA-binding peptides.
- One protocol is a PCR-based assembly procedure that utilizes overlapping oligonucleotides. These oligonucleotides contain substitutions primarily, but not limited to, positions 12 and 13 on the repeated domains making them specific for each of the different DNA-binding domains. Additionally, amino acid substitutions may be made at positions 4, 11 and 32. Amino acid substitutions may also be made at positions 2, 3, 4, 21, 23, 24, 25, 27, 30, 31, 33, 34 and/or 35 within one repeat unit. In some embodiments, the repeat unit contains a substitution in one position, and in others, the repeat unit contains from 2 to 18 amino acid substitutions. In some embodiments,
- the nucleotide sequence of the repeat units may be altered without altering the amino acid sequence.
- fusion molecules are constructed by methods of cloning and biochemical conjugation that are well known to those of skill in the art. Fusion molecules comprise a DNA-binding domain and a functional domain (e.g., a transcriptional activation or repression domain).
- Fusion molecules also optionally comprise nuclear localization signals (such as, for example, that from the S V40 medium T-antigen) and epitope tags (such as, for example, FLAG and hemagglutinin). Fusion proteins (and nucleic acids encoding them) are designed such that the translational reading frame is preserved among the components of the fusion.
- the fusion proteins as described herein may include one or more functional domains at the N- and/or C-terminus of the DNA-binding polypeptides as described herein.
- Fusions between a polypeptide component of a functional domain (or a functional fragment thereof) on the one hand, and a non-protein DNA-binding domain (e.g., antibiotic, intercalator, minor groove binder, nucleic acid) on the other, are constructed by methods of biochemical conjugation known to those of skill in the art. See, for example, the Pierce Chemical Company (Rockford, IL) Catalogue. Methods and compositions for making fusions between a minor groove binder and a polypeptide have been described. Mapp et al. (2000) Proc. Natl. Acad. Sci. USA 97:3930-3935.
- Any nuclease having a target site in any desired gene(s) can be used in the methods disclosed herein.
- homing endonucleases and meganucleases have very long recognition sequences, some of which are likely to be present, on a statistical basis, once in a human-sized genome.
- Any such nuclease having a target site in a desired gene can be used instead of, or in addition to, a TALE-repeat domain nuclease fusion, including for example, a zinc finger nuclease and/or a meganuclease, for targeted cleavage.
- the nuclease is a meganuclease (homing
- Naturally-occurring meganucleases recognize 15-40 base-pair cleavage sites and are commonly grouped into four families: the LAGLIDADG family, the GIY-YIG family, the His-Cyst box family and the HNH family.
- Exemplary homing endonucleases include I-Scel, l-Ceul, Pl-Pspl, Vl-Sce, 1-SceW, 1-Csml, I-Panl, l-Scell, l-Ppol, l-Scelll, I- Crel, I-Tevl, I-TevII and I-TevIII. Their recognition sequences are known. See also U.S. Patent No.
- DNA-binding domains from naturally-occurring meganucleases primarily from the LAGLIDADG family, have been used to promote site-specific genome modification in plants, yeast, Drosophila, mammalian cells and mice, but this approach has been limited to the modification of either homologous genes that conserve the meganuclease recognition sequence (Monet et al. (1999), Biochem. Biophysics. Res. Common. 255: 88-93) or to pre- engineered genomes into which a recognition sequence has been introduced (Route et al. (1994), Mol. Cell Biol. 14: 8096-106; Chilton et al. (2003), Plant Physiology. 133: 956-65; Puchta et al.
- TALE- fusion proteins, polynucleotides encoding same and compositions comprising the proteins and/or polynucleotides described herein may be delivered to a target cell by any suitable means, including, for example, by injection of mRNA encoding the TAL- fusion protein. See, Hammerschmidt et al. (1999) Methods Cell Biol. 59:87-115.
- TALE- protein fusions as described herein may also be delivered using vectors containing sequences encoding one or more of the TALE- protein fusions.
- Any vector systems may be used including, but not limited to, plasmid vectors, retroviral vectors, lentiviral vectors, adenovirus vectors, poxvirus vectors; herpesvirus vectors and adeno- associated virus vectors, etc. See, also, U.S. Patent Nos. 6,534,261 ; 6,607,882; 6,824,978; 6,933,113; 6,979,539; 7,013,219; and 7,163,824, incorporated by reference herein in their entireties.
- any of these vectors may comprise one or more TALE- protein fusions encoding sequences.
- TALE- protein fusions e.g., a pair of TALENs
- the TALE- protein fusions may be carried on the same vector or on different vectors.
- each vector may comprise a sequence encoding one or multiple TALE- protein fusions.
- Non-viral vector delivery systems include DNA plasmids, naked nucleic acid, and nucleic acid complexed with a delivery vehicle such as a liposome or poloxamer.
- Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell.
- Non- viral vector delivery systems include electroporation, lipofection, microinjection, biolistics, virosomes, liposomes, immuno liposomes, polycation or
- lipid:nucleic acid conjugates naked DNA, artificial virions, and agent-enhanced uptake of DNA.
- Sonoporation using, e.g., the Sonitron 2000 system (Rich-Mar) can also be used for delivery of nucleic acids.
- Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell. Additional exemplary nucleic acid delivery systems include those provided by Amaxa Biosystems (Cologne, Germany), Maxcyte, Inc. (Rockville, Maryland), BTX Molecular Delivery
- Lipofection is described in e.g., US 5,049,386, US 4,946,787; and US 4,897,355) and lipofection reagents are sold commercially (e.g., TransfectamTM and LipofectinTM). Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of
- polynucleotides include those of Feigner, WO 91/17424, WO 91/16024. Delivery can be to cells (ex vivo administration) or target tissues (in vivo administration).
- lipid:nucleic acid complexes including targeted liposomes such as immuno lipid complexes
- Boese et al Cancer Gene Ther. 2:291-297 (1995); Behr et al, Bioconjugate Chem. 5:382-389 (1994); Remy et al, Bioconjugate Chem. 5:647-654 (1994); Gao et al., Gene Therapy 2:710-722 (1995); Ahmad et al., Cancer Res. 52:4817-4820 (1992); U.S. Pat. Nos. 4,186,183, 4,217,344, 4,235,871, 4,261,975, 4,485,054, 4,501,728, 4,774,085, 4,837,028, and 4,946,787).
- Additional methods of delivery include the use of packaging the nucleic acids to be delivered into EnGeneIC delivery vehicles (EDVs). These EDVs are specifically delivered to target tissues using bispecific antibodies where one arm of the antibody has specificity for the target tissue and the other has specificity for the EDV. The antibody brings the EDVs to the target cell surface and then the EDV is brought into the cell by endocytosis. Once in the cell, the contents are released (see MacDiarmid et al (2009) Nature
- Suitable cells include but are not limited to eukaryotic and prokaryotic cells and/or cell lines.
- Non-limiting examples of such cells or cell lines generated from such cells include COS, CHO (e.g., CHO-S, CHO-K1, CHO-DG44, CHO-DUXB11, CHO-DUKX, CHOK1SV), VERO, MDCK, WI38, V79, B14AF28-G3, BHK, HaK, NS0, SP2/0-Agl4, HeLa, HEK293 (e.g., HEK293-F, HEK293-H, HEK293-T), and perC6 cells as well as insect cells such as Spodoptera fugiperda (Sf), or fungal cells such as Saccharomyces, Pichia and Schizosaccharomyces.
- COS e.g., CHO-S, CHO-K1, CHO-DG44, CHO-DUXB11, CHO-DU
- the cell line is a CHO-K1, MDCK or HEK293 cell line.
- primary cells may be isolated and used ex vivo for reintroduction into the subject to be treated following treatment with the TALE- fusions.
- Suitable primary cells include peripheral blood mononuclear cells (PBMC), and other blood cell subsets such as, but not limited to, CD4+ T cells or CD8+ T cells.
- PBMC peripheral blood mononuclear cells
- Suitable cells also include stem cells such as, by way of example, embryonic stem cells, induced pluripotent stem cells, hematopoietic stem cells, neuronal stem cells, mesenchymal stem cells, muscle stem cells and skin stem cells.
- stem cells such as, by way of example, embryonic stem cells, induced pluripotent stem cells, hematopoietic stem cells, neuronal stem cells, mesenchymal stem cells, muscle stem cells and skin stem cells.
- Stem cells that have been modified may also be used in some embodiment
- stem cells that have been made resistant to apoptosis may be used as therapeutic compositions where the stem cells also contain the TALE- fusion proteins of the invention.
- Resistance to apoptosis may come about, for example, by knocking out BAX and/or BAK using BAX- or BAK-specific TALENs in the stem cells, or those that are disrupted in a caspase, again using caspase-6 specific TALENs for example.
- Methods for introduction of DNA into hematopoietic stem cells are disclosed, for example, in U.S. Patent No. 5,928,638.
- Vectors useful for introduction of transgenes into hematopoietic stem cells include adenovirus Type 35.
- Vectors suitable for introduction of polynucleotides as described herein include described herein include non-integrating lentivirus vectors (EDLV). See, for example, Ory et al. (1996) Proc. Natl. Acad. Sci. USA 93:11382-11388; Dull et al. (1998) J. Virol. 72:8463-8471; Zuffery et al. (1998) J. Virol. 72:9873-9880; Follenzi et al. (2000) Nature Genetics 25:217-222; U.S. Patent Publication No 2009/054985. As noted above, the disclosed methods and compositions can be used in any type of cell. Progeny, variants and derivatives of animal cells can also be used.
- EDLV non-integrating lentivirus vectors
- DNA constructs may be introduced into (e.g., into the genome of) a desired plant host by a variety of conventional techniques. For reviews of such techniques see, for example, Weissbach & Weissbach Methods for Plant Molecular Biology (1988, Academic Press, N.Y.) Section VIII, pp. 421-463; and Grierson & Corey, Plant Molecular Biology (1988, 2d Ed.), Blackie, London, Ch. 7-9.
- the DNA construct may be introduced directly into the genomic DNA
- DNA of the plant cell using techniques such as electroporation and microinjection of plant cell protoplasts, or the DNA constructs can be introduced directly to plant tissue using biolistic methods, such as DNA particle bombardment (see, e.g., Klein et al (1987) Nature 327:70-73).
- the DNA constructs may be combined with suitable T-DNA flanking regions and introduced into a conventional Agrobacterium tumefaciens host vector.
- Agrobacterium tumefaciens-mediated transformation techniques, including disarming and use of binary vectors, are well described in the scientific literature. See, for example Horsch et al (1984) Science 233:496-498, and Fraley et al (1983) Proc. Natl Acad. Sci. USA 80:4803.
- gene transfer may be achieved using non- Agrobacterium bacteria or viruses such as Rhizobium sp. NGR234, Sinorhizoboium meliloti, Mesorhizobium loti, potato virus X, cauliflower mosaic virus and cassava vein mosaic virus and/or tobacco mosaic virus, See, e.g., Chung et al. (2006) Trends Plant Sci. 11(1): 1-4.
- the virulence functions of the Agrobacterium tumefaciens host will direct the insertion of the construct and adjacent marker into the plant cell DNA when the cell is infected by the bacteria using binary T DNA vector (Bevan (1984) Nuc. Acid Res.
- Agrobacterium transformation system is used to engineer dicotyledonous plants (Bevan et al (1982) Ann. Rev. Genet 16:357-384; Rogers et al (1986) Methods Enzymol. 1 18:627-641).
- the Agrobacterium transformation system may also be used to transform, as well as transfer, DNA to monocotyledonous plants and plant cells. See U.S. Patent No.
- Alternative gene transfer and transformation methods include, but are not limited to, protoplast transformation through calcium-, polyethylene glycol (PEG)- or electroporation-mediated uptake of naked DNA (see Paszkowski et al. (1984) EMBO J 3:2717-2722, Potrykus et al. (1985) Molec. Gen. Genet. 199: 169-177; Fromm et al. (1985) Proc. Nat. Acad. Sci. USA 82:5824-5828; and Shimamoto (1989) Nature 338:274-276) and electroporation of plant tissues (D'Halluin et al. (1992) Plant Cell 4:1495-1505).
- PEG polyethylene glycol
- Additional methods for plant cell transformation include microinjection, silicon carbide mediated DNA uptake (Kaeppler et al. (1990) Plant Cell Reporter 9:415-418), and microprojectile bombardment (see Klein et al. (1988) Proc. Nat. Acad. Sci. USA 85:4305-4309; and Gordon-Kamm et al. (1990) Plant Cell 2:603-618).
- the methods and compositions described herein are applicable to any organism in which it is desired to regulate gene expression and/or alter the organism through genomic modification, including but not limited to eukaryotic organisms such as plants, animals (e.g., mammals such as mice, rats, primates, farm animals, rabbits, etc.), fish, and the like.
- Eukaryotic e.g., yeast, plant, fungal, piscine and mammalian cells such as feline, canine, murine, bovine, ovine, and porcine
- Exemplary mammalian cells include any cell or cell line of the organism of interest, for example oocytes, K562 cells, CHO (Chinese hamster ovary) cells, HEP-G2 cells, BaF-3 cells, Schneider cells, COS cells (monkey kidney cells expressing S V40 T-antigen), CV-1 cells, HuTu80 cells, NTERA2 cells, NB4 cells, HL-60 cells and HeLa cells, 293 cells (see, e.g., Graham et al. (1977) J. Gen. Virol. 36:59), and myeloma cells like SP2 or NSO (see, e.g., Galfre and Milstein (1981) Meth. Enzymol 73(B):3 46).
- oocytes K562 cells
- CHO (Chinese hamster ovary) cells HEP-G2 cells
- BaF-3 cells BaF-3 cells
- Schneider cells COS cells (monkey kidney cells expressing S V40 T-antigen)
- PBMCs Peripheral blood mononucleocytes
- T-cells can also be used, as can embryonic and adult stem cells.
- stem cells that can be used include embryonic stem cells (ES), induced pluripotent stem cells (iPSC), mesenchymal stem cells, hematopoietic stem cells, liver stem cells, skin stem cells and neuronal stem cells.
- ES embryonic stem cells
- iPSC induced pluripotent stem cells
- mesenchymal stem cells mesenchymal stem cells
- hematopoietic stem cells liver stem cells
- skin stem cells and neuronal stem cells.
- Exemplary target plants and plant cells include, but are not limited to, those monocotyledonous and dicotyledonous plants, such as crops including grain crops (e.g., wheat, maize, rice, millet, barley), fruit crops (e.g., tomato, apple, pear, strawberry, orange), forage crops (e.g., alfalfa), root vegetable crops (e.g., carrot, potato, sugar beets, yam), leafy vegetable crops (e.g., lettuce, spinach); vegetative crops for consumption (e.g.
- crops including grain crops (e.g., wheat, maize, rice, millet, barley), fruit crops (e.g., tomato, apple, pear, strawberry, orange), forage crops (e.g., alfalfa), root vegetable crops (e.g., carrot, potato, sugar beets, yam), leafy vegetable crops (e.g., lettuce, spinach); vegetative crops for consumption (e.g.
- crops including grain crops (e.
- soybean and other legumes squash, peppers, eggplant, celery etc
- flowering plants e.g., petunia, rose, chrysanthemum
- conifers and pine trees e.g., pine fir, spruce
- poplar trees e.g. P. tremula x P. alba
- fiber crops cotton, jute, flax, bamboo
- oil crops e.g., sunflower, rape seed
- plants used for experimental purposes e.g., Arabidopsis.
- the disclosed methods and compositions have use over a broad range of plants, including, but not limited to, species from the genera Asparagus, Avena, Brassica, Citrus, Citrullus, Capsicum, Cucurbita, Daucus, Erigeron, Glycine, Gossypium, Hordeum, Lactuca, Lolium, Lycopersicon, Malus, Manihot, Nicotiana, Orychophragmus, Oryza, Persea, Phaseolus, Pisum, Pyrus, Prunus, Raphanus, Secale, Solanum, Sorghum, Triticum, Vitis, Vigna, and Zea.
- plant cells include isolated plant cells as well as whole plants or portions of whole plants such as seeds, callus, leaves, roots, etc.
- the present disclosure also encompasses seeds of the plants described above wherein the seed has the transgene or gene construct and/or has been modified using the compositions and/or methods described herein.
- the present disclosure further encompasses the progeny, clones, cell lines or cells of the transgenic plants described above wherein said progeny, clone, cell line or cell has the transgene or gene construct.
- Algae are being increasingly utilized for manufacturing compounds of interest, i.e. biofuels, plastics, hydrocarbons etc.
- Exemplary algae species include microalgae including diatoms and cyanobacteria as well as Botryococcus braunii, Chlorella, Dunaliella tertiolecta, Gracileria, Pleurochrysis carterae, Sorgassum and Ulva. Assays for Determining Regulation of Gene Expression by TALE fusion proteins
- a variety of assays can be used to determine the level of gene expression regulation by TALE- fusion proteins.
- the activity of a particular TALE- fusion proteins can be assessed using a variety of in vitro and in vivo assays, by measuring, e.g., protein or mRNA levels, product levels, enzyme activity, tumor growth; transcriptional activation or repression of a reporter gene; second messenger levels (e.g., cGMP, cAMP, EP3, DAG, Ca.sup.2+); cytokine and hormone production levels; and neovascularization, using, e.g., immunoassays (e.g., ELISA and immunohistochemical assays with antibodies), hybridization assays (e.g., RNase protection, northems, in situ hybridization, oligonucleotide array studies), colorimetric assays, amplification assays, enzyme activity assays, tumor growth assays, phenotypic assays, and the like
- TALE- fusion proteins are typically first tested for activity in vitro using cultured cells, e.g., 293 cells, CHO cells, VERO cells, BHK cells, HeLa cells, COS cells, plant cell lines, plant callous cultures and the like. Preferably, human cells are used.
- the TALE- fusion protein is often first tested using a transient expression system with a reporter gene, and then regulation of the target endogenous gene is tested in cells and in animals, both in vivo and ex vivo.
- the TALE fusion proteins can be recombinantly expressed in a cell, recombinantly expressed in cells transplanted into an animal or plant, or recombinantly expressed in a transgenic animal or plant, as well as administered as a protein to an animal, plant or cell using delivery vehicles described herein.
- the cells can be immobilized, be in solution, be injected into an animal, or be naturally occurring in a transgenic or non- transgenic animal.
- Modulation of gene expression is tested using one of the in vitro or in vivo assays described herein. Samples or assays are treated with a TALE- fusion proteins and compared to control samples without the test compound, to examine the extent of
- TALE- fusion proteins can be measured by examining any of the parameters described above. Any suitable gene expression, phenotypic, or
- TALE- fusion protein mediated regulation of endogenous gene expression can be performed in vitro.
- TALE- fusion protein mediated regulation of endogenous gene expression in cultured cells is measured by examining protein production using an ELISA assay. The test sample is compared to control cells treated with an empty vector or an unrelated TALE- fusion protein that is targeted to another gene.
- TALE- fusion protein-mediated regulation of endogenous gene expression is determined in vitro by measuring the level of target gene mRNA expression.
- the level of gene expression is measured using amplification, e.g., using PCR, LCR, or hybridization assays, e.g., northern hybridization, RNase protection, dot blotting. RNase protection is used in one embodiment.
- the level of protein or mRNA is detected using directly or indirectly labeled detection agents, e.g., fluorescently or radioactively labeled nucleic acids, radioactively or enzymatically labeled antibodies, and the like, as described herein.
- a reporter gene system can be devised using the target gene promoter operably linked to a reporter gene such as luciferase, green fluorescent protein, CAT, or beta-gal.
- a reporter gene such as luciferase, green fluorescent protein, CAT, or beta-gal.
- the reporter construct is typically co-transfected into a cultured cell. After treatment with the TALE- fusion proteins of choice, the amount of reporter gene
- transcription, translation, or activity is measured according to standard techniques known to those of skill in the art.
- FIG. 1 Another example of a preferred assay format useful for monitoring TALE- fusion protein mediated regulation of endogenous gene expression is performed in vivo.
- This assay is particularly useful for examining TALE- fusions that inhibit expression of tumor promoting genes, genes involved in tumor support, such as neovascularization (e.g., VEGF), or that activate tumor suppressor genes such as p53.
- cultured tumor cells expressing the TALE- fusions of choice are injected subcutaneously into an immune compromised mouse such as an athymic mouse, an irradiated mouse, or a SCID mouse.
- tumor growth is measured, e.g., by volume or by its two largest dimensions, and compared to the control. Tumors that have statistically significant reduction (using, e.g., Student's T test) are said to have inhibited growth.
- the extent of tumor neovascularization can also be measured. Imunoassays using endothelial cell specific antibodies are used to stain for vascularization of the tumor and the number of vessels in the tumor. Tumors that have a statistically significant reduction in the number of vessels (using, e.g., Student's T test) are said to have inhibited
- Transgenic and non-transgenic plants or animals as described above are also used as a preferred embodiment for examining regulation of endogenous gene expression in vivo.
- Transgenic organisms typically express the TALE- fusions of choice.
- organisms that transiently express the TALE- fusions of choice, or to which the TALE fusion proteins have been administered in a delivery vehicle can be used. Regulation of endogenous gene expression is tested using any one of the assays described herein.
- Non-viral vector delivery systems include DNA plasmids, naked nucleic acid, and nucleic acid complexed with a delivery vehicle such as a liposome.
- Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell.
- RNA or DNA viral based systems for the delivery of nucleic acids encoding engineered TALE domain fusions takes advantage of highly evolved processes for targeting a virus to specific cells in the body and trafficking the viral payload to the nucleus.
- Viral vectors can be administered directly to patients (in vivo) or they can be used to treat cells in vitro and the modified cells are administered to patients (ex vivo).
- Conventional viral based systems for the delivery of TALE domain fusions could include retroviral, lentivirus, adenoviral, adeno-associated and herpes simplex virus vectors for gene transfer.
- Viral vectors are currently the most efficient and versatile method of gene transfer in target cells and tissues. Integration in the host genome is possible with the retrovirus, lentivirus, and adeno- associated virus gene transfer methods, often resulting in long term expression of the inserted transgene. Additionally, high transduction efficiencies have been observed in many different cell types and target tissues.
- Lentiviral vectors are retroviral vector that are able to transduce or infect non-dividing cells and typically produce high viral titers. Selection of a retroviral gene transfer system would therefore depend on the target tissue. Retroviral vectors are comprised of cis-acting long terminal repeats with packaging capacity for up to 6-10 kb of foreign sequence. The minimum cis-acting LTRs are sufficient for replication and packaging of the vectors, which are then used to integrate the therapeutic gene into the target cell to provide permanent transgene expression.
- Widely used retroviral vectors include those based upon murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), Simian Immuno deficiency virus (SIV), human immuno deficiency virus (HIV), and combinations thereof (see, e.g., Buchscher et al, J. Virol. 66:2731-2739 (1992); Johann et al, J Virol. 66:1635-1640 (1992); Sommerfelt et al, Virol. 176:58-59
- Adenoviral based systems are typically used.
- Adenoviral based vectors are capable of very high transduction efficiency in many cell types and do not require cell division. With such vectors, high titer and levels of expression have been obtained. This vector can be produced in large quantities in a relatively simple system.
- Adeno-associated virus (“AAV”) vectors are also used to transduce cells with target nucleic acids, e.g., in the in vitro production of nucleic acids and peptides, and for in vivo and ex vivo gene therapy procedures (see, e.g., West et al, Virology 160:38-47 (1987); U.S. Pat. No.
- pLASN and MFG-S are examples are retroviral vectors that have been used in clinical trials (Dunbar et al, Blood 85:3048-305 (1995); Kohn et al, Nat. Med. 1 : 1017-102 (1995); Malech et al, Proc Natl Acad Sci USA 94:22 12133-12138 (1997)).
- PA317/pLASN was the first therapeutic vector used in a gene therapy trial.
- rAAV Recombinant adeno-associated virus vectors
- All vectors are derived from a plasmid that retains only the AAV 145 bp inverted terminal repeats flanking the transgene expression cassette. Efficient gene transfer and stable transgene delivery due to integration into the genomes of the transduced cell are key features for this vector system.
- Ad vectors Replication-deficient recombinant adenoviral vectors (Ad) are predominantly used for colon cancer gene therapy, because they can be produced at high titer and they readily infect a number of different cell types. Most adenovirus vectors are engineered such that a transgene replaces the Ad Ela, Elb, and E3 genes; subsequently the replication defector vector is propagated in human 293 cells that supply deleted gene function in trans. Ad vectors can transduce multiply types of tissues in vivo, including nondividing,
- differentiated cells such as those found in the liver, kidney and muscle system tissues.
- Ad vectors have a large carrying capacity.
- An example of the use of an Ad vector in a clinical trial involved polynucleotide therapy for antitumor immunization with intramuscular injection (Sterman et al, Hum. Gene Ther. 7: 1083-9 (1998)).
- Additional examples of the use of adenovirus vectors for gene transfer include Rosenecker et al, Infection 24: 1 5-10 (1996); Sterman et al, Hum. Gene Ther. 9:7 1083-1089 (1998); Welsh et al, Hum. Gene Ther. 2:205-18 (1995); Alvarez et al, Hum. Gene Ther. 5:597-613 (1997); Topf et al, Gene Ther. 5:507-513 (1998); Sterman et al, Hum. Gene Ther. 7:1083-1089 (1998); U.S. Patent Publication No. 2008/0159996.
- Packaging cells are used to form virus particles that are capable of infecting a host cell. Such cells include 293 cells, which package adenovirus, and psi2 cells or PA317 cells, which package retrovirus.
- Viral vectors used in gene therapy are usually generated by producer cell line that packages a nucleic acid vector into a viral particle. The vectors typically contain the minimal viral sequences required for packaging and subsequent integration into a host, other viral sequences being replaced by an expression cassette for the protein to be expressed. The missing viral functions are supplied in trans by the packaging cell line. For example, AAV vectors used in gene therapy typically only possess ITR sequences from the AAV genome, which are required for packaging and integration into the host genome.
- Viral DNA is packaged in a cell line, which contains a helper plasmid encoding the other AAV genes, namely rep and cap, but lacking ITR sequences.
- the cell line is also infected with adenovirus as a helper.
- the helper virus promotes replication of the AAV vector and expression of AAV genes from the helper plasmid.
- the helper plasmid is not packaged in. significant amounts due to a lack of ITR sequences. Contamination with adenovirus can be reduced by, e.g., heat treatment to which adenovirus is more sensitive than AAV.
- the gene therapy vector be delivered with a high degree of specificity to a particular tissue type.
- a viral vector is typically modified to have specificity for a given cell type by expressing a ligand as a fusion protein with a viral coat protein on the viruses outer surface.
- the ligand is chosen to have affinity for a receptor known to be present on the cell type of interest.
- Han et al Proc Natl Acad Sci USA 92:9747-9751 (1995), reported that Moloney murine leukemia virus can be modified to express human heregulin fused to gp70, and the recombinant virus infects certain human breast cancer cells expressing human epidermal growth factor receptor.
- filamentous phage can be engineered to display antibody fragments ⁇ e.g., FAB or Fv) having specific binding affinity for virtually any chosen cellular receptor.
- Gene therapy vectors can be delivered in vivo by administration to an individual patient, typically by systemic administration (e.g., intravenous, intraperitoneal, intramuscular, subdermal, or intracranial infusion) or topical application, as described below.
- vectors can be delivered to cells ex vivo, such as cells explanted from an individual patient (e.g., lymphocytes, bone marrow aspirates, tissue biopsy) or universal donor hematopoietic stem cells, followed by reimplantation of the cells into a patient, usually after selection for cells which have incorporated the vector.
- Ex vivo cell transfection for diagnostics, research, or for gene therapy is well known to those of skill in the art.
- cells are isolated from the subject organism, transfected with a TALE fusion nucleic acid (gene or cDNA), and re-infused back into the subject organism (e.g., patient).
- TALE fusion nucleic acid gene or cDNA
- Various cell types suitable for ex vivo transfection are well known to those of skill in the art (see, e.g., Freshney et al., Culture of Animal Cells, A Manual of Basic Technique (3rd ed. 1994)) and the references cited therein for a discussion of how to isolate and culture cells from patients).
- stem cells are used in ex vivo procedures for cell transfection and gene therapy.
- the advantage to using stem cells is that they can be differentiated into other cell types in vitro, or can be introduced into a mammal (such as the donor of the cells) where they will engraft in the bone marrow.
- Methods for differentiating CD34+ cells in vitro into clinically important immune cell types using cytokines such a GM- CSF, IFN-. gamma, and TNF-alpha are known (see Inaba et al., J. Exp. Med. 176:1693-1702 (1992)).
- Stem cells are isolated for transduction and differentiation using known methods.
- stem cells are isolated from bone marrow cells by panning the bone marrow cells with antibodies which bind unwanted cells, such as CD4+ and CD8+ (T cells), CD45+ (panb cells), GR-1 (granulocytes), and lad (differentiated antigen presenting cells) (see Inaba et al, J. Exp. Med. 176:1693-1702 (1992)).
- Exemplary stem cells include human embryonic stem cells (hES), induced pluripotent stem cells (iPSC), hematopoietic stem cells, mesenchymal stem cells, neuronal stem cells, and muscle stem cells.
- Vectors e.g., retroviruses, adenoviruses, liposomes, etc.
- therapeutic TALE domain fusion nucleic acids can be also administered directly to the organism for transduction of cells in vivo.
- naked DNA can be administered.
- Administration is by any of the routes normally used for introducing a molecule into ultimate contact with blood or tissue cells. Suitable methods of administering such nucleic acids are available and well known to those of skill in the art, and, although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route.
- compositions of the present invention are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions of the present invention, as described below (see, e.g., Remington's Pharmaceutical Sciences, 17th ed., 1989).
- TALE- fusions and expression vectors encoding TALE fusions can be administered directly to the patient for modulation of gene expression and for therapeutic or prophylactic applications, for example, cancer, ischemia, diabetic retinopathy, macular degeneration, rheumatoid arthritis, psoriasis, HIV infection, sickle cell anemia, Alzheimer's disease, muscular dystrophy, neurodegenerative diseases, vascular disease, cystic fibrosis, stroke, and the like.
- VZV HSV-1, HSV-6, HSV-II, CMV, and EBV
- HIV Ebola
- adenovirus influenza virus, flaviviruses, echovirus, rhinovirus, coxsackie virus, comovirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, poliovirus, rabies virus, and arboviral encephalitis virus, etc.
- TALE- fusions are administered in any suitable manner, preferably with pharmaceutically acceptable carriers. Suitable methods of administering such modulators are available and well known to those of skill in the art, and, although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route.
- Formulations suitable for parenteral administration include aqueous and nonaqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
- compositions can be administered, for example, by intravenous infusion, orally, topically, intraperitoneally, intravesically or intrathecally.
- the formulations of compounds can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials.
- Injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.
- TALE- fusions can be used to engineer plants for traits such as increased disease resistance, modification of structural and storage polysaccharides, flavors, proteins, and fatty acids, fruit ripening, yield, color, nutritional characteristics, improved storage capability, drought or submergence/flood tolerance, and the like.
- the engineering of crop species for enhanced oil production e.g., the modification of the fatty acids produced in oilseeds, is of interest. See, e.g., U.S. Patent No. 7,262,054; and U.S. Patent Publication Nos. 2008/0182332 and 20090205083.
- Seed oils are composed primarily of triacylglycerols (TAGs), which are glycerol esters of fatty acids. Commercial production of these vegetable oils is accounted for primarily by six major oil crops (soybean, oil palm, rapeseed, sunflower, cotton seed, and peanut.) Vegetable oils are used predominantly (90%) for human consumption as margarine, shortening, salad oils, and flying oil. The remaining 10% is used for non-food applications such as lubricants, oleochemicals, biofuels, detergents, and other industrial applications.
- TAGs triacylglycerols
- the desired characteristics of the oil used in each of these applications varies widely, particularly in terms of the chain length and number of double bonds present in the fatty acids making up the TAGs. These properties are manipulated by the plant in order to control membrane fluidity and temperature sensitivity. The same properties can be controlled using TALE domain fusions to produce oils with improved characteristics for food and industrial uses.
- the primary fatty acids in the TAGs of oilseed crops are 16 to 18 carbons in length and contain 0 to 3 double bonds. Palmitic acid (16:0 [16 carbons: 0 double bonds]), oleic acid (18:1), linoleic acid (18:2), and linolenic acid (18:3) predominate. The number of double bonds, or degree of saturation, determines the melting temperature, reactivity, cooking performance, and health attributes of the resulting oil.
- DELTA 12-oleate desaturase also referred to as omega-6 desaturase.
- a block at this step in the fatty acid desaturation pathway should result in the accumulation of oleic acid at the expense of polyunsaturates.
- proteins containing TALE domain(s) are used to regulate expression of the FAD2-1 gene in soybeans.
- Two genes encoding microsomal DELTA.6 desaturases have been cloned recently from soybean, and are referred to as FAD2-1 and FAD2-2 (Heppard et al, Plant Physiol. 110:311-319 (1996)).
- FAD2-1 delta 12 desaturase appears to control the bulk of oleic acid desaturation in the soybean seed.
- TALE- fusions can thus be used to modulate gene expression of FAD2-1 in plants.
- TALE domain fusions can be used to inhibit expression of the FAD2-1 gene in soybean in order to increase the accumulation of oleic acid (18: 1) in the oil seed.
- TALE- fusions can be used to modulate expression of any other plant gene, such as delta-9 desaturase, delta- 12 desaturases from other plants, delta- 15 desaturase, acetyl-CoA carboxylase, acyl-ACP- thioesterase, ADP-glucose pyrophosphorylase, starch synthase, cellulose synthase, sucrose synthase, senescence-associated genes, heavy metal chelators, fatty acid hydroperoxide lyase, polygalacturonase, EPSP synthase, plant viral genes, plant fungal pathogen genes, and plant bacterial pathogen genes.
- delta-9 desaturase delta- 12 desaturases from other plants
- delta- 15 desaturase
- acetyl-CoA carboxylase acetyl-CoA carboxylase
- acyl-ACP- thioesterase ADP-glucose pyrophosphorylase
- starch synthase
- TALE- fusions also have use for assays to determine the phenotypic consequences and function of gene expression.
- the recent advances in analytical techniques, coupled with focussed mass sequencing efforts have created the opportunity to identify and characterize many more molecular targets than were previously available. This new information about genes and their functions will speed along basic biological understanding and present many new targets for therapeutic intervention. In some cases analytical tools have not kept pace with the generation of new data.
- An example is provided by recent advances in the measurement of global differential gene expression. These methods, typified by gene expression microarrays, differential cDNA cloning frequencies, subtractive hybridization and differential display methods, can very rapidly identify genes that are up or down-regulated in different tissues or in response to specific stimuli.
- the TALE- fusion technology can be used to rapidly analyze differential gene expression studies.
- Engineered TALE domain fusions can be readily used to up or down- regulate any endogenous target gene. Very little sequence information is required to create a gene-specific DNA binding domain. This makes the TALE domain fusions technology ideal for analysis of long lists of poorly characterized differentially expressed genes.
- TALE domain fusions can be achieved by more conventional methods. This is because the production and/or function of an engineered TALE- fusions can be placed under small molecule control. Examples of this approach are provided by the Tet-On system, the ecdysone-regulated system and a system incorporating a chimeric factor including a mutant progesterone receptor. These systems are all capable of indirectly imparting small molecule control on any endogenous gene of interest or any transgene by placing the function and/or expression of a ZFP regulator under small molecule control.
- a further application of the TALE- fusion technology is manipulating gene expression and/or altering the genome to produce transgenic animals or plants.
- over-expression of an endogenous gene or the introduction of a heterologous gene to a transgenic animal, such as a transgenic mouse is a fairly straightforward process.
- production of transgenic plants is well known.
- the TALE domain fusions technology described herein can be used to readily generate transgenic animals and plants.
- TALE domain fusions to manipulate gene expression can be restricted to adult animals using the small molecule regulated systems described in the previous section. Expression and/or function of a TALE domain-based repressor can be switched off during development and switched on at will in the adult animals. This approach relies on the addition of the TALE- fusions expressing module only; homologous
- TALE domain fusions repressors are trans dominant, there is no concern about germline transmission or homozygosity. These issues dramatically affect the time and labor required to go from a poorly characterized gene candidate (a cDNA or EST clone) to a mouse model. This ability can be used to rapidly identify and/or validate gene targets for therapeutic intervention, generate novel model systems and permit the analysis of complex physiological phenomena (development, hematopoiesis, transformation, neural function etc.).
- Chimeric targeted mice can be derived according to Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual, (1988); Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, Robertson, ed., (1987); and Capecchi et al, Science 244: 1288 (1989).
- Genetically modified animals may be generated by deliver of the nucleic acid encoding the TALE fusion into a cell or an embryo. Typically, the embryo is a fertilized one cell stage embryo. Delivery of the nucleic acid may be by any of the methods known in the art including micro injection into the nucleus or cytoplasm of the embryo. TALE fusion encoding nucleic acids may be co-delivered with donor nucleic acids as desired. The embryos are then cultured as in known in the art to develop a genetically modified animal.
- genetically modified animals in which at least one chromosomal sequence encoding a gene or locus of interest has been edited are provided.
- the edited gene may become inactivated such that it is not transcribed or properly translated.
- the sequence may be edited such that an alternate form of the gene is expressed (e.g. insertion (knock in) or deletion (knock out) of one or more amino acids in the expressed protein).
- the gene of interest may comprise an inserted sequence such as a regulatory region.
- the genetically modified animal may be homozygous for the edited sequence or may be heterozygous.
- the genetically modified animal may have sequence inserted (knocked in) in a 'safe harbor' locus such as the Rosa26, HPRT, CCR5 or AAVS1 (PPP1R12C) loci. These knock in animals may be additionally edited at other chromosomal loci.
- the sequences of interest are inserted into the safe harbor without any selection markers, and/or without a promoter and so rely on the endogenous promoter to drive expression.
- the genetically modified animal may be "humanized" such that certain genes specific to the host species animal are replaced with the human homolog. In this way, genetically modified animals are produced with a human gene expressed ⁇ e.g.
- the gene of interest may further comprise a recombinase recognition site such as loxP or FRT for recognition of the cognate recombinase Cre and FLP, respectively, which can flank the inserted gene(s) of interest.
- Genes may be inserted containing the nuclease sites such that crossing the genetically modified animal with another genetically modified animal expressing the cognate recombinase (e.g Cre) will result in progeny that lack the inserted gene.
- the disclosed methods and compositions can be used to control gene regulation at a desired locus.
- Genes of choice may be activated or repressed, depending on the transcriptional regulatory domain that is fused to the TALE-repeat domain.
- TALE activators may be targeted to pluripotency-inducing genes for the goal of producing iPSCs from differentiated cells. This may be of use for in vitro and in vivo model development for specific disease states and for developing cell therapeutics derived from iPSCs.
- the TALE- fusions may be useful themselves as therapeutic agents, especially in immune privileged tissues such as in the brain or eye.
- Designed activators for example, are especially useful for increasing the dose of a gene product that requires natural splice variant ratios for proper function (e.g. VEGF), or for genes that are toxic where
- TALE regulators may also allow permanent switching of gene expression status via the use of functional domain that impose epigenetic changes. This technology could provide additional utility for generating stem cells and controlling their differentiation pathways. Additionally, TALE-fusions may be of use in immunosuppressed patients.
- the disclosed methods and compositions can also be used for genomic editing of any gene or genes. In certain applications, the methods and compositions can be used for inactivation of genomic sequences. To date, cleavage-based methods have been used to target modifications to the genomes of at least nine higher eukaryotes for which such capabilities were previously unavailable, including economically important species such as corn and rat.
- the methods and compositions allow for generation of random mutations, including generation of novel allelic forms of genes with different expression or biological properties as compared to unedited genes or integration of humanized genes, which in turn allows for the generation of cell or animal models.
- the methods and compositions can be used for creating random mutations at defined positions of genes that allows for the identification or selection of animals carrying novel allelic forms of those genes.
- the methods and compositions allow for targeted integration of an exogenous (donor) sequence into any selected area of the genome. Regulatory sequences (e.g. promoters) could be integrated in a targeted fashion at a site of interest.
- integration is meant both physical insertion (e.g., into the genome of a host cell) and, in addition, integration by copying of the donor sequence into the host cell genome via the specialized nucleic acid information exchange process that occurs during homology-directed DNA repair.
- Donor sequences can also comprise nucleic acids such as shRNAs, miRNAs etc. These small nucleic acid donors can be used to study their effects on genes of interest within the genome. Genomic editing (e.g., inactivation, integration and/or targeted or random mutation) of an animal gene can be achieved, for example, by a single cleavage event, by cleavage followed by non-homologous end joining, by cleavage followed by homology-directed repair mechanisms, by cleavage followed by physical integration of a donor sequence, by cleavage at two sites followed by joining so as to delete the sequence between the two cleavage sites, by targeted recombination of a missense or nonsense codon into the coding region, by targeted recombination of an irrelevant sequence (i.e., a "stuffer" sequence) into the gene or its regulatory region, so as to disrupt the gene or regulatory region, or by targeting recombination of a splice acceptor sequence into an intron to cause mis
- transgenes of interest may be integrated into a safe harbor locus within a mammalian or plant genome using TALEN-induced DSB at a specified location. See, U.S. Patent Publication Nos. 20030232410; 20050208489;
- TALENs may also be supplied as components of kits for targeted genetic manipulation.
- TALE-repeat domains optionally with novel or atypical RVDs, and moreover optionally attached to N-cap and/or C-cap residues, can also be fused to DNA manipulating enzymes such as recombinases, transposases, resolvases or integrases. Thus these domains can be used to make targeted fusion proteins that would allow the development of such tools and/or therapeutics as targeted transposons and the like. Additionally, a TALE-repeat domain, optionally attached to N-cap and C-cap residues, may be fused to nuclease domains to create designer restriction enzymes.
- a TALE-repeat domain may be fused to a single-chain Fokl domain (wherein two Fokl cleavage half domains are joined together using a linker of choice) such that treatment of a DNA preparation with the nuclease fusion can allow cleavage to occur exactly at the desired location.
- This technology would be useful for cloning and manipulation of DNA sequences that are not readily approached with standard restriction enzymes.
- Such a system would also be useful in specialized cell systems used in manufacturing.
- the CHO-derived cell lines do not have an endogenously active transposase/integrase system.
- TALE-transposase/integrase systems could be developed for specific targeting in CHO cells and could be useful for knock out/knock in, genome editing etc due to the highly specific nature of the TALE DNA binding domain.
- TALE- fusion proteins can be used to prevent binding of specific DNA- binding proteins to a given locus.
- a natural regulatory protein may be blocked from binding to its natural target in a promoter simply because an engineered TALE protein has been expressed in the host cell and it occupies the site on the DNA, thus preventing regulation by the regulatory protein.
- TALE-fusion proteins may be engineered to bind to RNA.
- RNA for example, splice donors and/or splice acceptor sites could be masked and would prevent splicing at specific locations in a mRNA.
- a TALE may be engineered to bind specific functional RNAs such as shRNAs, miRNA or RNAis, for example.
- TALE fusion proteins can be useful in diagnostics.
- the proteins may be engineered to recognize certain sequences in the genome to identify alleles known to be associated with a specific disease.
- TALE-fusions with a specified number of TALE repeat units may be utilized as a "yard stick" of sorts to measure the number of trinucleotide repeats in patients with the potential of having a trinucleotide repeat disorder (e.g. Huntingdon's Disease) to determine the likelihood of becoming afflicted with one of these diseases or to prognosticate the severity of the symptoms.
- These fusion proteins may also be supplied as components of diagnostic kits to allow rapid identification of genomic markers of interest.
- these proteins may be purified from cells and used in diagnostic kits or for diagnostic reagents for uses such as analyzing the allele type of a gene of interest, measuring mRNA expression levels etc.
- the TALE fusions may be attached to silicon chips or beads for multichannel or microfluidic analyses.
- TALE fusions may be useful in manufacturing settings.
- TALE-transcription factor fusions or TALENs may be used in cell lines of interest (e.g. CHO cells) or in algae (e.g. for biofuel production).
- TALE fusion proteins mediated genomic editing of a gene or genomic loci.
- the methods and compositions described herein allow for the generation of models of human diseases and for plant crops with desired characteristics.
- Example 1 Cloning of a natural TALE from Xanthomonas axonopodis
- TALE 13 TALE protein containing 12.5 TALE repeats (12 full repeats and a half repeat referred to as TALE 13) was cloned from Xanthomonas axonopodis by PCR amplification using the following primer pair: pthA_dl52N_EcoR,
- TALE 15 which has been reported as hssB3.0 (Shiotani et al (2007) J. Bacteriol 189 (8): 3271-9) the other TALE proteins isolated appear as novel proteins, as they have not been reported in the public literature. These include TALE13, TALE9, and TALE 16, with 13, 9, and 16 TALE repeats, respectively.
- the regions of the truncations are numbered as follows: On the N-terminus, the end point is represented by a number that enumerates the number of amino acid residues in an N-terminal direction from the first base of the first true TALE repeat (see Figure IB). For example, a label of N+91 describes a truncation on the N-terminus that leaves intact the 91 amino acids in the N-terminal direction from the N-terminus of the first true repeat. On the C terminus, the end point is represented by the number of amino acids in the C-terminal direction from the last amino acid of the last full TALE repeat.
- Truncation #1 termed TALE-13, clone #1, has the N-terminal 152 amino acids of the full length TALE protein removed and a single methionine residue added to the resulting N terminus and thus has an N+137 endpoint (N-cap), making this clone approximately 2.5 kb in length.
- Truncation #2 also has the N-terminal 152 amino acids of the full length TALE protein removed, and a single methionine residue added to the resulting N-terminus and thus has an N+137 endpoint, as well as the C-terminal sequences downstream of the 5' edge of the NLS, making this clone approximately 2.0 kb in length.
- Truncation #3 is similar to clone #2 except that it has the leucine-rich region deleted (the leucine-rich region is C-terminal to the half-repeat and extends to C +52 of the C-cap), making this clone approximately 1.6 kb in length.
- Truncation #4 is similar to clone #2 except that on the N-terminus, it has been deleted all the way up and including the R0 repeat sequence, making this clone approximately 1.6 kb in length.
- Truncation #5 is similar to clone #4 except that its deletion on the C-terminal side includes the leucine-rich sequence (similar to clone #2), making this clone approximately 1.4 kb in length.
- the deduced target sequence of the full length TALE 13 protein is
- Truncation #6 has 152 amino acids deleted from the N- terminus and in the C-terminal regions is similar to clone #2 except that 43 additional amino acids have been deleted.
- Truncation #7 has 165 amino acids deleted from the N-terminus and has the same C-terminal deletion as clone #6. Truncations #6 and #7 are discussed below.
- TALE 13 clone #1 protein appears to be highly selective in its binding despite lacking the N-terminal 152 amino acids.
- the SELEX data for TALE 13, clone #2 is presented in Table 6. In this figure, the SELEX was repeated with two different libraries of target sequences, and gave similar results with both libraries.
- TALE 9 has 8.5 TALE repeats that specify the following DNA target: TANAAACCTT (SEQ ID NO:56), while TALE16 has 15.5 TALE repeats that predict the following target:
- TALE 9 protein in the clone #2 configurations was used and the results are shown. As with TALE 13 clone #2, this experiment was repeated with a second partially randomized DNA library and gave similar data as the first library. As described above for TALE 13, TALE 9 is highly specific for its target sequence.
- Table 10 shows the SELEX data for the TALE 16 protein with the Nl 8TA library and again demonstrates a high degree of sequence specificity for the target identified.
- Example 4 Reporter gene activation by TALE- fusion proteins in mammalian cells
- engineered reporter constructs were made as follows. One or more copies of the target sequences for the cloned TALE 13 or TALE 15 were inserted in a reporter construct between the Nhel and Bgl II sites thereby placing the targets upstream from the firefly luciferase expression unit driven by the minimal SV40 promoter in the pGL3 plasmid (Promega) (see Figure 2).
- the promoter region of the pGL3 plasmid is shown in Figure 2A and the sequence containing the two predicted target sites for TALE13 is shown in Figure 2B.
- the TALE protein construct together with the reporter plasmid containing 2 targets ( Figure 3A), and an expression construct containing Renilla luciferase (Promega) as an internal control, were co-transfected into human 293 cells.
- the firefly luciferase activity induced by each TALE protein was then analyzed 2 days after transfection.
- TALE VP 16 fusions can synergistically activate the reporter gene expression in mammalian cells ( Figure 3).
- TALE proteins with addition of the VP 16 activation domain (TR13-VP16 and TR15- VP16) activate the luciferase reporter gene.
- the TALE target sequences were inserted in both distal and proximal locations relative to the targeted promoter.
- the TALE 13 target was used as shown in Figure 5 A where four target sequences were inserted either upstream (for example "R13x4") or downstream (“R13x4D") of the promoter.
- the results, shown in Figure 5B demonstrate that optimal activation is seen when the TALE 13 binding sites were placed upstream in close proximity to the promoter of interest.
- TALE proteins can be linked to a transcriptional regulatory domain to modulate reporter gene expression in mammalian cells
- experiments were performed to engineer TALE transcription factors with desired targeting specificities.
- Silent mutations i.e. a change in the nucleotide sequence without an alteration of amino acid sequence
- TR13 VP 16 Silent mutations (i.e. a change in the nucleotide sequence without an alteration of amino acid sequence) of TR13 VP 16 were introduced to create two unique restriction sites, Apal and Hpal, at the beginning of the first tandem repeat and the end of last tandem repeat, respectively. These Apal and Hpal sites were then used for cloning the synthetic tandem repeats into the TR13 VP 16 backbone to generate the engineered TALEs with complete N- and C-terminal sequences flanking the tandem repeats, as well as the VP 16 activation domain.
- the targeted sequence was GGAGCCATCTGGCCGGGT (SEQ ID NO:58) located within the NT3 promoter sequence.
- a ZFP TF 23570 targeting to this sequence has shown to activate the endogenous NTF3 gene expression (See co-owned US Provisional Patent application 61/206,770).
- the 17.5 tandem repeats from the TALE AvrBs3 were used as a backbone to engineer TALE 18 (also termed "NT-L”) such that the tandem repeats of the engineered TALE 18 amino acid sequences were altered to specify the intended target nucleotide.
- the amino acid sequence of the DNA-binding domain from engineered TALE18 is shown below in Table 12, where the RVDs are shown boxed in bold:
- NK RVD in a subset of TALE repeats at positions corresponding to G nucleotides in the DNA target site as it was observed with a cognate target site guanine in two naturally occurring proteins (see Moscou et al, ibid). Consistent with earlier experimental studies (see Boch et al, ibid), we found that on average NI, HD, NG showed a strong preference for adenine, cytosine, and thymine respectively and NN showed a preference for guanine, but can also bind adenine. In contrast, the NK RVD shows a strong preference for guanine, representing a potential improvement for engineered TALE proteins that target sites including at least one guanine.
- TALE 18 was then derived from the amino acid sequence and synthesized by 84 overlapping oligos, each about 40 nucleotides in length, as follows. First, the whole 1.8 kb DNA sequences were divided into 11 blocks, and overlapping oligos covering each block was assembled by PCR-based method; the 1 1 blocks was then fused together into 4 bigger blocks by overlapping PCR and finally, the 4 blocks were assembled into the full length by overlapping PCR using the outmost primer pairs. The synthesized tandem repeats was then sequence confirmed and cloned into the Apal and Hpal sites of TR13-VP16, as described above, to generate the expression construct of engineered TALE 18 (NT-L) targeting to the NT-3 promoter (R23570V).
- NT-L engineered TALE 18 targeting to the NT-3 promoter
- NT-L The specificity of this engineered protein (termed NT-L) was then determined by SELEX, and the results are shown below in Table 13. As can be seen, the data demonstrate that it is possible to engineer an entirely novel TALE protein to bind to a desired sequence.
- the SELEX selection was also performed with NT-L in the clone #6 truncation (see above) as is also shown below in Table 13 demonstrating that, similar to TALE 9, the specificity of the NT-L is maintained within this truncation.
- the SELEX experiment was also performed with NT-L in the clone #7 truncation that showed that DNA binding specificity was maintained.
- the transcriptional activity of the engineered NT-L proteins was then analyzed against a luciferase reporter construct containing two copies of the target sequence.
- the engineered NT-L fusion protein R23570V
- the engineered 17.5 tandem repeats but otherwise identical to TR13-VP16 is capable of driving potent reporter gene activation, whereas the similar construct with no tandem repeats (R0-VP16) does not activate luciferase.
- nR23570S-dNC contains the SV40 nuclear localization signal (n) and the engineered NT-L repeats (R23570) fused to a single p65 activation domain (S). This construct contained only the repeats but no N-terminal or C-terminal sequence from TALE (dNC).
- dNC N-terminal or C-terminal sequence from TALE
- the constructs were used to target the endogenous NTF3 gene to see if the engineered fusion protein was capable of activating an endogenous gene in its chromosomal locus in a mammalian cell.
- the engineered NT-L (R23570V), as well as the control constructs (R0-VP16, GFP) were transiently transfected into human 293 cells. After 2 days following transfection, the NT-3 expression level was analyzed by Taqman analysis.
- Figure 7 shows a diagram of these two constructs (the +278 construct was referred to as R23570V in Figure 6) and the effect of these proteins on NTF3 activation at the mRNA and protein levels. Also shown are the SELEX results for the longer of these constructs
- both TALE transcription factor constructs are able to up-regulate NTF3 expression at both mRNA and protein levels.
- Example 6 Dissection of the TALE functional domains involved in DNA targeting in mammalian cells
- the minimal region that retains robust reporter activation activity in this set of constructs is R13V-dl82C, which lacks 152 amino acids at its N-terminus and 183 amino acids at its C-terminus.
- the result confirms that RO region preceding the first tandem repeats and the leucine rich region following the last repeat is provides optimal binding in this assay, whereas the region containing nuclear localization signal, and the native activation domain at its C-terminus is dispensable for DNA-targeting in mammalian cells.
- Example 7 Demonstration of nuclease cleavage activity of a TALE linked to nuclease domains
- TALEs DNA targeting ability in the context of artificial TALE nucleases
- the DNA targeting domain of TALE 13 as defined in Example 6 was linked to nuclease domains to generate a construct named as R13dl82C- scFokl, which is the same as R13V-dl82C described above, except that two copies of the Fokl nuclease domain, linked by 12 copies of GGGS sequence between the Fokl domains, were used to replace the VP 16 activation domain.
- the TALEN construct was then tested for nuclease activity in a single stranded annealing (SSA) based reporter assay (see co-owned US Patent Publication No. 20110014616).
- SSA single stranded annealing
- the reporter construct ( Figure 11 A, SSA-R13) used in this assay contains the predicted TALE 13 target, sandwiched by the N-terminal (GF) and C-terminal part (FP) of the GFP coding sequence.
- the reporter SSA-R13 by itself cannot drive the GFP expression, but the cleavage at the TALE 13 target will promote homologous recombination (HR) among the N- and C-terminal part of GFP to form a functional GFP transgene.
- HR homologous recombination
- the SSA-R13 reporter construct, together with or without (mock) the TALEN construct was transiently nucleofected into K562 cells as described previously.
- TALE DNA binding domains can be used to generate functional TALENs for site specific cleavage of DNA in mammalian cells.
- TALE domain fusions were also constructed using Fokl cleavage half domains.
- wild type Fokl half cleavage domains were used so that for nuclease activity, a homodimer must be formed from two of the fusions.
- the TALE 13 DNA binding domain was fused to each Fokl half domain by cloning the TALE DNA binding domain into a plasmid adjacent to FokI-specifying sequence.
- the target sites were cloned into a TOP02.1 target vector (Invitrogen) with varying gap spacings between each target binding site such that the two were separated from each other by 2 to 22 bp. PCR amplification of an approximately 1 kb region of the target vector was done to generate the target DNAs.
- the TALE DNA binding domains were also truncated as described previously, and are described using the same nomenclature as described above in Examples 2 and 6.
- the TALE domain nuclease fusion clones were expressed in the TNT Rabbit Reticulocyte Lysate system by adding 5 ⁇ L of water containing 250 nanograms of the nuclease fusion clone plasmid to 20 ⁇ L of lysate and incubating at 30°C for 90 minutes.
- the lysate was then used to cleave the target DNAs as follows: 2.5 ⁇ L, of lysate were added to a 50 ⁇ L reaction containing 50 nanograms of PCR-amplified target DNA and a final Buffer 2 (New England Biolabs) concentration of IX. The cleavage reaction was for one hour at 37°C, followed by a 20 minute heat inactivation stage at 65°C. The reaction was then centrifuged at high speed to separate the target DNA from the lysate, causing the lysate to condense into a pellet in the reaction well.
- Buffer 2 New England Biolabs
- the DNA-containing supernatant was pipetted off and run on an ethidium bromide-stained agarose gel (Invitrogen) to separate intact target DNA from cleaved target DNA.
- the agarose gel was then analyzed using AlphaEaseFC (Alpha Innotech) software to measure the amount of target DNA present in the large uncleaved DNA band and the two smaller DNA bands resulting from a single cleavage event of the target DNA.
- AlphaEaseFC Alpha Innotech
- Figure 12 shows the cleavage of the target sequencesby visualizing the cleavage products on ethidium bromide stained agarose gels.
- L2 or L8 indicates the linker used, and the number beneath each lane indicated the bp gap between the two target DNA binding sites of the dimer.
- 'S' indicates the presence of only one target DNA binding site such that an active nuclease homodimer cannot form on the DNA.
- Pmll indicates the positive control reaction of cleavage using a commercially-available restriction enzyme (New England Biolabs) of a unique restriction site located in the cloned DNA target sequence next to the TALE binding sites.
- Cleavage at the Pmll site indicates that the cloned target site exists in the PCR-amplified target DNA and also shows the approximate expected size of cleaved DNA.
- Blank indicates the negative control TNT reaction without the TALEN encoding plasmid such that no TALEN was produced.
- the data is depicted in a graphical format in Figure 13, and shows that the cleavage activity of the protein greatly increases with C+28 and C+39 C-caps for a spacer length of at least 9 bases.
- TALENs can be quite active when linked to either Fokl half domains or to two half domains which can interact in a single chain configuration, but the length of the N-cap and C-cap has an effect on the DNA cleavage properties of the resulting TALENs.
- TALENs were constructed to bind to an endogenous target in a mammalian cell.
- the 10 repeat NTF3 binding domain was linked to a Fokl half domain as described above.
- a NTF3 specific partner (rNTF3) was constructed commercially using standard overlapping oligonucleotide construction technology.
- the synthetic NTF3 partner was made with three variants at the C terminus: C+63, C+39 and C+28, and the TALE DNA binding domain was cloned into a standard ZFN vector which appends an epitope tag and a nuclear localization signal to the C-terminus and the wild-type Fokl cleavage domain to the C-terminus.
- the complete amino acid sequences of the constructs used in these experiments are shown in Example 23.
- TALENs were also made to target a site specific for the VEGF A gene.
- This fusion protein contained 9.5 repeat units and was constructed as described above.
- the 18 repeat NT-L and the VEGF-specific TALENs were also made with either a C terminal truncation of either +28, +39 or +63.
- These synthetic fusion nucleases were then used in vitro in nuclease assays as above, in various combinations. The substrate sequences are shown below with the capital letters indicating the target binding sites for the various fusions:
- Table 18 shows duplicate testing of each TALEN pair.
- samples 1 and 16 are the same combination of TALEN monomers.
- N refers to the relevant portion of the endogenous NTF3 target w th a n ng or ot the left (NT-L) and the right (NT-R) NTF3 TALENs. #1 or #2 refers to different clones of the same construct.
- FIG. 15 A A target substrate (shown in Figure 15 A, SEQ ID NO:452) was cloned in between the disjointed GFP reporter such that cleavage at the NTF3 site followed by resection will result in a whole GFP reporter capable of expression.
- This substrate contains both a NTF3 target sequence and a target sequence specific for targeting the CCR5 gene.
- Figure 15B depicts the results of this experiment using a selection of the NTF3 -specific TALE proteins. In this experiment the following NTF3- specific TALEN fusions were used.
- TALE13C28L2 is the TALE 13 derivative described above with a C+28 truncation and the L2 linker.
- rNT3R17C28L2 is the 17.5 repeat NT3- specific protein (that targets the reverse strand of the DNA with respect to the coding strand of the NT3 gene) with the C+28 truncation and L2 linker.
- rNT3R17C39L2 is the similar construct with the C+39 C terminus, and rNT3R17C63L2 has the C+63 C terminus.
- This rNT3R17 DNA binding domain is also termed NT-R.
- the 8267EL/8196zKK is a control using a pair of CCR5 specific zinc finger nucleases.
- the data labeled as "-NT3R18C28L8” depicts the results in the absence of the NTF3 specific partner (that targets the forward strand of DNA with respect to the coding strand of the NTF3 gene), while the data labeled as "+NT3 R18 C28L8” depicts the results in the presence of the partner.
- the partner is an NTF3 specific protein with 17.5 repeats, truncated at the C28 position and containing the L8 linker.
- the correct pairing of the TALENs leads to efficient cleavage of the reporter gene and thus reporter gene expression.
- Example 8 Use of engineered TALENs to cleave an endogenous locus in a mammalian cell
- compositions that may be used to link a nuclease domain to a TALE repeat array that provides highly active nuclease function were also subjected to deep sequencing at the NTF3 locus. Samples were barcoded with a 4 bp sequence and a 50 bp read length was used on an Illumina Genome Analyzer instrument (Illumina, San Diego CA). Sequences were processed with a custom python script.
- Example 9 Targeted integration into an endogenous locus following TALEN cleavage
- TALE-mediated targeted integration at NTF3 could happen via the HDR DNA repair pathway or via the NHEJ pathway.
- Fokl naturally creates 4 bp 5' overhangs; ' in the context of a ZFN, the Fokl nuclease domain creates either 4 bp or 5 bp 5' overhangs. Since the position and composition of the overhangs left by NTF3 TALENs is unknown, we designed nine double-stranded oligonucleotide donors with all possible 4 bp 5' overhangs in the 12 bp spacer region between the NTF3 TALEN binding sites (NT3-1F to NT3-9R). (see Table 20).
- Donor oligonucleotides (5 ⁇ L of 40 ⁇ annealed oligonucleotide) were individually transfected with each of eight different TALEN pairs (A-H, 400 ng each plasmid, see Table 21) in a 20 transfection mix into 200,000 K562 cells using an Amaxa Nucleofector (Lonza) set to program FF-120 and using solution SF.
- oligonucleotide and the chromosome using the Internal F and GJC 273R primers.
- the expected size of the PCR amplicon based on perfect ligation of the oligonucleotide donor varies depending on the position of the break in the chromosome. As can be seen in Figure 19, integration of the donor was detected with many combinations of TALEN and donor overhangs. Maximal signal was seen with the CTGG and TGGT overhangs near the center of the 12 bp spacer region. Endogenous chromosomal loci containing donors captured by NHEJ were sequenced and are shown in Figure 20.
- NTF3 target locus top duplex
- bottom duplex The binding sites for NT-L+28 and NT-R+63 are underlined in the top sequence.
- the cleavage overhang that will most efficiently capture the duplex (5' CTGG) is also highlighted.
- Figure 20B Also shown in Figure 20B is a second oligonucleotide duplex used for this study. Binding sites for NT- L+28 and NT-R+63 are underlined in the top sequence. The cleavage overhang that will most efficiently capture this second duplex (5' TGGT) is also shown.
- the TALENs NT- L+28 and NT-R+63 were then expressed in K562 cells in the presence of the oligonucleotide duplex shown in Figure 20A. Junctions between successfully integrated duplex and genomic DNA were then amplified using one primer that anneals within the duplex and one primer that anneals to the native NTF3 locus. The resulting amplicons were cloned and sequenced.
- the "expected" sequence in Figure 20C indicates the sequence that would result from a perfect ligation of oligonucleotide duplex to the cleaved locus.
- the box highlights the location of the duplex overhang in the junction sequences.
- the bottom two lines provide junction sequences obtained from this study.
- FIG. 20D shows results from experiments as shown in Figure 20C except that the oligonucleotide duplex shown in Figure 20B was used, which has a 4 bp overhang that is shifted by one base relative to the duplex shown in Figure 20 A.
- the lowest four lines provide junction sequences obtained from this study. As shown, four distinct sequences were identified, which each exhibit short deletions consistent with resection prior to NHEJ-mediated repair.
- the DNA sequence encoding TALE repeats found in natural proteins is as repetitive as their corresponding amino acid sequence.
- the natural TALE typically have only a few base pairs' worth of difference between the sequences of each repeat.
- Repetitive DNA sequence can make it difficult to efficiently amplify the desired full-length DNA amplicon. This has been shown when attempting to amplify DNA for natural TALE-containing proteins.
- Further analysis of the DNA sequence of the TALE -repeat protein above using Mfold revealed that not only do they have repetitive sequence disrupting efficient amplification, but also that they contain very stable secondary structure. In this analysis, 800 base pairs of sequence were analyzed starting at the 5' end of the nucleic acid encoding the first full repeat sequence. Thus, the nucleic acid sequence analyzed contained approximately 7.5 repeat sequences.
- TALE repeats can occur between any of the TALE repeats or between repeats that are not adjacent.
- introduction of silent mutations to disrupt this secondary structure and bias the reaction towards the full-length amplicon were made in the regions of the TALE repeats that serve to stabilize the secondary structure.
- Primers were then made to allow efficient amplification of the TALE sequence or interest.
- the PCR amplification product was then sequenced for verification and cloned for use in fusion proteins.
- silent mutations were made in the TALE nucleotide sequence for codon optimization in mammalian cells. Similar codon optimization can be used for optimal expression in other host cell systems (e.g. plant, fungal etc.).
- Example 11 Method for rapid construction of genes encoding TALE fusion proteins
- Modules containing four TALE repeat units were constructed with specificity for each of the 256 possible DNA tetranucleotide sequence (for example, one module for the AAAA target, one for AAAT etc.). In addition, modules were also created for all 64 possible DNA trinucleotide targets, all possible 64 dinucleotide DNA targets as well as 4 single nucleotide targets.
- the dipeptide recognition region also referred to as an RVD- Repeat Variable Dipeptide
- the following code was used: For recognition of Adenine, the RVD was NI (asparagine-isoleucine), for Cytosine, the RVD was HD (histadine-aspartate), for recognition of Adenine, the RVD was NI (asparagine-isoleucine), for Cytosine, the RVD was HD (histadine-aspartate), for
- the RVD was NG (asparagine-glycine), and for R (comparable specificity for Guanine or Adenine), the RVD was NN (asparagine-asparagine).
- the RVD NK (asparagine-lysine) was chosen for recognition of G because it appeared to give higher specificity for G than NN in some proteins.
- the penultimate position N- terminal of the RVD was N or asparagine (typically this position is an S or serine). This module archive can be expanded by using any other RVDs.
- nucleotide sequence encoding the various repeat modules was also altered to exploit the redundancy in the genetic code such that codons encoding specific amino acids may be interchanged allowing the DNA strand encoding the repeat unit to have a different sequence from another repeat unit, but the amino acid sequence will remain the same. All of these techniques were utilized to pools of modules that could be used to construct engineered TALE DNA binding domains where the interior of the DNA binding domain could recognize any desired target.
- the vector backbone that the ligated modules are cloned into also contains specific Bsal cleaved sticky ends, such that only the 5' end of the "A” module, and only the 3' end of the "D” module will ligate to complete the vector circle.
- position of each module within the engineered TALE DNA binding domain is determined by the PCR primers chosen by the user.
- DNA target sites for TALE DNA binding domains are typically flanked by T nucleotides at the 5' end of the target (which is recognized by the R0 repeat) and at the 3' end of the target (which is recognized by the Rl/2 repeat).
- the vector backbone has been designed such that the ligated PCR amplicons containing the specified modules are cloned in frame between R0 and Rl/2 sequences within the vector.
- the vector contains the user specified C-terminal domain type (truncated or not) of the TALE protein and the exogenous domain of choice for fusion partner.
- the exogenous domain is a Fokl domain, allowing for the production of a TALE nuclease.
- the vector further contains sequences necessary for expression of the fusion protein such as a CMV promoter, a nuclear localization signal, a tag for monitoring expression, and a poly A site. This vector can now be transfected into a cell of the user's choice.
- the vector can be further modified to contain selection markers, domains or other genes as desired and/or required for different cellular systems.
- Example 12 Design and characterization of specific endogenous TALENs
- the data from Table 22 and Table 23 can be compared to determine that the range of gap sizes where these pairs are most active includes 12 to 21 bp but excludes gaps of less than 11 bp or more than 23 bp.
- HDR homology directed repair
- the region containing the insert site can be PCR amplified and then subject to BglI digestion, as is shown below where the top strand shows the sequence of the target site (SEQ ID NO: 133) and the bottom strand (SEQ ID NO: 134) shows the sequence of a target had the tag donor inserted.
- the underlined sequence in the top strand shows the TALEN binding site while the underlined sequence in the bottom strand shows the BgB. restriction site (SEQ ID NO:s 445 through 450):
- PCR products of clones containing an insert had two fragments following BglI digestion.
- the PCR and Bg ⁇ l digestion scheme is shown in Figure 24A, while the results are shown in Figure 24B, and revealed highly efficient editing.
- our TALEN architecture induced efficient gene modification via HDR at an endogenous locus.
- Example 14 Systematic mapping of compositions that may be used to link a nuclease domain to a TALE repeat array that provide highly active nuclease function
- a fine series of truncations was assembled comprising 30 C-caps: C-41, C-35, C-28, C-21, C-16, C-8, C-2, C-l, C+5, C+l 1 , C+17, C+22, C+28, C+34, C+39, C+47, C+55, C+63, C+72, C+79, C+87, C+95, C+109, C+123, C+138, C+153, C+183, C+213, C+231, and C+278. Note that our C- cap notation starts at residue -20.
- C-41, C-35, C-28, and C-21 indicates a construct completely lacking a C-cap and with 20, 14, 7, or 0 residues removed from the C-terminus of the last full 34-residue TALE repeat. Pairs of the constructs were tested against the appropriate target sites with the following gap spacings between target sites: 0, 2, 4, 7, 10, 14, 18, 23, 28, and 34 base pairs. The pairs were tested against a reporter gene in an SSA assay as well as in a mammalian cell against the endogenous locus.
- the C-caps are illustrated below where the illustration starts at the last full repeat of a TALE DNA binding domain and shows the points towards the C terminus.
- TALE-proteins as described herein can tolerate C-terminal truncations relative to full-length TALE-proteins, including truncations extending into a half repeat and TALE repeat domain itself without complete loss of functionality against an endogenous locus.
- Negative control is the assay performed in the absence of TALENs.
- the reporter #4 has the exact DNA binding sequence and the same gap sequences as the endogenous sequence, and thus can be compared with the Cel-I data at the endogenous locus.
- the DLSSA data of the four TALEN pairs from reporter #4 is shown in Table 26A. These data illustrate a general correlation between the results found with a reporter system and those observed on an endogenous target are close and thus the reporter system is useful as a screening tool for candidate nucleases to test in any endogenous assay. This is a useful tool when working in systems with precious model cells or when the intended target cell type is either not available or difficult to be used for screening purpose. This is also useful tool to develop and to optimize TALEN technology platform when the target sequences are not available in endogenous genome. Active nucleases can be identified by DLSSA and then ported into the endogenous system for final evaluation.
- the Cel-I and DLSSA results indicate that these proteins have substantial and robust activity when the appropriate C-cap is used and an N-cap is present. Further, gap spacings may play a role in the maximum activity observed with smaller gap spacings being active with a smaller subset of C-terminal truncations as compared to larger gap spacings.
- the relative DLSSA activity does not appear to be linearly related to the endogenous activity for the same TALENs obtained at the same temperature (37 degrees Celsius).
- the reporter results yield a significantly higher relative activity for constructs with C+153, C+183, C+213, C+231 , and C+278 C-caps than observed at the native endogenous locus of human cells. Thus activity in reporter systems, even reporter systems in mammalian cells, does not necessarily predict the activity at the native endogenous in mammalian cells.
- RVDs were explored to determine if other amino acids at the positions that determine DNA binding specificity could be altered.
- a TALE binding domain was constructed whose binding activity was shown by SELEX and ELISA to be sensitive to a mismatch at the middle position. This protein bound the sequence 5'- TTGAC AATCCT-3 ' (SEQ ID NO: 178) and displayed little binding activity against the sequences 5'-TTGACCATCCT-3' (SEQ ID NO: 179), 5'-TTGACGATCCT-3' (SEQ ED).
- CXA targets denoting the middle triplet nucleic acid, where X is either A, C, T or G.
- This TALE backbone was then used to characterize the DNA-binding specificity of alternative RVDs (amino acids 12 and 13) for the TALE repeat that targets the base at the 6 th position.
- RVDs amino acids 12 and 13
- the two codons that encode this RVD were randomized and clones were screened by sequencing to ensure that the complete repeat units were present. Correct clones were then analyzed by a DNA-binding ELISA against four versions of the target sequence wherein each sequence had either an A, C, T or G at the position the novel (i.e., atypical) RVD would interact with (i.e.
- TTGACAATCCT SEQ ID NO: 178
- TTGACCATCCT SEQ ID NO: 182
- TTGACTATCCT SEQ ID NO: 183
- TTGACGATCCT SEQ ID NO: 184
- RVDs were identified that bound equally well to all bases tested.
- the data are presented in numeric format below in Table 27B and also in Figure 28. In the data shown below, all data was background corrected by subtracting the background ELISA signal and then normalized to the average value of NI with the CAA site, HD with the CCA site, NN with the CGA site, and NG with the CTA site.
- FIG. 28 This data is also presented in Figure 28 where the data is shown in a 20x20 grid.
- the first amino acid of the RVD (position 12) is indicated to the left of the grid and the second amino acid of the RVD (position 13) is indicated above the grid.
- the size of the letters A, C, G, and T in each grid is scaled based on the square root of the normalized ELISA signal for the CAA site, CCA site, and CGA site and CTA site respectively.
- the boxed RVDs indicate frequently occurring natural RVDs found in TALE proteins encoded by Xanthomonas. Many RVDs have improved DNA binding properties with respect to the naturally occurring HD, NI, NG, NS, NN, IG, HG, and NK RVDs.
- Exemplary novel RVDs and their cognate nucleotide bases include where N represents positive interaction with all bases:
- T VG, IA, ⁇ , TP, QA, YG, LA, SG, HA, NA, GG, KG, QG
- N KS, AT, KT, RA.
- RVD sequences were tested:
- Oligonucleotides were made to allow the specific alteration of the TALE construct described above. These specific oligonucleotides are then cloned into the expression vectors and assembled as described in Example 1 1, and resultant protein extracts are analyzed by DNA-binding ELISA and SELEX to determine the binding characteristics of the RVDs.
- a CCR5-specific 18 repeat TALEN was produced with all novel RVDs for comparison with the CCR5- specific TALEN described in Example 12.
- the target sites for this TALEN pair is reshown below.
- the 101041 TALEN monomer was the partner that was modified while the 101047 partner was left with all natural RVDs:
- RVDs were also constructed in CCR5 specific TALENs in which novel RVDs were substituted of all one type, for example, all RVDs recognizing 'T' or ⁇ '.
- cND' indicates that positions 11, 12 and 13 in the repeat unit were altered.
- candidate RVDs were chosen by the data presented in Table 27B and used to create proof of principal proteins. Additional TALE proteins may be constructed using alternative atypical RVDs from the entire set. In addition, atypical RVDs may be chosen such that a mixture of RVDs specifying a base may be created (e.g. one TALEN protein may be constructed using both TP and IA RVDs to specify 'T' in different positions).
- RVD sequences for the repeat units are shown below in Tables 29 A- 29C and all mutated positions are indicated in bold font.
- each TALE-repeat unit includes a novel RVD, as well as in type substituted or singly substituted TALENs.
- TALEs use the NG RVD in the C-terminal half repeat to specify interaction with a T nucleotide base.
- generation of novel C-terminal half repeats was investigated to allow for the expansion of TALE targeting.
- TALENs targeting the Pou5Fl and PITX3 genes were used as backbones, and the RVD within the C-terminal half repeat (C-cap amino acids C-9 and C-8) was altered to specify alternate nucleic acids.
- the NI RVD was inserted to recognize A, HD for C, NK for G and the control was NG for T.
- the TALENs used contained between 15 and 18 RVDs and targeted a variety of target sequences in these two genes.
- Results are summarized in Tables 31 , 32and 33.
- the values in Table 31 are log-odds scores calculated as the logarithm (base 4) of the ratio between the observed frequency of the targeted base and the frequency of that base expected by chance ⁇ i.e. 0.25). A score of 1.0 would indicate that the targeted base was observed 100% of the time ⁇ i.e. 4 times more frequent than expected by chance), a score of 0.0 would indicate that the targeted base was observed 25% of the time, and a negative score would indicate that the targeted base was observed less than 25% of the time.
- the values in Table 31 were calculated from the average base frequency for the appropriate positions of a data set consisting of SELEX data from 62 separate TALE proteins.
- Rl RVD refers to the N-terminal TALE repeat (and cognate position in each binding site).
- R2+ RVD refer to all other RVDs (and cognate positions in each binding site). This data indicates a dramatic different in the specificity of TALE repeats bearing HD, NN, and NG RVDs at the N-terminal position versus all other positions.
- Tables 32 and 33 represent the change in those log-odds scores determined for each base independently versus the score in either the dimer (Table 32) or trimer (Table 33) setting and were determined from SELEX data for 67 separate TALE proteins.
- the -0.12 value for an NN RVD adjacent to an HD RVD indicates that the sum of the log-odds scores for both positions in the dimer was 0.12 less than would be expected if these two RVDs behaved independently of each other.
- the -0.34 value in Table 33C indicates that an NN RVD flanked on the N-terminal side by a second NN RVD and flanked on the C-terminal side by an HD RVD indicates that the NN RVD of interest has a log-odds score 0.34 less than the average value for all NN RVDs.
- negative values indicate combinations of adjacent RVDs that perform more poorly than if they were completely independent of each other.
- Example 18 Demonstration of TALEN-driven targeted integration in human stem cells
- TALENs were used to drive targeted integration in human embryonic stem cells (ESC) and induced pluripotent stem cells (iPSC).
- Human ESCs and iPSCs were used for the targeted integration of a puromycin donor nucleic acid additionally comprising a restriction site, into the AAVS1 locus where expression of the puromycin marker is driven by the AAVS 1 promoter.
- Donors and methods followed were those described previously in co-owned WO20101 17464 (see also
- this locus was targeted with a gene trap approach in which the puromycin resistance gene (PURO) was expressed under the control of the endogenous PPP1R12C promoter only following a correct targeting event.
- the PPP1R12C locus was targeted using an autonomous selection cassette that expressed the puromycin resistance gene PURO from the phosphoglycerate kinase (PG ) promoter.
- PG phosphoglycerate kinase
- Targeting efficiency was high independent of the donor used, with approximately 50% of isolated clones possessing either heterozygous or homozygous correctly targeted events and carrying the transgene only at the desired locus. This efficiency is comparable to that previously observed with ZFNs.
- Targeting to the PPP1R12C locus resulted in expression of the introduced transgene.
- Uniform expression of enhanced green fluorescent protein (eGFP) was observed in hESCs and iPSC when targeted with the SA-PURO donor plasmids that additionally carries a constitutive eGFP expression cassette.
- hESCs that have been genetically engineered using TALENs remained pluripotent as indicated by their expression of the pluripotency markers OCT4, NANOG, SSEA4, Tra-1-81 and Tra-1-60.
- TALENs were also designed against the first intron of the human OCT4 gene
- the TALENs utilized a +63 C-cap and used the typical RVDs (NI, HD, NN, and NG to target A, C, G, and T respectively).
- 101125 comprised 15.5 TALE repeats and 101225 comprised 16.5 TALE repeats.
- 101225 utilized a half repeat with an NN RVD to recognize the 3' G in its target site.
- Correct targeting events are characterized by expression of both puromycin and an OCT4 exonl-eGFP fusion protein under control of the endogenous OCT4 promoter.
- the first two donor plasmids were designed to integrate a splice acceptor eGFP-2A-self- cleaving peptide (2A)-puromycin cassette into the first intron of OCT4, and differed solely in the design of the homology arms, while the third donor was engineered to generate a direct fusion of exon 1 to the reading frame of the eGFP-2 A-puromycin cassette. Both strategies resulted in correct targeted gene addition to the OCT4 locus as determined by Southern blot analysis and DNA sequencing of single-cell-derived clones. Targeting efficiencies ranged from 67 % to 100 % in both hESCs and iPSCs.
- TALENs were engineered (using the same design and assembly procedure used for 101125 and 101225) to cleave within the first coding exon of the PITX3 gene.
- the target sequences are shown below:
- CAGACGCTGGCACT SEQ ID NO:332
- Example 19 Examples of TALEN mediated gene editing in vivo
- TALEN genome editing in C. elegans To demonstrate that TALENs could be used in animals for in vivo gene editing, the following experiments were conducted. A TALEN pair specific for the Caenorhabditis elegans ben-1 mutation were delivered as RNA and screened for benomyl resistance as described in Driscoll et al ( (1989) J. Cell. Biol. 109:2993-3003). The ben-1 mutant phenotype is dominant and visible in 100% of progeny under a regular dissecting microscope. Briefly, wild-type C. elegans hermaphrodites were reared on regular NGM agar plates before injection with mRNAs encoding TALENs targeting ben-1.
- the nucleic acids encoding the TALENs were inserted into an SP6 in vitro transcription vector (IVT) using standard restriction cloning procedures.
- the ICT vector backbone was derived from pJK370 and contains 5' and 3' UTR sequences shown previously to support germ-line translation (see Marin and Evans (2003) Development 130: 2623-2632).
- Production of mRNAs containing 5' CAP structures and poly A was performed in vitro using the mMessage mMachine® (Ambion) and polyA tailing kits (Ambion) and purified over a Ambion MEGAClearTM column prior to quantitation using a NanoDrop spectrophotometer (Thermoscientific).
- mRNA injections were performed under a Zeiss Axiovert microscope using a Narishige DVI300 injector. Injection of mRNAs were performed according to standard C. elegans DNA injection protocols (see Stinchcomb et al. (1985) Mol Cell Biol 5:3484-3496) with the following differences: the regulator was adjusted such that the pressure from the N2 gas tank was 60 psi. The Pj n j ec t and Pbaiance measurements were adjusted to 15 psi and 2 psi, respectively. These pressure values are lower than those typically used for DNA injections to allow a more gentle release of fluid into the worm gonad. All mRNAs were injected at 500 ng/ ⁇ L, and all mRNAs encoding the TALENs were injected as pairs, thus the total mRNA concentration in the needle was 1000 ng//jL.
- TALENs are capable of genomic editing in vivo.
- TALEN genome editing in rats Next, TALENs were used to edit the rat genome.
- the rat IgM-specific TALEN pair 101 187/101188 that targets Exon 2 in the endogenous rat IgM gene was constructed as previously described in Examples 11 and 12 above.
- the target sequence in the rat genome is shown below where the bold and upper case letters indicate the target site for the TALE DNA binding domain and the lowercase letters indicate the gap or spacer region:
- Nucleic acids encoding these TALEN pair were then injected into rat embryos as described in Menoret et al (2010) Eur J Immunol. Oct;40(10): 2932-41. Nucleic acids encoding the TALENs were injected either as a pronuclear (PNI, DNA) or an
- GJC 153F primer 5' ggaggcaagaagatggattc (SEQ ID NO:453)
- GJC 154R primer 5' gaatcggcacatgcagatct (SEQ ID NO:454)
- NHEJ associated indels e.g. 1 bp deletion in rat 3.3 and a 90 bp deletion in rat 3.4
- TALEN pairs are also used for targeted integration with a nucleic acid of interest into rat cells to generate transgenic animals.
- the rat cells targeted by the TALEN pair are rat embryonic stem cells, one- or more-celled GFP-containing rat embryos or any rat cell type convertible to an induced pluripotent stem (iPS) cell.
- the TALEN pair is delivered to the cell and can be plasmid DNA, optimally containing a CAG promoter, mRNA, optimally with a 5' cap structure and a 3' poly-adenosine tail, purified protein or viral particles containing nucleic acid encoding the TALEN open reading frames.
- the donor DNA can single- or double-stranded circular plasmid DNA containing 50-1000 bp of homology on both sides of the break site or single- or double-stranded linear plasmid DNA containing 50- 1000 bp of homology on both sides of the break site.
- the TALEN and donor are delivered by microinjection of rat cells or embryos, transfection of rat cells via electroporation, lipid- based membrane fusion, calcium phosphate precipitation, PEI, etc., incubation with purified nuclease protein (for example, if fused to a cell-penetrating peptide), or infection of rat cells or embryos with a virus. These methods are known in the art.
- the means of generating a modified rat from the injected or transfected cells or embryos will depend on the delivery method chosen. For embryos, the embryos will be implanted into the uterus of a pseudo- pregnant rat and allowed to come to term as described previously. For modified cells, three methods are possible: a) if the rat cells are embryonic stem cells, rat blastocysts should be injected with the modified rat stem cells.
- Blastocysts will be implanted into the uterus of a pseudo-pregnant rat and allowed to come to term; b) the cell (or its nucleus) should be microinjected into an enucleated oocyte (somatic cell nuclear transfer) and the resulting embryo implanted into the uterus of a pseudo-pregnant rat and allowed to come to term or c) the cell should be converted to an iPS cell and should be injected into a rat blastocyst.
- Blastocysts will be implanted into the uterus of a pseudo-pregnant rat and allowed to come to term. Pups are then assayed for presence of the transgene by PCR or any other means known in the art.
- TALEN genome editing in plants [0364] TALEN genome editing in plants. TALEN pairs specific for the Z maize
- RPD1 and CI genes were constructed as described above in Example 11 and their target sequences are shown below in comparison with the RPDl locus (SEQ ID NOs: 382 through
- DLSSA Dual-Luciferase Single Strand Annealing Assay
- the Firefly Luciferase reporter construct contains two incomplete copies of the Firefly coding regions that are separated by DNA binding sites for either ZFNs or TALENs.
- the 5' copy is derived from approximately two third of the N-terminal part of the Firefly gene and the 3' copy is derived from approximately two third of the C-terminal part of the Firefly gene.
- the two incomplete copies contain about 600-bp homology arms.
- the separated Firefly fragments have no luciferase activity.
- a DNA double strand break caused by a ZFN or TALEN pair will stimulate recombination between flanking repeats by the single-strand annealing pathway and then restore the Firefly luciferase function.
- the co-transfected Renilla Luciferase plasmid provides an internal control.
- the luminescent activity of each reporter is read on a luminometer. Normalizing the activity of the experimental reporter (Firefly) to the activity of the internal control (Renilla) minimizes experimental variability caused by differences in cell viability and/or transfection efficiency.
- the normalized value is used to determine the activity of a given ZFN or TALEN pair. This is a useful tool when working in systems with precious model cells or when the intended target cell type is either not available or difficult to be used for screening purpose. This is also useful tool to develop and to optimize TALEN technology platform when the target sequences are not available in endogenous genome. Active nucleases can be identified by DLSSA and then ported into the endogenous system for final evaluation. The active TALEN pairs on the plant targets are shown below in Table 35 A.
- the TALEN pairs were then delivered via gold-particle bombardment to maize Hi ⁇ embryos using standard methods (Frame et al, (2000) In vitro cellular & developmental biology. 36(1): 21-29). In total, approximately 90 pollinated maize embryos per TALEN pair were transformed and allowed to grow for ca. seven days on callus initiation media prior to pooling and freezing in liquid N2 for genomic DNA extraction. Genomic DNA was isolated from 4-6 frozen embryos per bombarded plate using the DNeasy Plant Miniprep kit (Qiagen). Each TALEN target was then amplified by two-step PCR using High- Fidelity Phusion Hot Start II Polymerase (NEB) from pooled genomic DNA consisting of three biological triplicates.
- NEB High- Fidelity Phusion Hot Start II Polymerase
- each site was amplified in a 20-cycle PCR using 400 ng genomic DNA and the primers listed in Table 35B.
- an additional 20 cycles were performed using 1 ul of product from the first PCR round and the primers SOLEXA-OUT-F1 and SOLEXA-OUT-R1 to generate complete Illumina sequencing amplicons.
- the resulting PCR products were then purified on Qiaquick PCR Purification columns (Qiagen), normalized to 50 nM each, and combined in equal volumes so that a total of eight sites were sequenced in a single Illumina lane. Control amplicons from untreated genomic DNA were submitted in a separate lane. Illumina single-read 100 bp sequencing was performed at ELIM Biopharmaceuticals (Hayward, CA).
- Indels consisting of at least 2 contiguous inserted or deleted bases within a 10 bp window centered on the expected TALEN cleavage sites were considered potential NHEJ events and were processed further. InDels that occurred with similar frequency in both a given TALEN treated sample and the cognate mock treated sample were considered sequencing artifacts and were discarded.
- Table 37 shows the most observed indels in the eight samples shown above, demonstrating that the TALENs were capable of inducing NHEJ with both gene targets and all pairs of nucleases.
- the unaltered genomic sequence is shown with the gap between the two TALEN binding sites underlined.
- Deleted bases are indicated by colons and inserted bases are indicated by curved brackets with " ⁇ " indicating the start of the inserted sequence and " ⁇ " indicating the end of the inserted sequence.
- the InDel frequency was similar in all samples (from 0.0087% to 0.0185% or about 1 in 11,000 events to 1 in 5,400 events). This implies that the limiting factor is the biolistic delivery to the maize embryos rather than the TALEN activity. Barcoded sequences derived from TALEN treated Zea maize embryos were pooled together and submitted for 100 bp read-length sequencing on an Illumina GA2 sequencer.
- these TALENs are used to drive targeted integration (TI) of any desired
- DNA of interest into the DSB created by TALENs can be accomplished in monocots or dicots using methods known in the art (see for example Shukla et al (2009) Nature 459:437 and Cai et al (2009) Plant Mol Biol 69:699). Novel plant species may also be generated stably transgenic for a selected TALEN as desired, allowing crossing of the TALEN strain to another in which a mutation is desired, followed by segregation of progeny such that some progeny contain only the desired mutation and the TALEN transgene has been segregated away.
- repeat units then can be combined with those from Xanthamonas to create unique repeat units.
- Repeat sequences that are combinations of residues found in Ralstonia repeats and residues found in Xanthomonas residues could yield proteins with improved properties such as increased DNA binding affinity, increased DNA binding specificity, or decreased sensitivity to oxidation. Examples of such repeat unit combinations include, with altered residues indicated in bold and a larger font size,:
- Xanthomonas repeat unit on the second Novel repeats, containing both Ralstonia derived residues and other variations designed to probe the sequence requirements for TALE repeats, are shown on subsequent lines. All differences from the typical Xanthomonas repeat unit on the second line are underlined.
- repeat units were engineered by varying the positions that are in bold in rows 3- 27. These novel, engineered repeat units were then substituted into the system designed to test the novel RVDs in Example 15 and shown in Figure 27, and the resultant constructs were translated in vitro and used in an ELISA.
- the target sequence used in the ELISA was the 'C variant described in Example 15 (e.g.
- Hybrid repeat units are combined in series to create novel TALE proteins able to recognize any desired proteins. These novel TALE DNA binding domains are also linked to nuclease domains, transcriptional regulatory domain, or any other active protein domain to cause a measurable result following DNA interaction.
- Example 21 Construction of TALE-zinc finger DNA binding domain hybrids.
- Zinc fingers were fused to TALE DNA binding domains to create a hybrid
- the target DNA sequences are shown below, and comprise a region surrounding a locus within the CCR5 gene. Shown above and below the binding site are the target binding sites for the TALE DNA binding domain and the zinc finger binding site is shown on the target sequence in Bold underline.
- the "TAG” sequence in Bold/underline is the binding site for the fourth finger from the CCR5-specific ZFN SBS#8267, while the "AAACTG” sequence in Bold/underline is the binding site for the third and fourth fingers in the CCR5-specific ZFN SBS#8196 (see United States Patent Application 1 1/805,707).
- Table 40 shows the results of the studies.
- one nuclease partner is held constant with an inner gap of either 7, 10, or 13 bases.
- the partner nuclease is then paired with proteins that comprise an inner gap of between 4 and 16 bases.
- TALE/zinc finger hybrid DNA binding domains can form active nuclease pairs when the inner gaps range from 4 to 16 bases.
- Example 22 Construction of a TALE-integrase fusion protein
- retroviral vectors During the life cycle of retroviruses, viral genomic RNAs are reverse transcribed and integrated at many different sites into host genome, even though there are preferences for certain hot spots. For applications utilizing retroviral vectors, especially gene therapy, the possible carcinogenicity of retroviral vectors due to random integration of engineered viral genome near oncogene loci presents a potential risk factor. To overcome such potential problems, the specificity of viral integrases is re-directed to pre-determined sites by utilizing specific TALE DNA-binding domains. Fusions are made with whole or truncated integrases and with whole or truncated integrase-binding proteins (for example LEDGF for HIV integrase).
- fusion pairs are made where one member of the pair is an integrate fused to one protein (for example protein 1) and the second pair is a fusion of a TALE DNA binding domain with another protein (for example protein2) where protein 1 and protein2 bind to each other.
- the fusion pairs are cloned into an expression vector such that the pair is expressed in the cell of interest.
- the fusion pair is expressed using a mammalian expression vector.
- a donor DNA is supplied such that the donor is incorporated into the cleavage site following TALEN-induced DNA fusion.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020127032393A KR101953237B1 (en) | 2010-05-17 | 2011-05-17 | Novel dna-binding proteins and uses thereof |
AU2011256838A AU2011256838B2 (en) | 2010-05-17 | 2011-05-17 | Novel DNA-binding proteins and uses thereof |
EP11783865.6A EP2571512B1 (en) | 2010-05-17 | 2011-05-17 | Novel dna-binding proteins and uses thereof |
CA2798988A CA2798988C (en) | 2010-05-17 | 2011-05-17 | Tal-effector (tale) dna-binding polypeptides and uses thereof |
JP2013511148A JP6208580B2 (en) | 2010-05-17 | 2011-05-17 | Novel DNA binding protein and use thereof |
CN201180034243.1A CN103025344B (en) | 2010-05-17 | 2011-05-17 | Novel DNA-associated proteins and application thereof |
IL222961A IL222961B (en) | 2010-05-17 | 2012-11-11 | Dna-binding proteins and uses thereof |
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39583610P | 2010-05-17 | 2010-05-17 | |
US61/395,836 | 2010-05-17 | ||
US40142910P | 2010-08-12 | 2010-08-12 | |
US61/401,429 | 2010-08-12 | ||
US45512110P | 2010-10-13 | 2010-10-13 | |
US61/455,121 | 2010-10-13 | ||
US201061459891P | 2010-12-20 | 2010-12-20 | |
US61/459,891 | 2010-12-20 | ||
US201161462482P | 2011-02-02 | 2011-02-02 | |
US61/462,482 | 2011-02-02 | ||
US201161465869P | 2011-03-24 | 2011-03-24 | |
US61/465,869 | 2011-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011146121A1 true WO2011146121A1 (en) | 2011-11-24 |
Family
ID=44991974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/000885 WO2011146121A1 (en) | 2010-05-17 | 2011-05-17 | Novel dna-binding proteins and uses thereof |
Country Status (9)
Country | Link |
---|---|
US (8) | US8586526B2 (en) |
EP (2) | EP2571512B1 (en) |
JP (2) | JP6208580B2 (en) |
KR (1) | KR101953237B1 (en) |
CN (1) | CN103025344B (en) |
AU (1) | AU2011256838B2 (en) |
CA (1) | CA2798988C (en) |
IL (1) | IL222961B (en) |
WO (1) | WO2011146121A1 (en) |
Cited By (202)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012168124A1 (en) | 2011-06-06 | 2012-12-13 | Bayer Cropscience Nv | Methods and means to modify a plant genome at a preselected site |
WO2013026740A2 (en) | 2011-08-22 | 2013-02-28 | Bayer Cropscience Nv | Methods and means to modify a plant genome |
EP2575439A1 (en) * | 2010-06-07 | 2013-04-10 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins comprising a dna-binding domain of a tal effector protein and a non-specific cleavage domain of a restriction nuclease and their use |
US8420782B2 (en) | 2009-01-12 | 2013-04-16 | Ulla Bonas | Modular DNA-binding domains and methods of use |
US8440431B2 (en) | 2009-12-10 | 2013-05-14 | Regents Of The University Of Minnesota | TAL effector-mediated DNA modification |
US8470973B2 (en) | 2009-01-12 | 2013-06-25 | Ulla Bonas | Modular DNA-binding domains and methods of use |
CN103193871A (en) * | 2012-01-04 | 2013-07-10 | 清华大学 | Method for designing novel TALE (transcription activator like effector) according to protein-DNA compound crystal structure |
WO2013102289A1 (en) * | 2012-01-04 | 2013-07-11 | 清华大学 | Specific binding and targeting method for dna-rna heteroduplex |
WO2013102290A1 (en) * | 2012-01-04 | 2013-07-11 | 清华大学 | Method for specifically recognizing dna containing 5-methylated cytosine |
WO2013130824A1 (en) | 2012-02-29 | 2013-09-06 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
WO2013136175A2 (en) | 2012-03-15 | 2013-09-19 | Cellectis | New repeat variable diresidues for targeting nucleotides |
WO2013160230A1 (en) | 2012-04-23 | 2013-10-31 | Bayer Cropscience Nv | Targeted genome engineering in plants |
EP2660318A1 (en) * | 2010-02-09 | 2013-11-06 | Sangamo BioSciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
WO2014039702A2 (en) | 2012-09-07 | 2014-03-13 | Dow Agrosciences Llc | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
WO2014011817A3 (en) * | 2012-07-11 | 2014-04-17 | The Board Of Regents Of Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas | Genome surgery with paired, permeant endonuclease excision |
JP2014509195A (en) * | 2011-02-25 | 2014-04-17 | リコンビネティクス・インコーポレイテッド | Genetically modified animal and method for producing the same |
CN103772506A (en) * | 2012-10-22 | 2014-05-07 | 北京唯尚立德生物科技有限公司 | Transcription activator like effector-functional group-estrogen receptor function protein and application thereof |
WO2014078819A2 (en) | 2012-11-16 | 2014-05-22 | Transposagen Biopharmaceuticals, Inc. | Site-specific enzymes and methods of use |
WO2014076571A2 (en) | 2012-11-16 | 2014-05-22 | Cellectis | Method for targeted modification of algae genomes |
WO2014018601A3 (en) * | 2012-07-24 | 2014-06-26 | Cellectis | New modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteins |
EP2764103A2 (en) | 2012-12-12 | 2014-08-13 | The Broad Institute, Inc. | Crispr-cas systems and methods for altering expression of gene products |
WO2014144155A1 (en) * | 2013-03-15 | 2014-09-18 | Regents Of The University Of Minnesota | Engineering plant genomes using crispr/cas systems |
WO2014161821A1 (en) | 2013-04-02 | 2014-10-09 | Bayer Cropscience Nv | Targeted genome engineering in eukaryotes |
WO2014169810A1 (en) * | 2013-04-16 | 2014-10-23 | 深圳华大基因科技服务有限公司 | Isolated oligonucleotide and use thereof |
US8912138B2 (en) | 2010-05-17 | 2014-12-16 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
JP2015500648A (en) * | 2011-12-16 | 2015-01-08 | ターゲットジーン バイオテクノロジーズ リミテッド | Compositions and methods for modifying a given target nucleic acid sequence |
FR3008424A1 (en) * | 2013-07-09 | 2015-01-16 | Centre Nat Rech Scient | METHOD OF TARGETED MODIFICATION OF GENOME FOR THE GENERATION OF ANIMAL ORGANISM |
US8945868B2 (en) | 2010-07-21 | 2015-02-03 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a HLA locus |
WO2015030881A1 (en) * | 2013-08-27 | 2015-03-05 | Recombinetics, Inc. | Efficient non-meiotic allele introgression |
WO2015033343A1 (en) | 2013-09-03 | 2015-03-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions and methods for expressing recombinant polypeptides |
WO2015040402A1 (en) | 2013-09-18 | 2015-03-26 | Kymab Limited | Methods. cells & organisms |
US8993233B2 (en) | 2012-12-12 | 2015-03-31 | The Broad Institute Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
EP2784162B1 (en) | 2012-12-12 | 2015-04-08 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
JP2015510778A (en) * | 2012-03-20 | 2015-04-13 | ヴィリニュス・ユニヴァーシティー | RNA-directed DNA cleavage by Cas9-crRNA complex |
WO2015073867A1 (en) * | 2013-11-15 | 2015-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Engineering neural stem cells using homologous recombination |
CN104694539A (en) * | 2015-03-09 | 2015-06-10 | 上海市同济医院 | Method for establishing plasmid capable of knocking out mouse CRAMP gene by use of TALEN technique |
KR20150070120A (en) * | 2012-09-04 | 2015-06-24 | 더 스크립스 리서치 인스티튜트 | Chimeric polypeptides having targeted binding specificity |
CN104769112A (en) * | 2012-11-01 | 2015-07-08 | 菲克特生物科学股份有限公司 | Methods and products for expressing proteins in cells |
EP2898075A1 (en) | 2012-12-12 | 2015-07-29 | The Broad Institute, Inc. | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
EP2780460A4 (en) * | 2011-11-16 | 2015-08-26 | Sangamo Biosciences Inc | Modified dna-binding proteins and uses thereof |
EP2785831A4 (en) * | 2011-11-30 | 2015-09-09 | Broad Inst Inc | Nucleotide-specific recognition sequences for designer tal effectors |
EP2922393A1 (en) | 2013-02-27 | 2015-09-30 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Gene editing in the oocyte by cas9 nucleases |
EP2928496A1 (en) | 2012-12-06 | 2015-10-14 | Sigma Aldrich Co. LLC | Crispr-based genome modification and regulation |
EP2931897A2 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
WO2015169314A1 (en) | 2014-05-07 | 2015-11-12 | Universitätsklinikum Hamburg-Eppendorf (UKE) | Tal-effector nuclease for targeted knockout of the hiv co-receptor ccr5 |
US9228208B2 (en) | 2013-12-11 | 2016-01-05 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
JP2016500254A (en) * | 2012-12-05 | 2016-01-12 | サンガモ バイオサイエンシーズ, インコーポレイテッド | Methods and compositions for the regulation of metabolic diseases |
WO2016005985A2 (en) | 2014-07-09 | 2016-01-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method for reprogramming cells |
JP2016501036A (en) * | 2012-12-17 | 2016-01-18 | プレジデント アンド フェローズ オブ ハーバード カレッジ | RNA-induced human genome modification |
JP2016504026A (en) * | 2012-12-12 | 2016-02-12 | ザ・ブロード・インスティテュート・インコーポレイテッド | Engineering systems, methods and optimization guide compositions for sequence manipulation |
WO2016038616A1 (en) | 2014-09-14 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Nmda receptor antagonists for treating gaucher disease |
JP2016521995A (en) * | 2013-06-17 | 2016-07-28 | ザ・ブロード・インスティテュート・インコーポレイテッド | Delivery, use and therapeutic applications of CRISPR-Cas systems and compositions for targeting disorders and diseases using viral components |
WO2016135507A1 (en) * | 2015-02-27 | 2016-09-01 | University Of Edinburgh | Nucleic acid editing systems |
US9434782B2 (en) | 2009-07-08 | 2016-09-06 | Kymab Limited | Animal models and therapeutic molecules |
US9476884B2 (en) | 2013-10-04 | 2016-10-25 | University Of Massachusetts | Hybridization- independent labeling of repetitive DNA sequence in human chromosomes |
US9504236B2 (en) | 2009-07-08 | 2016-11-29 | Kymab Limited | Animal models and therapeutic molecules |
US9522936B2 (en) | 2014-04-24 | 2016-12-20 | Sangamo Biosciences, Inc. | Engineered transcription activator like effector (TALE) proteins |
WO2016203088A1 (en) * | 2015-06-19 | 2016-12-22 | Biopraxis Research Aie | Nucleic acid molecule, fusion protein and method for altering the genetic material of a cell |
WO2017009842A2 (en) | 2015-07-16 | 2017-01-19 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
EP2825654B1 (en) | 2012-12-12 | 2017-04-26 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
WO2017118985A1 (en) | 2016-01-06 | 2017-07-13 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating malignant, autoimmune and inflammatory diseases |
WO2017125931A1 (en) | 2016-01-21 | 2017-07-27 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Parthenocarpic plants and methods of producing same |
WO2017130205A1 (en) | 2016-01-31 | 2017-08-03 | Hadasit Medical Research Services And Development Ltd. | Autosomal-identical pluripotent stem cell populations having non-identical sex chromosomal composition and uses thereof |
WO2017138008A2 (en) | 2016-02-14 | 2017-08-17 | Yeda Research And Development Co. Ltd. | Methods of modulating protein exocytosis and uses of same in therapy |
WO2017153982A1 (en) | 2016-03-06 | 2017-09-14 | Yeda Research And Development Co. Ltd. | Method for modulating myelination |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US9834786B2 (en) | 2012-04-25 | 2017-12-05 | Regeneron Pharmaceuticals, Inc. | Nuclease-mediated targeting with large targeting vectors |
US9834791B2 (en) | 2013-11-07 | 2017-12-05 | Editas Medicine, Inc. | CRISPR-related methods and compositions with governing gRNAS |
US9890364B2 (en) | 2012-05-29 | 2018-02-13 | The General Hospital Corporation | TAL-Tet1 fusion proteins and methods of use thereof |
WO2018033929A1 (en) | 2016-08-18 | 2018-02-22 | Yeda Research And Development Co. Ltd. | Diagnostic and therapeutic uses of exosomes |
EP3241902B1 (en) | 2012-05-25 | 2018-02-28 | The Regents of The University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
US9924705B2 (en) | 2012-03-28 | 2018-03-27 | Kymab Limited | Animal models and therapeutic molecules |
US9938521B2 (en) | 2014-03-10 | 2018-04-10 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10) |
US9963716B2 (en) | 2011-09-26 | 2018-05-08 | Kymab Limited | Chimaeric surrogate light chains (SLC) comprising human VpreB |
WO2018096547A1 (en) | 2016-11-28 | 2018-05-31 | Yeda Research And Development Co. Ltd. | Isolated polynucleotides and polypeptides and methods of using same for expressing an expression product of interest |
US10006011B2 (en) | 2013-08-09 | 2018-06-26 | Hiroshima University | Polypeptide containing DNA-binding domain |
WO2018122771A1 (en) | 2016-12-29 | 2018-07-05 | Ukko Inc. | Methods for identifying and de-epitoping allergenic polypeptides |
WO2018129021A1 (en) * | 2017-01-06 | 2018-07-12 | The Johns Hopkins University | Modular, inducible repressors for the control of gene expression |
US10030235B2 (en) | 2013-08-09 | 2018-07-24 | Hiroshima University | Polypeptide containing DNA-binding domain |
WO2018142416A1 (en) | 2017-02-06 | 2018-08-09 | Yeda Research And Development Co. Ltd. | Isolated cells genetically modified to express a disarm system having an anti-phage activity and methods of producing same |
WO2018189360A1 (en) | 2017-04-13 | 2018-10-18 | Cellectis | New sequence specific reagents targeting ccr5 in primary hematopoietic cells |
US10113162B2 (en) | 2013-03-15 | 2018-10-30 | Cellectis | Modifying soybean oil composition through targeted knockout of the FAD2-1A/1B genes |
WO2018207178A1 (en) | 2017-05-07 | 2018-11-15 | Yeda Research And Development Co. Ltd. | Methods of treating psychiatric stress disorders |
US10137206B2 (en) | 2016-08-17 | 2018-11-27 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
US10149462B2 (en) | 2013-10-01 | 2018-12-11 | Kymab Limited | Animal models and therapeutic molecules |
WO2019021284A1 (en) | 2017-07-24 | 2019-01-31 | Yeda Research And Development Co. Ltd. | Combination therapy for the treatment of cancer |
WO2019038771A1 (en) | 2017-08-23 | 2019-02-28 | Technion Research & Development Foundation Limited | Compositions and methods for improving alcohol tolerance in yeast |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
US10266851B2 (en) | 2016-06-02 | 2019-04-23 | Sigma-Aldrich Co. Llc | Using programmable DNA binding proteins to enhance targeted genome modification |
US10273271B2 (en) | 2011-07-15 | 2019-04-30 | The General Hospital Corporation | Methods of transcription activator like effector assembly |
WO2019097514A1 (en) | 2017-11-14 | 2019-05-23 | Yeda Research And Development Co. Ltd. | Hematopoietic stem cells with improved properties |
US10301637B2 (en) | 2014-06-20 | 2019-05-28 | Cellectis | Potatoes with reduced granule-bound starch synthase |
US10329582B2 (en) | 2013-02-20 | 2019-06-25 | Regeneron Pharmaceuticals, Inc. | Genetic modification of rats |
EP3501268A1 (en) | 2017-12-22 | 2019-06-26 | Kws Saat Se | Regeneration of plants in the presence of histone deacetylase inhibitors |
EP3508581A1 (en) | 2018-01-03 | 2019-07-10 | Kws Saat Se | Regeneration of genetically modified plants |
WO2019145964A1 (en) | 2018-01-29 | 2019-08-01 | Yeda Research And Development Co. Ltd. | Combination of a mek inhibitor and a cdk4/6 inhibitor for the treatment of sarcoma |
US10369201B2 (en) | 2013-11-11 | 2019-08-06 | Sangamo Therapeutics, Inc. | Methods and compositions for treating Huntington's disease |
US10377998B2 (en) | 2013-12-12 | 2019-08-13 | The Broad Institute, Inc. | CRISPR-CAS systems and methods for altering expression of gene products, structural information and inducible modular CAS enzymes |
US10385359B2 (en) | 2013-04-16 | 2019-08-20 | Regeneron Pharmaceuticals, Inc. | Targeted modification of rat genome |
EP3494997B1 (en) | 2012-07-25 | 2019-09-18 | The Broad Institute, Inc. | Inducible dna binding proteins and genome perturbation tools and applications thereof |
WO2019183123A1 (en) | 2018-03-19 | 2019-09-26 | Regeneron Pharmaceuticals, Inc. | Transcription modulation in animals using crispr/cas systems |
EP3545756A1 (en) | 2018-03-28 | 2019-10-02 | KWS SAAT SE & Co. KGaA | Regeneration of plants in the presence of inhibitors of the histone methyltransferase ezh2 |
US10457960B2 (en) | 2014-11-21 | 2019-10-29 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification using paired guide RNAs |
EP3567111A1 (en) | 2018-05-09 | 2019-11-13 | KWS SAAT SE & Co. KGaA | Gene for resistance to a pathogen of the genus heterodera |
US10494621B2 (en) | 2015-06-18 | 2019-12-03 | The Broad Institute, Inc. | Crispr enzyme mutations reducing off-target effects |
US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
WO2019238909A1 (en) | 2018-06-15 | 2019-12-19 | KWS SAAT SE & Co. KGaA | Methods for improving genome engineering and regeneration in plant |
WO2019238832A1 (en) | 2018-06-15 | 2019-12-19 | Nunhems B.V. | Seedless watermelon plants comprising modifications in an abc transporter gene |
WO2019238911A1 (en) | 2018-06-15 | 2019-12-19 | KWS SAAT SE & Co. KGaA | Methods for improving genome engineering and regeneration in plant ii |
WO2019238908A1 (en) | 2018-06-15 | 2019-12-19 | KWS SAAT SE & Co. KGaA | Methods for enhancing genome engineering efficiency |
US10513698B2 (en) | 2012-12-21 | 2019-12-24 | Cellectis | Potatoes with reduced cold-induced sweetening |
WO2020008412A1 (en) | 2018-07-04 | 2020-01-09 | Ukko Inc. | Methods of de-epitoping wheat proteins and use of same for the treatment of celiac disease |
US10550372B2 (en) | 2013-12-12 | 2020-02-04 | The Broad Institute, Inc. | Systems, methods and compositions for sequence manipulation with optimized functional CRISPR-Cas systems |
US10550402B2 (en) | 2016-02-02 | 2020-02-04 | Cellectis | Modifying soybean oil composition through targeted knockout of the FAD3A/B/C genes |
US10577630B2 (en) | 2013-06-17 | 2020-03-03 | The Broad Institute, Inc. | Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy |
EP3623379A1 (en) | 2018-09-11 | 2020-03-18 | KWS SAAT SE & Co. KGaA | Beet necrotic yellow vein virus (bnyvv)-resistance modifying gene |
WO2020089892A1 (en) | 2018-10-28 | 2020-05-07 | Yeda Research And Development Co. Ltd. | Prevention of age related clonal hematopoiesis and diseases associated therewith |
US10667501B2 (en) | 2012-05-17 | 2020-06-02 | Kymab Limited | Transgenic non-human vertebrate for the in vivo production of dual specificity immunoglobulins or hypermutated heavy chain only immunoglobulins |
US10676749B2 (en) | 2013-02-07 | 2020-06-09 | The General Hospital Corporation | Tale transcriptional activators |
US10696986B2 (en) | 2014-12-12 | 2020-06-30 | The Board Institute, Inc. | Protected guide RNAS (PGRNAS) |
US10711285B2 (en) | 2013-06-17 | 2020-07-14 | The Broad Institute, Inc. | Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation |
WO2020157573A1 (en) | 2019-01-29 | 2020-08-06 | The University Of Warwick | Methods for enhancing genome engineering efficiency |
US10745695B2 (en) | 2012-04-04 | 2020-08-18 | Life Technologies Corporation | TAL-effector assembly platform, customized services, kits and assays |
EP3699293A1 (en) * | 2013-08-22 | 2020-08-26 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (tale) domains and uses thereof |
US10767156B2 (en) | 2013-10-24 | 2020-09-08 | Yeda Research And Development Co., Ltd. | Polynucleotides encoding BREX system polypeptides and methods of using same |
WO2020178822A1 (en) | 2019-03-05 | 2020-09-10 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Genome-edited birds |
EP3708651A1 (en) | 2019-03-12 | 2020-09-16 | KWS SAAT SE & Co. KGaA | Improving plant regeneration |
US10779518B2 (en) | 2013-10-25 | 2020-09-22 | Livestock Improvement Corporation Limited | Genetic markers and uses therefor |
US10781444B2 (en) | 2013-06-17 | 2020-09-22 | The Broad Institute, Inc. | Functional genomics using CRISPR-Cas systems, compositions, methods, screens and applications thereof |
WO2020190932A1 (en) | 2019-03-18 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Crispr/cas screening platform to identify genetic modifiers of tau seeding or aggregation |
WO2020190927A1 (en) | 2019-03-18 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Crispr/cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation |
US10801017B2 (en) | 2011-11-30 | 2020-10-13 | The Broad Institute, Inc. | Nucleotide-specific recognition sequences for designer TAL effectors |
WO2020209332A1 (en) * | 2019-04-09 | 2020-10-15 | 国立研究開発法人科学技術振興機構 | Nucleic acid binding protein |
CN111893140A (en) * | 2011-12-05 | 2020-11-06 | 菲克特生物科学股份有限公司 | Methods and products for transfecting cells |
US10837024B2 (en) | 2015-09-17 | 2020-11-17 | Cellectis | Modifying messenger RNA stability in plant transformations |
US10851380B2 (en) | 2012-10-23 | 2020-12-01 | Toolgen Incorporated | Methods for cleaving a target DNA using a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein |
US10851357B2 (en) | 2013-12-12 | 2020-12-01 | The Broad Institute, Inc. | Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders |
WO2020252340A1 (en) | 2019-06-14 | 2020-12-17 | Regeneron Pharmaceuticals, Inc. | Models of tauopathy |
WO2020260682A1 (en) | 2019-06-28 | 2020-12-30 | KWS SAAT SE & Co. KGaA | Enhanced plant regeneration and transformation by using grf1 booster gene |
WO2021001784A1 (en) | 2019-07-04 | 2021-01-07 | Ukko Inc. | De-epitoped alpha gliadin and use of same for the management of celiac disease and gluten sensitivity |
US10893667B2 (en) | 2011-02-25 | 2021-01-19 | Recombinetics, Inc. | Non-meiotic allele introgression |
WO2021009763A1 (en) | 2019-07-16 | 2021-01-21 | Yeda Research And Development Co. Ltd. | Methods of treating pain |
US10930367B2 (en) | 2012-12-12 | 2021-02-23 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for Cas enzymes or CRISPR-Cas systems for target sequences and conveying results thereof |
WO2021050940A1 (en) | 2019-09-13 | 2021-03-18 | Regeneron Pharmaceuticals, Inc. | Transcription modulation in animals using crispr/cas systems delivered by lipid nanoparticles |
WO2021069684A1 (en) * | 2019-10-11 | 2021-04-15 | Basf Plant Science Company Gmbh | Increase in corn transformation efficacy by the n-terminus of a tale |
WO2021084540A1 (en) | 2019-10-30 | 2021-05-06 | Yeda Research And Development Co. Ltd. | Inhibitors of mmej pathway for prevention and treatment of pre-myeloid and myeloid malignancies |
US11008588B2 (en) | 2013-06-17 | 2021-05-18 | The Broad Institute, Inc. | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
WO2021093943A1 (en) | 2019-11-12 | 2021-05-20 | KWS SAAT SE & Co. KGaA | Gene for resistance to a pathogen of the genus heterodera |
WO2021108363A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-mediated upregulation of humanized ttr allele |
US11028388B2 (en) | 2014-03-05 | 2021-06-08 | Editas Medicine, Inc. | CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa |
WO2021130752A1 (en) | 2019-12-22 | 2021-07-01 | Yeda Research And Development Co. Ltd. | Systems and methods for identifying cells that have undergone genome editing |
US11051497B2 (en) | 2011-09-19 | 2021-07-06 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
WO2021152587A1 (en) | 2020-01-30 | 2021-08-05 | Yeda Research And Development Co. Ltd. | Treating acute liver disease with tlr-mik inhibitors |
EP3663310A4 (en) * | 2017-08-04 | 2021-08-11 | Peking University | Tale rvd specifically recognizing dna base modified by methylation and application thereof |
WO2021178556A1 (en) | 2020-03-04 | 2021-09-10 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for sensitization of tumor cells to immune therapy |
WO2021195079A1 (en) | 2020-03-23 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use |
US11141493B2 (en) | 2014-03-10 | 2021-10-12 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
US11149267B2 (en) | 2013-10-28 | 2021-10-19 | The Broad Institute, Inc. | Functional genomics using CRISPR-Cas systems, compositions, methods, screens and applications thereof |
US11155795B2 (en) | 2013-12-12 | 2021-10-26 | The Broad Institute, Inc. | CRISPR-Cas systems, crystal structure and uses thereof |
US11174493B2 (en) | 2016-05-26 | 2021-11-16 | Nunhems B.V. | Seedless fruit producing plants |
US11180793B2 (en) | 2015-04-24 | 2021-11-23 | Editas Medicine, Inc. | Evaluation of Cas9 molecule/guide RNA molecule complexes |
US11242525B2 (en) | 2014-03-26 | 2022-02-08 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating sickle cell disease |
US11241505B2 (en) | 2015-02-13 | 2022-02-08 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
WO2022074646A1 (en) | 2020-10-05 | 2022-04-14 | Protalix Ltd. | Dicer-like knock-out plant cells |
WO2022079719A1 (en) | 2020-10-15 | 2022-04-21 | Yeda Research And Development Co. Ltd. | Method of treating myeloid malignancies |
US11312972B2 (en) | 2016-11-16 | 2022-04-26 | Cellectis | Methods for altering amino acid content in plants through frameshift mutations |
EP3814524A4 (en) * | 2018-06-27 | 2022-04-27 | Altius Institute For Biomedical Sciences | Gapped and tunable repeat units for use in genome editing and gene regulation compositions |
US11339437B2 (en) | 2014-03-10 | 2022-05-24 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
WO2022115498A1 (en) | 2020-11-26 | 2022-06-02 | Ukko Inc. | Modified high molecular weight glutenin subunit and uses thereof |
WO2022120022A1 (en) | 2020-12-02 | 2022-06-09 | Regeneron Pharmaceuticals, Inc. | Crispr sam biosensor cell lines and methods of use thereof |
WO2022130388A2 (en) | 2020-12-18 | 2022-06-23 | Yeda Research And Development Co. Ltd. | Compositions for use in the treatment of chd2 haploinsufficiency and methods of identifying same |
WO2022130384A1 (en) | 2020-12-17 | 2022-06-23 | Yeda Research And Development Co. Ltd. | Controlling ubiquitination of mlkl for treatment of disease |
EP4019639A1 (en) | 2020-12-22 | 2022-06-29 | KWS SAAT SE & Co. KGaA | Promoting regeneration and transformation in beta vulgaris |
EP4019638A1 (en) | 2020-12-22 | 2022-06-29 | KWS SAAT SE & Co. KGaA | Promoting regeneration and transformation in beta vulgaris |
US11384360B2 (en) | 2012-06-19 | 2022-07-12 | Regents Of The University Of Minnesota | Gene targeting in plants using DNA viruses |
US11407985B2 (en) | 2013-12-12 | 2022-08-09 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for genome editing |
US11473082B2 (en) | 2015-06-17 | 2022-10-18 | Poseida Therapeutics, Inc. | Compositions and methods for directing proteins to specific loci in the genome |
US11479782B2 (en) | 2017-04-25 | 2022-10-25 | Cellectis | Alfalfa with reduced lignin composition |
WO2022239001A1 (en) | 2021-05-10 | 2022-11-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Pharmaceutical compositions for treating neurological conditions |
US11512311B2 (en) | 2016-03-25 | 2022-11-29 | Editas Medicine, Inc. | Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency |
WO2022264132A1 (en) | 2021-06-13 | 2022-12-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method for reprogramming human cells |
US11555198B2 (en) | 2012-11-01 | 2023-01-17 | Cellectis Sa | Method for making nicotiana plants with mutations in XylT and FucT alleles using rare-cutting endonucleases |
US11566263B2 (en) | 2016-08-02 | 2023-01-31 | Editas Medicine, Inc. | Compositions and methods for treating CEP290 associated disease |
US11564380B2 (en) | 2009-07-08 | 2023-01-31 | Kymab Limited | Animal models and therapeutic molecules |
EP4130028A1 (en) | 2021-08-03 | 2023-02-08 | Rhazes Therapeutics Ltd | Engineered tcr complex and methods of using same |
WO2023012584A2 (en) | 2021-08-03 | 2023-02-09 | Genicity Limited | Engineered tcr complex and methods of using same |
US11578312B2 (en) | 2015-06-18 | 2023-02-14 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of CAS9 orthologs and variants for sequence manipulation |
US11624077B2 (en) | 2017-08-08 | 2023-04-11 | Peking University | Gene knockout method |
WO2023062636A1 (en) | 2021-10-14 | 2023-04-20 | Weedout Ltd. | Methods of weed control |
WO2023077053A2 (en) | 2021-10-28 | 2023-05-04 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-related methods and compositions for knocking out c5 |
WO2023108047A1 (en) | 2021-12-08 | 2023-06-15 | Regeneron Pharmaceuticals, Inc. | Mutant myocilin disease model and uses thereof |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
EP4218771A1 (en) | 2015-03-27 | 2023-08-02 | Yeda Research and Development Co. Ltd | Methods of treating motor neuron diseases |
WO2023240282A1 (en) | 2022-06-10 | 2023-12-14 | Umoja Biopharma, Inc. | Engineered stem cells and uses thereof |
US11845965B2 (en) | 2016-08-24 | 2023-12-19 | Sangamo Therapeutics, Inc. | Regulation of gene expression using engineered nucleases |
US11851690B2 (en) | 2017-03-14 | 2023-12-26 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
US11891631B2 (en) | 2012-10-12 | 2024-02-06 | The General Hospital Corporation | Transcription activator-like effector (tale) - lysine-specific demethylase 1 (LSD1) fusion proteins |
US11963982B2 (en) | 2017-05-10 | 2024-04-23 | Editas Medicine, Inc. | CRISPR/RNA-guided nuclease systems and methods |
US11970711B2 (en) | 2021-09-21 | 2024-04-30 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
Families Citing this family (358)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120196370A1 (en) | 2010-12-03 | 2012-08-02 | Fyodor Urnov | Methods and compositions for targeted genomic deletion |
US8772008B2 (en) * | 2009-05-18 | 2014-07-08 | Sangamo Biosciences, Inc. | Methods and compositions for increasing nuclease activity |
EP2615106B1 (en) | 2010-02-08 | 2018-04-25 | Sangamo Therapeutics, Inc. | Engineered cleavage half-domains |
US20110197290A1 (en) * | 2010-02-11 | 2011-08-11 | Fahrenkrug Scott C | Methods and materials for producing transgenic artiodactyls |
US8771985B2 (en) | 2010-04-26 | 2014-07-08 | Sangamo Biosciences, Inc. | Genome editing of a Rosa locus using zinc-finger nucleases |
EP2622090B1 (en) | 2010-09-27 | 2019-06-19 | Sangamo Therapeutics, Inc. | Compositions for inhibiting viral entry into cells |
US9175280B2 (en) | 2010-10-12 | 2015-11-03 | Sangamo Biosciences, Inc. | Methods and compositions for treating hemophilia B |
WO2012094132A1 (en) | 2011-01-05 | 2012-07-12 | Sangamo Biosciences, Inc. | Methods and compositions for gene correction |
US20140115726A1 (en) | 2011-04-05 | 2014-04-24 | Cellectis | New tale-protein scaffolds and uses thereof |
CA2833870C (en) | 2011-04-22 | 2020-03-10 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
EP2737063B1 (en) | 2011-07-25 | 2016-06-01 | Sangamo BioSciences, Inc. | Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene |
US9370551B2 (en) * | 2011-07-27 | 2016-06-21 | The Broad Institute, Inc. | Compositions and methods of treating head and neck cancer |
WO2013044008A2 (en) | 2011-09-21 | 2013-03-28 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of transgene expression |
AU2012328682B2 (en) | 2011-10-27 | 2017-09-21 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of the HPRT locus |
JP6259766B2 (en) * | 2011-11-18 | 2018-01-10 | ユニヴェルシテ ラヴァルUniversite Laval | Methods and products for increasing frataxin levels and uses thereof |
US20130137173A1 (en) * | 2011-11-30 | 2013-05-30 | Feng Zhang | Nucleotide-specific recognition sequences for designer tal effectors |
GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
US9738879B2 (en) | 2012-04-27 | 2017-08-22 | Duke University | Genetic correction of mutated genes |
EP3597741A1 (en) | 2012-04-27 | 2020-01-22 | Duke University | Genetic correction of mutated genes |
CN104428414B (en) | 2012-05-02 | 2022-01-21 | 陶氏益农公司 | Targeted modification of malate dehydrogenase |
RU2650819C2 (en) | 2012-05-07 | 2018-04-17 | Сангамо Терапьютикс, Инк. | Methods and compositions for nuclease-mediated targeting of transgenes |
EP3964567A1 (en) * | 2012-05-25 | 2022-03-09 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
US20150017136A1 (en) * | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
US10815500B2 (en) * | 2012-06-05 | 2020-10-27 | Cellectis | Transcription activator-like effector (TALE) fusion protein |
AR091482A1 (en) * | 2012-06-21 | 2015-02-04 | Recombinetics Inc | GENETICALLY MODIFIED CELLS AND METHODS FOR OBTAINING |
US10648001B2 (en) | 2012-07-11 | 2020-05-12 | Sangamo Therapeutics, Inc. | Method of treating mucopolysaccharidosis type I or II |
HUE051612T2 (en) | 2012-07-11 | 2021-03-01 | Sangamo Therapeutics Inc | Methods and compositions for the treatment of lysosomal storage diseases |
US10883119B2 (en) | 2012-07-11 | 2021-01-05 | Sangamo Therapeutics, Inc. | Methods and compositions for delivery of biologics |
US10058078B2 (en) | 2012-07-31 | 2018-08-28 | Recombinetics, Inc. | Production of FMDV-resistant livestock by allele substitution |
CN104704110B (en) | 2012-08-29 | 2018-06-01 | 桑格摩生物科学股份有限公司 | For treating the method and composition of heredity symptom |
CN105264067B (en) | 2012-09-07 | 2020-11-10 | 美国陶氏益农公司 | FAD3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
UA119135C2 (en) | 2012-09-07 | 2019-05-10 | ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі | Engineered transgene integration platform (etip) for gene targeting and trait stacking |
ES2824024T3 (en) | 2012-10-10 | 2021-05-11 | Sangamo Therapeutics Inc | T cell modifying compounds and uses thereof |
KR20150085846A (en) | 2012-11-20 | 2015-07-24 | 제이.알.심프롯캄패니 | Tal-Mediated Transfer DNA Insertion |
US9708589B2 (en) | 2012-12-18 | 2017-07-18 | Monsanto Technology Llc | Compositions and methods for custom site-specific DNA recombinases |
AU2014218621B2 (en) | 2013-02-25 | 2019-11-07 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
AU2014235794A1 (en) | 2013-03-14 | 2015-10-22 | Caribou Biosciences, Inc. | Compositions and methods of nucleic acid-targeting nucleic acids |
ES2786253T3 (en) | 2013-03-14 | 2020-10-09 | Immusoft Corp | Methods for the in vitro differentiation and transduction of memory b cells with pseudotyped viral vectors vsv-g |
US11332719B2 (en) * | 2013-03-15 | 2022-05-17 | The Broad Institute, Inc. | Recombinant virus and preparations thereof |
US11039586B2 (en) | 2013-03-15 | 2021-06-22 | Monsanto Technology Llc | Creation and transmission of megaloci |
US10793867B2 (en) | 2013-03-15 | 2020-10-06 | Monsanto Technology, Llc | Methods for targeted transgene-integration using custom site-specific DNA recombinases |
US20140363561A1 (en) * | 2013-03-15 | 2014-12-11 | J.R. Simplot Company | Tal-mediated transfer dna insertion |
US9828582B2 (en) * | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
WO2014153470A2 (en) | 2013-03-21 | 2014-09-25 | Sangamo Biosciences, Inc. | Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases |
EP2981166B1 (en) | 2013-04-05 | 2020-09-09 | Dow AgroSciences LLC | Methods and compositions for integration of an exogenous sequence within the genome of plants |
CN103233004B (en) * | 2013-04-28 | 2015-04-29 | 新疆农垦科学院 | Artificial DNA (deoxyribonucleic acid) molecule and method for detecting expression of target gene |
WO2014182700A1 (en) | 2013-05-10 | 2014-11-13 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
US11311575B2 (en) | 2013-05-13 | 2022-04-26 | Cellectis | Methods for engineering highly active T cell for immunotherapy |
US11077144B2 (en) | 2013-05-13 | 2021-08-03 | Cellectis | CD19 specific chimeric antigen receptor and uses thereof |
CA2910489A1 (en) | 2013-05-15 | 2014-11-20 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a genetic condition |
KR20230136697A (en) * | 2013-06-05 | 2023-09-26 | 듀크 유니버시티 | Rna-guided gene editing and gene regulation |
IL282489B (en) | 2013-07-10 | 2022-07-01 | Harvard College | Orthogonal cas9 proteins for rna-guided gene regulation and editing |
WO2015007194A1 (en) * | 2013-07-16 | 2015-01-22 | 中国科学院上海生命科学研究院 | Method for plant genome site-directed modification |
US10563225B2 (en) * | 2013-07-26 | 2020-02-18 | President And Fellows Of Harvard College | Genome engineering |
ES2915377T3 (en) | 2013-08-02 | 2022-06-22 | Enevolv Inc | Procedures and host cells for genomic, pathway and biomolecular engineering |
US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
WO2015020218A1 (en) * | 2013-08-09 | 2015-02-12 | 独立行政法人理化学研究所 | Highly-active tale protein by altering dna-bound protein domain |
EP3988654A1 (en) | 2013-08-28 | 2022-04-27 | Sangamo Therapeutics, Inc. | Compositions for linking dna-binding domains and cleavage domains |
US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
CA2926078C (en) | 2013-10-17 | 2021-11-16 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells |
CA2926094C (en) | 2013-10-17 | 2024-04-02 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
JP6484987B2 (en) | 2013-10-21 | 2019-03-20 | Jnc株式会社 | Evil luciferase catalytic protein mutant gene and its usage |
AU2014341925B2 (en) | 2013-11-04 | 2017-06-29 | Corteva Agriscience Llc | Optimal soybean loci |
CN107223156A (en) | 2013-11-04 | 2017-09-29 | 美国陶氏益农公司 | Optimal corn seat |
MX358066B (en) | 2013-11-04 | 2018-08-03 | Dow Agrosciences Llc | Optimal soybean loci. |
US10093940B2 (en) | 2013-11-04 | 2018-10-09 | Dow Agrosciences Llc | Optimal maize loci |
WO2015068785A1 (en) | 2013-11-06 | 2015-05-14 | 国立大学法人広島大学 | Vector for nucleic acid insertion |
SI3068881T1 (en) | 2013-11-13 | 2019-05-31 | Children's Medical Center Corporation | Nuclease-mediated regulation of gene expression |
WO2015071474A2 (en) * | 2013-11-18 | 2015-05-21 | Crispr Therapeutics Ag | Crispr-cas system materials and methods |
EP2878667A1 (en) * | 2013-11-29 | 2015-06-03 | Institut Pasteur | TAL effector means useful for partial or full deletion of DNA tandem repeats |
EP3077520A1 (en) | 2013-12-06 | 2016-10-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for expressing a polynucleotide of interest in the retinal pigment epithelium of a subject |
ES2813367T3 (en) | 2013-12-09 | 2021-03-23 | Sangamo Therapeutics Inc | Methods and compositions for genomic engineering |
US20150166982A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting pi3k point mutations |
US10774338B2 (en) | 2014-01-16 | 2020-09-15 | The Regents Of The University Of California | Generation of heritable chimeric plant traits |
MX2016009771A (en) | 2014-01-31 | 2016-11-14 | Factor Bioscience Inc | Methods and products for nucleic acid production and delivery. |
HUE051232T2 (en) | 2014-02-03 | 2021-03-01 | Sangamo Therapeutics Inc | Methods and compositions for treatment of a beta thalessemia |
CN113215219A (en) | 2014-02-13 | 2021-08-06 | 宝生物工程(美国) 有限公司 | Methods of depleting target molecules from an initial collection of nucleic acids, and compositions and kits for practicing same |
CN104844696A (en) * | 2014-02-19 | 2015-08-19 | 北京大学 | Design, synthesis and application of transcription activator like effector function protein |
US10370680B2 (en) | 2014-02-24 | 2019-08-06 | Sangamo Therapeutics, Inc. | Method of treating factor IX deficiency using nuclease-mediated targeted integration |
TW201538518A (en) | 2014-02-28 | 2015-10-16 | Dow Agrosciences Llc | Root specific expression conferred by chimeric gene regulatory elements |
WO2015143046A2 (en) | 2014-03-18 | 2015-09-24 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of zinc finger protein expression |
WO2015153889A2 (en) | 2014-04-02 | 2015-10-08 | University Of Florida Research Foundation, Incorporated | Materials and methods for the treatment of latent viral infection |
CN103923215B (en) * | 2014-04-15 | 2016-02-10 | 中国农业大学 | Make material and the application thereof of ACC-α gene promoter P III inactivation |
JP6265020B2 (en) | 2014-04-16 | 2018-01-24 | Jnc株式会社 | Evil luciferase catalytic protein mutant gene and its usage |
BR112016025849A2 (en) | 2014-05-08 | 2017-10-17 | Chdi Foundation Inc | methods and compositions for the treatment of huntington's disease |
US9574211B2 (en) | 2014-05-13 | 2017-02-21 | Sangamo Biosciences, Inc. | Methods and compositions for prevention or treatment of a disease |
WO2015188065A1 (en) | 2014-06-05 | 2015-12-10 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease design |
EP3166964A1 (en) | 2014-07-08 | 2017-05-17 | Vib Vzw | Means and methods to increase plant yield |
CN107072183B (en) | 2014-07-14 | 2022-01-04 | 华盛顿州立大学 | Eliminating NANOS knockouts in germline cells |
MA40253A (en) | 2014-07-15 | 2017-05-24 | Juno Therapeutics Inc | Engineered cells for adoptive cell therapy |
US9816074B2 (en) | 2014-07-25 | 2017-11-14 | Sangamo Therapeutics, Inc. | Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells |
WO2016014837A1 (en) | 2014-07-25 | 2016-01-28 | Sangamo Biosciences, Inc. | Gene editing for hiv gene therapy |
US9616090B2 (en) | 2014-07-30 | 2017-04-11 | Sangamo Biosciences, Inc. | Gene correction of SCID-related genes in hematopoietic stem and progenitor cells |
WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
KR102500531B1 (en) | 2014-09-04 | 2023-02-17 | 메모리얼 슬로안 케터링 캔서 센터 | Globin gene therapy for treating hemoglobinopathies |
RS62334B1 (en) | 2014-09-16 | 2021-10-29 | Sangamo Therapeutics Inc | Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells |
CN105440111B (en) * | 2014-09-30 | 2019-08-13 | 深圳华大基因研究院 | Pair of transcription activator-like effector nucleases (CTFs), coding sequences and application thereof |
US11021718B2 (en) | 2014-10-01 | 2021-06-01 | The General Hospital Corporation | Methods for increasing efficiency of nuclease-induced homology-directed repair |
CN107532142A (en) * | 2014-11-11 | 2018-01-02 | 应用干细胞有限公司 | Mescenchymal stem cell is transformed using homologous recombination |
US11319555B2 (en) | 2014-11-20 | 2022-05-03 | Duke University | Compositions, systems and methods for cell therapy |
US10889834B2 (en) | 2014-12-15 | 2021-01-12 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing targeted transgene integration |
ES2785329T3 (en) | 2014-12-23 | 2020-10-06 | Syngenta Participations Ag | Methods and Compositions for Identifying and Enriching Cells Comprising Site-Specific Genomic Modifications |
US20180002379A1 (en) | 2015-01-21 | 2018-01-04 | Sangamo Therapeutics, Inc. | Methods and compositions for identification of highly specific nucleases |
JP6929791B2 (en) | 2015-02-09 | 2021-09-01 | デューク ユニバーシティ | Compositions and methods for epigenome editing |
WO2016159110A1 (en) * | 2015-03-31 | 2016-10-06 | 国立研究開発法人農業生物資源研究所 | Binary gene expression system |
WO2016161446A1 (en) | 2015-04-03 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
RU2017137599A (en) | 2015-04-15 | 2019-05-15 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | VEGETABLE PROMOTER FOR THE TRANSGEN EXPRESSION |
BR112017021703B1 (en) | 2015-04-15 | 2023-11-28 | Corteva Agriscience Llc | PLANT PROMOTER FOR TRANSGENE EXPRESSION |
WO2016176652A2 (en) | 2015-04-29 | 2016-11-03 | Fred Hutchinson Cancer Research Center | Modified stem cells and uses thereof |
US10179918B2 (en) | 2015-05-07 | 2019-01-15 | Sangamo Therapeutics, Inc. | Methods and compositions for increasing transgene activity |
US10808020B2 (en) | 2015-05-12 | 2020-10-20 | Sangamo Therapeutics, Inc. | Nuclease-mediated regulation of gene expression |
CA2986060A1 (en) | 2015-05-29 | 2016-12-08 | Valerie Odegard | Composition and methods for regulating inhibitory interactions in genetically engineered cells |
US9957501B2 (en) | 2015-06-18 | 2018-05-01 | Sangamo Therapeutics, Inc. | Nuclease-mediated regulation of gene expression |
WO2017005806A1 (en) | 2015-07-07 | 2017-01-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for expressing a polynucleotide of interest in the peripheral nervous system of a subject |
CN108024544B (en) | 2015-07-13 | 2022-04-29 | 桑格摩生物治疗股份有限公司 | Delivery methods and compositions for nuclease-mediated genome engineering |
MA42895A (en) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | MODIFIED CELLS FOR ADOPTIVE CELL THERAPY |
JP2018525000A (en) | 2015-08-06 | 2018-09-06 | ザ・キュレーターズ・オブ・ザ・ユニバーシティ・オブ・ミズーリThe Curators Of The University Of Missouri | Pathogen resistant animal having modified CD163 gene |
CA2996001A1 (en) | 2015-08-25 | 2017-03-02 | Duke University | Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases |
TW201718862A (en) | 2015-09-22 | 2017-06-01 | Dow Agrosciences Llc | Plant promoter and 3' UTR for transgene expression |
TW201718861A (en) | 2015-09-22 | 2017-06-01 | 道禮責任有限公司 | Plant promoter and 3'UTR for transgene expression |
AU2016325613B2 (en) | 2015-09-23 | 2020-06-25 | Sangamo Therapeutics, Inc. | Htt repressors and uses thereof |
UY36957A (en) | 2015-10-22 | 2017-05-31 | Dow Agrosciences Llc | VEGETABLE PROMOTER FOR TRANSGENIC EXPRESSION |
JP7109784B2 (en) | 2015-10-23 | 2022-08-01 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Evolved Cas9 protein for gene editing |
CN108473976B (en) | 2015-10-28 | 2022-07-19 | 桑格摩生物治疗股份有限公司 | Liver-specific constructs, factor VIII expression cassettes, and methods of use thereof |
WO2017078935A1 (en) | 2015-11-04 | 2017-05-11 | Dow Agrosciences Llc | Plant promoter for transgene expression |
WO2017079428A1 (en) | 2015-11-04 | 2017-05-11 | President And Fellows Of Harvard College | Site specific germline modification |
AU2016361350B2 (en) | 2015-11-23 | 2023-04-06 | Sangamo Therapeutics, Inc. | Methods and compositions for engineering immunity |
JP7128741B2 (en) | 2015-12-18 | 2022-08-31 | サンガモ セラピューティクス, インコーポレイテッド | Targeted disruption of T-cell receptors |
CN108699132B (en) | 2015-12-18 | 2023-08-11 | 桑格摩生物治疗股份有限公司 | Targeted disruption of MHC cell receptors |
WO2017123757A1 (en) | 2016-01-15 | 2017-07-20 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of neurologic disease |
CA3011049A1 (en) | 2016-02-02 | 2017-08-10 | Sangamo Therapeutics, Inc. | Compositions for linking dna-binding domains and cleavage domains |
WO2017135316A1 (en) * | 2016-02-04 | 2017-08-10 | 花王株式会社 | Mutant of genus rhizopus |
AU2017238512B2 (en) | 2016-03-23 | 2022-12-08 | Dana-Farber Cancer Institute, Inc. | Methods for enhancing the efficiency of gene editing |
JP6246258B2 (en) * | 2016-04-25 | 2017-12-13 | 国立大学法人広島大学 | Polypeptide comprising a DNA binding domain |
ES2908467T3 (en) | 2016-04-29 | 2022-04-29 | Adverum Biotechnologies Inc | Evasion of neutralizing antibodies by a recombinant adeno-associated virus |
RU2725286C2 (en) | 2016-05-13 | 2020-06-30 | 4Д Молекьюлар Терапьютикс Инк. | Versions of adenoassociated virus capsids and methods of use thereof |
CN117431234A (en) | 2016-05-27 | 2024-01-23 | 阿迪根有限公司 | Peptides and nanoparticles for intracellular delivery of genome editing molecules |
MA45491A (en) | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES |
CA3028002A1 (en) | 2016-06-27 | 2018-01-04 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
MA45793A (en) | 2016-07-27 | 2021-03-24 | Univ Case Western Reserve | MYELINATION STIMULATION COMPOUNDS AND METHODS |
EP3827812A1 (en) | 2016-07-29 | 2021-06-02 | The Regents of the University of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
JP7066126B2 (en) | 2016-08-09 | 2022-05-13 | ブイアイビー ブイゼットダブリュ | Cellulose synthase inhibitors and mutant plants |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
CA2941315C (en) | 2016-08-12 | 2018-03-06 | Api Labs Inc. | High thebaine poppy and methods of producing the same |
EP3497605A4 (en) | 2016-08-15 | 2020-04-15 | enEvolv, Inc. | Cell-free sensor systems |
WO2018035354A1 (en) | 2016-08-17 | 2018-02-22 | Monsanto Technology Llc | Methods and compositions for short stature plants through manipulation of gibberellin metabolism to increase harvestable yield |
SG11201901364VA (en) | 2016-08-24 | 2019-03-28 | Sangamo Therapeutics Inc | Engineered target specific nucleases |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
AU2017324462B2 (en) | 2016-09-07 | 2024-03-21 | Sangamo Therapeutics, Inc. | Modulation of liver genes |
WO2018058002A1 (en) | 2016-09-23 | 2018-03-29 | Fred Hutchinson Cancer Research Center | Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof |
CN109996436B (en) | 2016-10-03 | 2023-09-29 | 科迪华农业科技有限责任公司 | Plant promoters for transgene expression |
CN110139873A (en) | 2016-10-03 | 2019-08-16 | 朱诺治疗学股份有限公司 | HPV specific binding molecules |
CN110291199B (en) | 2016-10-03 | 2023-12-22 | 美国陶氏益农公司 | Plant promoters for transgene expression |
WO2018067826A1 (en) | 2016-10-05 | 2018-04-12 | Cellular Dynamics International, Inc. | Generating mature lineages from induced pluripotent stem cells with mecp2 disruption |
US11896615B2 (en) | 2016-10-13 | 2024-02-13 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
WO2018071868A1 (en) | 2016-10-14 | 2018-04-19 | President And Fellows Of Harvard College | Aav delivery of nucleobase editors |
GB201617559D0 (en) | 2016-10-17 | 2016-11-30 | University Court Of The University Of Edinburgh The | Swine comprising modified cd163 and associated methods |
AU2017345470B2 (en) | 2016-10-19 | 2023-08-03 | Adverum Biotechnologies, Inc. | Modified AAV capsids and uses thereof |
BR112019007210A2 (en) | 2016-10-20 | 2019-08-13 | Sangamo Therapeutics Inc | Methods and Compositions for the Treatment of Fabry Disease |
CA3041668A1 (en) | 2016-10-31 | 2018-05-03 | Sangamo Therapeutics, Inc. | Gene correction of scid-related genes in hematopoietic stem and progenitor cells |
IL266862B2 (en) | 2016-12-01 | 2024-01-01 | Sangamo Therapeutics Inc | Tau modulators and methods and compositions for delivery thereof |
CN110494565A (en) | 2016-12-02 | 2019-11-22 | 朱诺治疗学股份有限公司 | It is engineered B cell and compositions related and method |
JP2019536461A (en) | 2016-12-05 | 2019-12-19 | ジュノー セラピューティクス インコーポレイテッド | Production of engineered cells for adoptive cell therapy |
EP4276187A3 (en) | 2016-12-08 | 2024-01-17 | Case Western Reserve University | Methods and compositions for enhancing functional myelin production |
US20190323019A1 (en) * | 2016-12-21 | 2019-10-24 | Yi-Hua Hsu | Composition for editing a nucleic acid sequence and method using the same |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
KR20190127797A (en) | 2017-03-10 | 2019-11-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Cytosine to Guanine Base Editing Agent |
EP3595708A4 (en) | 2017-03-15 | 2020-12-16 | Fred Hutchinson Cancer Research Center | High affinity mage-a1-specific tcrs and uses thereof |
CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
CN110799492B (en) | 2017-04-28 | 2023-06-27 | 爱康泰生治疗公司 | Novel carbonyl lipid and lipid nanoparticle formulations for delivery of nucleic acids |
WO2018204469A2 (en) | 2017-05-03 | 2018-11-08 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
CA3064000A1 (en) | 2017-05-24 | 2018-11-29 | Effector Therapeutics, Inc. | Methods and compositions for cellular immunotherapy |
US11512287B2 (en) | 2017-06-16 | 2022-11-29 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell and/or HLA receptors |
KR20200027512A (en) | 2017-06-20 | 2020-03-12 | 엥스띠뛰 퀴리 | Immune cells defective in SUV39H1 |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
JP2020533957A (en) | 2017-07-31 | 2020-11-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | CRISPR Reporter Non-Human Animals and Their Use |
CN110891419A (en) | 2017-07-31 | 2020-03-17 | 瑞泽恩制药公司 | Evaluation of CRISPR/CAS-induced in vivo recombination with exogenous donor nucleic acids |
MX2020001178A (en) | 2017-07-31 | 2020-09-25 | Regeneron Pharma | Cas-transgenic mouse embryonic stem cells and mice and uses thereof. |
CN109384833B (en) * | 2017-08-04 | 2021-04-27 | 北京大学 | TALE RVD for specifically recognizing methylated modified DNA base and application thereof |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
WO2019051135A1 (en) | 2017-09-06 | 2019-03-14 | Fred Hutchinson Cancer Research Center | Methods for improving adoptive cell therapy |
CA3071661A1 (en) | 2017-09-06 | 2019-03-14 | Fred Hutchinson Cancer Research Center | Strep-tag specific chimeric receptors and uses thereof |
NZ763018A (en) | 2017-09-20 | 2023-02-24 | 4D Molecular Therapeutics Inc | Adeno-associated virus variant capsids and methods of use thereof |
CA3080546A1 (en) | 2017-10-03 | 2019-04-11 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
US20210069241A1 (en) | 2017-10-20 | 2021-03-11 | Fred Hutchinson Cancer Research Center | Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression |
US11851679B2 (en) | 2017-11-01 | 2023-12-26 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
EP3710576A1 (en) | 2017-11-17 | 2020-09-23 | Iovance Biotherapeutics, Inc. | Til expansion from fine needle aspirates and small biopsies |
CA3083118A1 (en) | 2017-11-22 | 2019-05-31 | Iovance Biotherapeutics, Inc. | Expansion of peripheral blood lymphocytes (pbls) from peripheral blood |
FI3717636T3 (en) | 2017-11-27 | 2023-06-01 | 4D Molecular Therapeutics Inc | Adeno-associated virus variant capsids and use for inhibiting angiogenesis |
US20220267403A1 (en) | 2017-12-01 | 2022-08-25 | Fred Hutchinson Cancer Research Center | Binding proteins specific for 5t4 and uses thereof |
EP3720509A4 (en) | 2017-12-06 | 2021-12-08 | Memorial Sloan-Kettering Cancer Center | Globin gene therapy for treating hemoglobinopathies |
WO2019140278A1 (en) | 2018-01-11 | 2019-07-18 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting core binding factor antigens |
KR20200118468A (en) | 2018-02-08 | 2020-10-15 | 상가모 테라퓨틱스, 인코포레이티드 | Engineered target specific nuclease |
WO2019161133A1 (en) | 2018-02-15 | 2019-08-22 | Memorial Sloan Kettering Cancer Center | Foxp3 targeting agent compositions and methods of use for adoptive cell therapy |
EP3752618A4 (en) | 2018-02-15 | 2021-11-03 | Monsanto Technology LLC | Compositions and methods for improving crop yields through trait stacking |
JP2021514631A (en) | 2018-02-26 | 2021-06-17 | フレッド ハッチンソン キャンサー リサーチ センター | Compositions and Methods for Cellular Immunotherapy |
CN111936617A (en) | 2018-03-16 | 2020-11-13 | 益缪索夫特公司 | B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders, and enhance muscle growth and strength |
CN112566698A (en) | 2018-04-05 | 2021-03-26 | 朱诺治疗学股份有限公司 | T cell receptor and engineered cells expressing the same |
MX2020010461A (en) | 2018-04-05 | 2021-01-15 | Juno Therapeutics Inc | T cells expressing a recombinant receptor, related polynucleotides and methods. |
EP3775238A1 (en) | 2018-04-05 | 2021-02-17 | Juno Therapeutics, Inc. | Methods of producing cells expressing a recombinant receptor and related compositions |
KR20210005138A (en) | 2018-04-27 | 2021-01-13 | 이오반스 바이오테라퓨틱스, 인크. | Closure method for expansion and gene editing of tumor infiltrating lymphocytes and their use in immunotherapy |
US11690921B2 (en) | 2018-05-18 | 2023-07-04 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
GB201809273D0 (en) | 2018-06-06 | 2018-07-25 | Vib Vzw | Novel mutant plant cinnamoyl-coa reductase proteins |
JP2021527397A (en) | 2018-06-07 | 2021-10-14 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | Methods for producing hematopoietic stem cells |
US20230257722A1 (en) * | 2018-06-27 | 2023-08-17 | Altius Institute For Biomedical Sciences | Nucleases For Genome Editing |
EP3814493A4 (en) * | 2018-06-27 | 2022-03-30 | Altius Institute For Biomedical Sciences | Nucleic acid binding domains and methods of use thereof |
WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
CN112912387A (en) | 2018-08-22 | 2021-06-04 | 弗雷德哈钦森癌症研究中心 | Immunotherapy targeting KRAS or HER2 antigens |
AU2019326408A1 (en) | 2018-08-23 | 2021-03-11 | Sangamo Therapeutics, Inc. | Engineered target specific base editors |
JP2021534785A (en) | 2018-08-28 | 2021-12-16 | フレッド ハッチンソン キャンサー リサーチ センター | Methods and Compositions for Adoptive T Cell Therapy Using Induced Notch Signaling |
US20210317430A1 (en) | 2018-09-18 | 2021-10-14 | Sangamo Therapeutics, Inc. | Programmed cell death 1 (pd1) specific nucleases |
WO2020068702A1 (en) | 2018-09-24 | 2020-04-02 | Fred Hutchinson Cancer Research Center | Chimeric receptor proteins and uses thereof |
KR20210099573A (en) | 2018-11-05 | 2021-08-12 | 이오반스 바이오테라퓨틱스, 인크. | Selection of improved tumor-reactive T-cells |
JP2022506586A (en) | 2018-11-05 | 2022-01-17 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Process for the production of tumor-infiltrating lymphocytes and their use in immunotherapy |
CA3118493A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathway inhibitors |
KR20210091212A (en) | 2018-11-05 | 2021-07-21 | 이오반스 바이오테라퓨틱스, 인크. | Treatment of NSCLC Patients Refractory to Anti-PD-1 Antibodies |
BR112021008973A8 (en) | 2018-11-09 | 2023-05-02 | Juno Therapeutics Inc | SPECIFIC T CELL RECEPTORS FOR MESOTHELIN AND THEIR USE IN IMMUNOTHERAPY |
EP3886869A4 (en) | 2018-11-28 | 2022-07-06 | Forty Seven, Inc. | Genetically modified hspcs resistant to ablation regime |
EA202191463A1 (en) | 2018-11-28 | 2021-10-13 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | MULTIPLEX EDITING OF THE GENOME OF IMMUNE CELLS TO INCREASE FUNCTIONALITY AND RESISTANCE TO SUPPRESSIVE ENVIRONMENT |
EP3886874A1 (en) | 2018-11-29 | 2021-10-06 | Board of Regents, The University of Texas System | Methods for ex vivo expansion of natural killer cells and use thereof |
GB201820109D0 (en) | 2018-12-11 | 2019-01-23 | Vib Vzw | Plants with a lignin trait and udp-glycosyltransferase mutation |
CA3123392A1 (en) | 2018-12-19 | 2020-06-25 | Iovance Biotherapeutics, Inc. | Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof |
EP3908568A1 (en) | 2019-01-11 | 2021-11-17 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
AU2019428629A1 (en) | 2019-02-06 | 2021-01-28 | Sangamo Therapeutics, Inc. | Method for the treatment of mucopolysaccharidosis type I |
WO2020163017A1 (en) | 2019-02-06 | 2020-08-13 | Klogenix Llc | Dna binding proteins and uses thereof |
JP2022521513A (en) | 2019-02-20 | 2022-04-08 | フレッド ハッチンソン キャンサー リサーチ センター | RAS neoantigen-specific binding proteins and their use |
KR20210136050A (en) | 2019-03-01 | 2021-11-16 | 이오반스 바이오테라퓨틱스, 인크. | Expansion of tumor-infiltrating lymphocytes from liquid tumors and their therapeutic use |
AU2020236937B2 (en) | 2019-03-08 | 2023-06-15 | Obsidian Therapeutics, Inc. | CD40L compositions and methods for tunable regulation |
CN113784978A (en) | 2019-03-11 | 2021-12-10 | 弗雷德哈钦森癌症研究中心 | High affinity WT 1T cell receptor and uses thereof |
MX2021011426A (en) | 2019-03-19 | 2022-03-11 | Broad Inst Inc | Methods and compositions for editing nucleotide sequences. |
EP3946384A1 (en) | 2019-04-02 | 2022-02-09 | Sangamo Therapeutics, Inc. | Methods for the treatment of beta-thalassemia |
JP2022527809A (en) | 2019-04-03 | 2022-06-06 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Methods and compositions for inserting antibody coding sequences into safe harbor loci |
PE20212332A1 (en) | 2019-04-23 | 2021-12-14 | Sangamo Therapeutics Inc | MODULATORS OF THE EXPRESSION OF THE GENE OF OPEN READING FRAME 72 OF CHROMOSOME 9 AND USES THEREOF |
US20200370137A1 (en) | 2019-04-26 | 2020-11-26 | Sangamo Therapeutics, Inc. | Engineering aav |
TW202106699A (en) | 2019-04-26 | 2021-02-16 | 美商愛德維仁生物科技公司 | Variant aav capsids for intravitreal delivery |
MX2021013223A (en) | 2019-05-01 | 2022-02-17 | Juno Therapeutics Inc | Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods. |
AU2020265741A1 (en) | 2019-05-01 | 2021-11-25 | Editas Medicine, Inc. | Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods |
WO2020232029A1 (en) | 2019-05-13 | 2020-11-19 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
DK3840767T3 (en) * | 2019-05-29 | 2024-02-12 | Hubro Therapeutics As | PEPTIDES |
WO2020244759A1 (en) | 2019-06-05 | 2020-12-10 | Klemm & Sohn Gmbh & Co. Kg | New plants having a white foliage phenotype |
WO2021011936A2 (en) | 2019-07-18 | 2021-01-21 | University Of Rochester | Cell-type selective immunoprotection of cells |
WO2021013950A1 (en) | 2019-07-23 | 2021-01-28 | Mnemo Therapeutics | Immune cells defective for suv39h1 |
EP4007596A1 (en) | 2019-08-01 | 2022-06-08 | Sana Biotechnology, Inc. | Dux4 expressing cells and uses thereof |
US20220409661A1 (en) | 2019-08-20 | 2022-12-29 | Fred Hutchinson Cancer Research Center | T-cell immunotherapy specific for wt-1 |
AU2020336302A1 (en) | 2019-08-23 | 2022-03-03 | Sana Biotechnology, Inc. | CD24 expressing cells and uses thereof |
WO2021067864A1 (en) | 2019-10-02 | 2021-04-08 | Sangamo Therapeutics, Inc. | Zinc finger protein transcription factors for treatment of prion disease |
EP4048295A1 (en) | 2019-10-25 | 2022-08-31 | Iovance Biotherapeutics, Inc. | Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
TW202132565A (en) | 2019-11-01 | 2021-09-01 | 美商聖加莫治療股份有限公司 | Gin recombinase variants |
TW202130812A (en) | 2019-11-01 | 2021-08-16 | 美商聖加莫治療股份有限公司 | Compositions and methods for genome engineering |
WO2021092513A1 (en) | 2019-11-08 | 2021-05-14 | Regeneron Pharmaceuticals, Inc. | Crispr and aav strategies for x-linked juvenile retinoschisis therapy |
JP2023506734A (en) | 2019-12-11 | 2023-02-20 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Process for the production of tumor-infiltrating lymphocytes (TIL) and methods of using same |
WO2021142376A1 (en) | 2020-01-08 | 2021-07-15 | Obsidian Therapeutics, Inc. | Compositions and methods for tunable regulation of transcription |
CA3173096A1 (en) | 2020-03-25 | 2021-09-30 | Sonja SCHREPFER | Hypoimmunogenic neural cells for the treatment of neurological disorders and conditions |
JP2023523855A (en) | 2020-05-04 | 2023-06-07 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Method for producing tumor-infiltrating lymphocytes and their use in immunotherapy |
CN115698268A (en) | 2020-05-04 | 2023-02-03 | 萨利欧基因治疗公司 | Transposition-based therapies |
EP4146812A1 (en) | 2020-05-06 | 2023-03-15 | Cellectis S.A. | Methods for targeted insertion of exogenous sequences in cellular genomes |
CN115715203A (en) | 2020-05-06 | 2023-02-24 | 塞勒克提斯公司 | Methods of genetically modifying cells to deliver therapeutic proteins |
IL297761A (en) | 2020-05-08 | 2022-12-01 | Broad Inst Inc | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
KR20230022868A (en) | 2020-05-13 | 2023-02-16 | 주노 쎄러퓨티크스 인코퍼레이티드 | Method for producing donor-batch cells expressing a recombinant acceptor |
CN111518220A (en) * | 2020-05-14 | 2020-08-11 | 重庆英茂盛业生物科技有限公司 | Fusion protein and design method thereof |
WO2021236852A1 (en) | 2020-05-20 | 2021-11-25 | Sana Biotechnology, Inc. | Methods and compositions for treatment of viral infections |
GB202007577D0 (en) | 2020-05-21 | 2020-07-08 | Oxford Genetics Ltd | Hdr enhancers |
US20230183751A1 (en) | 2020-05-21 | 2023-06-15 | Oxford Genetics Limited | Hdr enhancers |
GB202007578D0 (en) | 2020-05-21 | 2020-07-08 | Univ Oxford Innovation Ltd | Hdr enhancers |
US20230183750A1 (en) | 2020-05-21 | 2023-06-15 | Oxford Genetics Limited | Hdr enhancers |
WO2021247836A1 (en) | 2020-06-03 | 2021-12-09 | Board Of Regents, The University Of Texas System | Methods for targeting shp-2 to overcome resistance |
WO2021260186A1 (en) | 2020-06-26 | 2021-12-30 | Juno Therapeutics Gmbh | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
AU2021316727A1 (en) | 2020-07-30 | 2023-03-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Immune cells defective for SOCS1 |
IL300516A (en) | 2020-08-13 | 2023-04-01 | Sana Biotechnology Inc | Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions |
EP4204545A2 (en) | 2020-08-25 | 2023-07-05 | Kite Pharma, Inc. | T cells with improved functionality |
WO2022066965A2 (en) | 2020-09-24 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting sox2 antigens |
WO2022066973A1 (en) | 2020-09-24 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting pbk or oip5 antigens |
AU2021350099A1 (en) | 2020-09-25 | 2023-04-27 | Sangamo Therapeutics, Inc. | Zinc finger fusion proteins for nucleobase editing |
WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
EP4225330A1 (en) | 2020-10-06 | 2023-08-16 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2022076353A1 (en) | 2020-10-06 | 2022-04-14 | Fred Hutchinson Cancer Research Center | Compositions and methods for treating mage-a1-expressing disease |
WO2022098787A1 (en) | 2020-11-04 | 2022-05-12 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
CA3201517A1 (en) * | 2020-11-11 | 2022-05-19 | Monsanto Technology Llc | Methods to improve site-directed integration frequency |
IL302728A (en) | 2020-11-13 | 2023-07-01 | Catamaran Bio Inc | Genetically modified natural killer cells and methods of use thereof |
EP4243609A1 (en) | 2020-11-16 | 2023-09-20 | Pig Improvement Company UK Limited | Influenza a-resistant animals having edited anp32 genes |
EP4251645A1 (en) | 2020-11-25 | 2023-10-04 | Catamaran Bio, Inc. | Cellular therapeutics engineered with signal modulators and methods of use thereof |
EP4259651A2 (en) | 2020-12-14 | 2023-10-18 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
JP2023554395A (en) | 2020-12-17 | 2023-12-27 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Treatment with tumor-infiltrating lymphocyte therapy in combination with CTLA-4 and PD-1 inhibitors |
WO2022133149A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocytes |
EP4271404A2 (en) | 2020-12-31 | 2023-11-08 | Sana Biotechnology, Inc. | Methods and compositions for modulating car-t activity |
WO2022165260A1 (en) | 2021-01-29 | 2022-08-04 | Iovance Biotherapeutics, Inc. | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
CA3212439A1 (en) | 2021-03-19 | 2022-09-22 | Michelle SIMPSON-ABELSON | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils |
KR20230158573A (en) | 2021-03-22 | 2023-11-20 | 주노 쎄러퓨티크스 인코퍼레이티드 | Methods for Assessing Potency of Viral Vector Particles |
CA3213080A1 (en) | 2021-03-23 | 2022-09-29 | Krit RITTHIPICHAI | Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
KR20240037185A (en) | 2021-04-19 | 2024-03-21 | 이오반스 바이오테라퓨틱스, 인크. | Chimeric costimulatory receptors, chemokine receptors, and their uses in cellular immunotherapy |
JP2024516992A (en) | 2021-05-05 | 2024-04-18 | フジフィルム セルラー ダイナミクス,インコーポレイテッド | Methods and Compositions for IPSC-Derived Microglia |
WO2022241227A1 (en) | 2021-05-14 | 2022-11-17 | Akoya Biosciences, Inc. | Amplification of rna detection signals in biological samples |
EP4340850A1 (en) | 2021-05-17 | 2024-03-27 | Iovance Biotherapeutics, Inc. | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
AU2022280051A1 (en) | 2021-05-26 | 2023-11-23 | FUJIFILM Cellular Dynamics, Inc. | Methods to prevent rapid silencing of genes in pluripotent stem cells |
IL308097A (en) | 2021-05-27 | 2023-12-01 | Sana Biotechnology Inc | Hypoimmunogenic cells comprising engineered hla-e or hla-g |
AU2022309875A1 (en) | 2021-07-14 | 2024-01-25 | Sana Biotechnology, Inc. | Altered expression of y chromosome-linked antigens in hypoimmunogenic cells |
WO2023288281A2 (en) | 2021-07-15 | 2023-01-19 | Fred Hutchinson Cancer Center | Chimeric polypeptides |
WO2023009716A1 (en) | 2021-07-28 | 2023-02-02 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
WO2023010133A2 (en) | 2021-07-30 | 2023-02-02 | Tune Therapeutics, Inc. | Compositions and methods for modulating expression of frataxin (fxn) |
AU2022318664A1 (en) | 2021-07-30 | 2024-02-29 | Tune Therapeutics, Inc. | Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) |
US20230130371A1 (en) | 2021-08-03 | 2023-04-27 | Akoya Biosciences, Inc. | RNA Detection by Selective Labeling and Amplification |
CA3228262A1 (en) | 2021-08-04 | 2023-02-09 | The Regents Of The University Of Colorado, A Body Corporate | Lat activating chimeric antigen receptor t cells and methods of use thereof |
WO2023019226A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
AU2022325231A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
CA3227108A1 (en) | 2021-08-11 | 2023-02-16 | Xiaomeng HU | Genetically modified primary cells for allogeneic cell therapy |
CA3227613A1 (en) | 2021-08-11 | 2023-02-16 | William Dowdle | Inducible systems for altering gene expression in hypoimmunogenic cells |
AU2022325955A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
AU2022343729A1 (en) | 2021-09-09 | 2024-03-21 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1 talen knockdown |
WO2023039567A2 (en) | 2021-09-10 | 2023-03-16 | FUJIFILM Cellular Dynamics, Inc. | Compositions of induced pluripotent stem cell-derived cells and methods of use thereof |
AU2022343793A1 (en) | 2021-09-13 | 2024-03-14 | Life Technologies Corporation | Gene editing tools |
WO2023069790A1 (en) | 2021-10-22 | 2023-04-27 | Sana Biotechnology, Inc. | Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods |
WO2023076880A1 (en) | 2021-10-25 | 2023-05-04 | Board Of Regents, The University Of Texas System | Foxo1-targeted therapy for the treatment of cancer |
US20230149563A1 (en) | 2021-10-27 | 2023-05-18 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for expressing factor ix for hemophilia b therapy |
AR127482A1 (en) | 2021-10-27 | 2024-01-31 | Iovance Biotherapeutics Inc | SYSTEMS AND METHODS TO COORDINATE THE MANUFACTURE OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY |
CA3235390A1 (en) | 2021-10-29 | 2023-05-04 | Deepika Rajesh | Dopaminergic neurons comprising mutations and methods of use thereof |
WO2023081900A1 (en) | 2021-11-08 | 2023-05-11 | Juno Therapeutics, Inc. | Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods |
WO2023105244A1 (en) | 2021-12-10 | 2023-06-15 | Pig Improvement Company Uk Limited | Editing tmprss2/4 for disease resistance in livestock |
GB202118058D0 (en) | 2021-12-14 | 2022-01-26 | Univ Warwick | Methods to increase yields in crops |
WO2023122722A1 (en) | 2021-12-22 | 2023-06-29 | Sangamo Therapeutics, Inc. | Novel zinc finger fusion proteins for nucleobase editing |
WO2023122337A1 (en) | 2021-12-23 | 2023-06-29 | Sana Biotechnology, Inc. | Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods |
WO2023126458A1 (en) | 2021-12-28 | 2023-07-06 | Mnemo Therapeutics | Immune cells with inactivated suv39h1 and modified tcr |
WO2023129940A1 (en) | 2021-12-30 | 2023-07-06 | Regel Therapeutics, Inc. | Compositions for modulating expression of sodium voltage-gated channel alpha subunit 1 and uses thereof |
WO2023131616A1 (en) | 2022-01-05 | 2023-07-13 | Vib Vzw | Means and methods to increase abiotic stress tolerance in plants |
WO2023131637A1 (en) | 2022-01-06 | 2023-07-13 | Vib Vzw | Improved silage grasses |
WO2023137471A1 (en) | 2022-01-14 | 2023-07-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation |
WO2023137472A2 (en) | 2022-01-14 | 2023-07-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression |
WO2023144199A1 (en) | 2022-01-26 | 2023-08-03 | Vib Vzw | Plants having reduced levels of bitter taste metabolites |
WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
WO2023150623A2 (en) | 2022-02-02 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease |
WO2023150798A1 (en) | 2022-02-07 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for defining optimal treatment timeframes in lysosomal disease |
WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
WO2023158836A1 (en) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
TW202340457A (en) | 2022-02-28 | 2023-10-16 | 美商凱特製藥公司 | Allogeneic therapeutic cells |
WO2023173123A1 (en) | 2022-03-11 | 2023-09-14 | Sana Biotechnology, Inc. | Genetically modified cells and compositions and uses thereof |
WO2023196877A1 (en) | 2022-04-06 | 2023-10-12 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2023201207A1 (en) | 2022-04-11 | 2023-10-19 | Tenaya Therapeutics, Inc. | Adeno-associated virus with engineered capsid |
WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
WO2023220035A1 (en) | 2022-05-09 | 2023-11-16 | Synteny Therapeutics, Inc. | Erythroparvovirus compositions and methods for gene therapy |
WO2023220040A1 (en) | 2022-05-09 | 2023-11-16 | Synteny Therapeutics, Inc. | Erythroparvovirus with a modified capsid for gene therapy |
WO2023220043A1 (en) | 2022-05-09 | 2023-11-16 | Synteny Therapeutics, Inc. | Erythroparvovirus with a modified genome for gene therapy |
WO2023220608A1 (en) | 2022-05-10 | 2023-11-16 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist |
EP4279085A1 (en) | 2022-05-20 | 2023-11-22 | Mnemo Therapeutics | Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease |
WO2023250511A2 (en) | 2022-06-24 | 2023-12-28 | Tune Therapeutics, Inc. | Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression |
WO2024006911A1 (en) | 2022-06-29 | 2024-01-04 | FUJIFILM Holdings America Corporation | Ipsc-derived astrocytes and methods of use thereof |
GB2621813A (en) | 2022-06-30 | 2024-02-28 | Univ Newcastle | Preventing disease recurrence in Mitochondrial replacement therapy |
WO2024015881A2 (en) | 2022-07-12 | 2024-01-18 | Tune Therapeutics, Inc. | Compositions, systems, and methods for targeted transcriptional activation |
WO2024013514A2 (en) | 2022-07-15 | 2024-01-18 | Pig Improvement Company Uk Limited | Gene edited livestock animals having coronavirus resistance |
US20240067968A1 (en) | 2022-08-19 | 2024-02-29 | Tune Therapeutics, Inc. | Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression |
WO2024055018A1 (en) | 2022-09-09 | 2024-03-14 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
WO2024055017A1 (en) | 2022-09-09 | 2024-03-14 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
WO2024064642A2 (en) | 2022-09-19 | 2024-03-28 | Tune Therapeutics, Inc. | Compositions, systems, and methods for modulating t cell function |
WO2024062138A1 (en) | 2022-09-23 | 2024-03-28 | Mnemo Therapeutics | Immune cells comprising a modified suv39h1 gene |
WO2024073606A1 (en) | 2022-09-28 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Antibody resistant modified receptors to enhance cell-based therapies |
Family Cites Families (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4535060A (en) | 1983-01-05 | 1985-08-13 | Calgene, Inc. | Inhibition resistant 5-enolpyruvyl-3-phosphoshikimate synthetase, production and use |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4761373A (en) | 1984-03-06 | 1988-08-02 | Molecular Genetics, Inc. | Herbicide resistance in plants |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
US4940835A (en) | 1985-10-29 | 1990-07-10 | Monsanto Company | Glyphosate-resistant plants |
CA1293460C (en) | 1985-10-07 | 1991-12-24 | Brian Lee Sauer | Site-specific recombination of dna in yeast |
US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
ES2018274T5 (en) | 1986-03-11 | 1996-12-16 | Plant Genetic Systems Nv | VEGETABLE CELLS RESISTANT TO GLUTAMINE SYNTHETASE INHIBITORS, PREPARED BY GENETIC ENGINEERING. |
US4975374A (en) | 1986-03-18 | 1990-12-04 | The General Hospital Corporation | Expression of wild type and mutant glutamine synthetase in foreign hosts |
US5273894A (en) | 1986-08-23 | 1993-12-28 | Hoechst Aktiengesellschaft | Phosphinothricin-resistance gene, and its use |
US5276268A (en) | 1986-08-23 | 1994-01-04 | Hoechst Aktiengesellschaft | Phosphinothricin-resistance gene, and its use |
US5013659A (en) | 1987-07-27 | 1991-05-07 | E. I. Du Pont De Nemours And Company | Nucleic acid fragment encoding herbicide resistant plant acetolactate synthase |
US5422251A (en) | 1986-11-26 | 1995-06-06 | Princeton University | Triple-stranded nucleic acids |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5006333A (en) | 1987-08-03 | 1991-04-09 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US5162602A (en) | 1988-11-10 | 1992-11-10 | Regents Of The University Of Minnesota | Corn plants tolerant to sethoxydim and haloxyfop herbicides |
US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
US5501967A (en) | 1989-07-26 | 1996-03-26 | Mogen International, N.V./Rijksuniversiteit Te Leiden | Process for the site-directed integration of DNA into the genome of plants |
US5484956A (en) | 1990-01-22 | 1996-01-16 | Dekalb Genetics Corporation | Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
WO1991017424A1 (en) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
US5204253A (en) | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5767366A (en) | 1991-02-19 | 1998-06-16 | Louisiana State University Board Of Supervisors, A Governing Body Of Louisiana State University Agricultural And Mechanical College | Mutant acetolactate synthase gene from Ararbidopsis thaliana for conferring imidazolinone resistance to crop plants |
US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
US5792640A (en) | 1992-04-03 | 1998-08-11 | The Johns Hopkins University | General method to clone hybrid restriction endonucleases using lig gene |
US5356802A (en) | 1992-04-03 | 1994-10-18 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease |
US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
US5487994A (en) | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
ATE398679T1 (en) | 1992-07-07 | 2008-07-15 | Japan Tobacco Inc | METHOD FOR TRANSFORMING A MONOCOTYLEDON PLANT |
JPH08510375A (en) | 1993-02-12 | 1996-11-05 | ザ・ジョンズ−ホプキンス・ユニバーシティー | Functional domain of Flavobacterium oceanocoytes (FOKI) restriction endonuclease |
US6242568B1 (en) | 1994-01-18 | 2001-06-05 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
CA2681922C (en) | 1994-01-18 | 2012-05-15 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
ES2316148T3 (en) | 1994-03-23 | 2009-04-01 | Ohio University | COMPACTED NUCLEIC ACIDS AND ITS SUPPLY TO CELLS. |
US5585245A (en) | 1994-04-22 | 1996-12-17 | California Institute Of Technology | Ubiquitin-based split protein sensor |
US6808904B2 (en) | 1994-06-16 | 2004-10-26 | Syngenta Participations Ag | Herbicide-tolerant protox genes produced by DNA shuffling |
GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
US7285416B2 (en) | 2000-01-24 | 2007-10-23 | Gendaq Limited | Regulated gene expression in plants |
EP2022856B1 (en) | 1994-08-20 | 2011-09-14 | Gendaq Limited | Improvements in or relating to binding proteins for recognition of DNA |
US6326166B1 (en) | 1995-12-29 | 2001-12-04 | Massachusetts Institute Of Technology | Chimeric DNA-binding proteins |
US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
US5853973A (en) | 1995-04-20 | 1998-12-29 | American Cyanamid Company | Structure based designed herbicide resistant products |
US6084155A (en) | 1995-06-06 | 2000-07-04 | Novartis Ag | Herbicide-tolerant protoporphyrinogen oxidase ("protox") genes |
US5928638A (en) | 1996-06-17 | 1999-07-27 | Systemix, Inc. | Methods for gene transfer |
US5925523A (en) * | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
JPH10117776A (en) | 1996-10-22 | 1998-05-12 | Japan Tobacco Inc | Transformation of indica rice |
GB2338237B (en) | 1997-02-18 | 2001-02-28 | Actinova Ltd | In vitro peptide or protein expression library |
GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
US6342345B1 (en) | 1997-04-02 | 2002-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of molecular interactions by reporter subunit complementation |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
EP1060261B1 (en) | 1998-03-02 | 2010-05-05 | Massachusetts Institute of Technology | Poly zinc finger proteins with improved linkers |
GB9819693D0 (en) | 1998-09-10 | 1998-11-04 | Zeneca Ltd | Glyphosate formulation |
US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
WO2000046386A2 (en) | 1999-02-03 | 2000-08-10 | The Children's Medical Center Corporation | Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site |
US6451732B1 (en) | 1999-06-04 | 2002-09-17 | Syngenta, Limited | Herbicidal compositions of glyphosate trimesium |
WO2001040798A2 (en) | 1999-12-06 | 2001-06-07 | Sangamo Biosciences, Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
CN1280155C (en) | 2000-01-26 | 2006-10-18 | 大日本印刷株式会社 | heat seal device, ehat seal method, embossing method, work pressing device and work |
WO2001059450A2 (en) | 2000-02-08 | 2001-08-16 | Sangamo Biosciences, Inc. | Cells expressing zinc finger protein for drug discovery |
US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
DE60126483T2 (en) | 2000-04-28 | 2007-12-06 | Sangamo BioSciences, Inc., Richmond | Targeted modification of the chromatin structure |
ATE374249T1 (en) | 2000-04-28 | 2007-10-15 | Sangamo Biosciences Inc | DATABASES OF REGULATORY SEQUENCES, METHODS OF THEIR PRODUCTION AND USE |
WO2001088197A2 (en) | 2000-05-16 | 2001-11-22 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
US6919204B2 (en) | 2000-09-29 | 2005-07-19 | Sangamo Biosciences, Inc. | Modulation of gene expression using localization domains |
US6368227B1 (en) | 2000-11-17 | 2002-04-09 | Steven Olson | Method of swinging on a swing |
AU2002217929A1 (en) | 2000-11-28 | 2002-06-11 | Sangamo Biosciences, Inc. | Modulation of gene expression using insulator binding proteins |
US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
CA2435394C (en) | 2001-01-22 | 2018-01-09 | Sangamo Biosciences, Inc. | Modified zinc finger binding proteins |
GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
US8106255B2 (en) | 2002-01-23 | 2012-01-31 | Dana Carroll | Targeted chromosomal mutagenasis using zinc finger nucleases |
WO2009095742A1 (en) | 2008-01-31 | 2009-08-06 | Cellectis | New i-crei derived single-chain meganuclease and uses thereof |
US8206965B2 (en) | 2002-03-15 | 2012-06-26 | Cellectis S.A. | Hybrid and single chain meganucleases and use thereof |
AU2003218382B2 (en) | 2002-03-21 | 2007-12-13 | Sangamo Therapeutics, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
US7361635B2 (en) | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
AU2003298574B2 (en) | 2002-09-05 | 2008-04-24 | California Institute Of Technology | Use of chimeric nucleases to stimulate gene targeting |
US20060206949A1 (en) | 2003-01-28 | 2006-09-14 | Sylvain Arnould | Custom-made meganuclease and use thereof |
US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US7189691B2 (en) | 2004-04-01 | 2007-03-13 | The Administrators Of The Tulane Educational Fund | Methods and compositions for treating leukemia |
AU2005287278B2 (en) | 2004-09-16 | 2011-08-04 | Sangamo Biosciences, Inc. | Compositions and methods for protein production |
KR101419729B1 (en) | 2005-07-26 | 2014-07-17 | 상가모 바이오사이언스 인코포레이티드 | Targeted integration and expression of exogenous nucleic acid sequences |
CA2626262C (en) | 2005-10-18 | 2015-09-08 | Homme W. Hellinga | Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity |
WO2007060495A1 (en) | 2005-10-25 | 2007-05-31 | Cellectis | I-crei homing endonuclease variants having novel cleavage specificity and use thereof |
JP2009537140A (en) | 2006-05-19 | 2009-10-29 | サンガモ バイオサイエンシーズ, インコーポレイテッド | Methods and compositions for inactivation of dihydrofolate reductase |
EP2765195A1 (en) | 2006-05-25 | 2014-08-13 | Sangamo BioSciences, Inc. | Methods and compositions for gene inactivation |
CA2651494C (en) | 2006-05-25 | 2015-09-29 | Sangamo Biosciences, Inc. | Engineered cleavage half-domains |
WO2008010009A1 (en) | 2006-07-18 | 2008-01-24 | Cellectis | Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof |
WO2008076290A2 (en) | 2006-12-14 | 2008-06-26 | Dow Agrosciences Llc | Optimized non-canonical zinc finger proteins |
WO2008133938A2 (en) | 2007-04-26 | 2008-11-06 | Sangamo Biosciences, Inc. | Targeted integration into the ppp1r12c locus |
US8790345B2 (en) | 2007-08-21 | 2014-07-29 | Zimmer, Inc. | Titanium alloy with oxidized zirconium for a prosthetic implant |
US8563314B2 (en) | 2007-09-27 | 2013-10-22 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
CA2937438C (en) | 2007-09-27 | 2020-07-07 | Dow Agrosciences Llc | Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes |
BRPI0817447A8 (en) | 2007-09-28 | 2016-12-27 | Two Blades Found | ISOLATED OR RECOMBINANT NUCEIC ACID MOLECULE, EXPRESSION CASSETTE, VECTOR, TRANSFORMED PLANT, NON-HUMAN HOST CELL, METHODS FOR INCREASING THE RESISTANCE OF A PLANT TO AT LEAST ONE PLANT PATHOGEN, FOR EXPRESSING A GENE OF INTEREST IN A PLANT OR CELL OF PLANT, TO EXPRESS GENES AT A HIGH LEVEL IN A PLANT OR PLANT CELL, AND TO CAUSE CELL DEATH IN A PART OF THE PLANT OF INTEREST, AND, ISOLATED POLYPEPTIDE |
EP2205249B1 (en) | 2007-09-28 | 2018-11-07 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
AU2008317354B2 (en) | 2007-10-25 | 2014-04-10 | Ospedale San Raffaele S.R.L. | Methods and compositions for targeted integration |
WO2010054348A2 (en) | 2008-11-10 | 2010-05-14 | Two Blades Foundation | Pathogen-inducible promoters and their use in enhancing the disease resistance of plants |
EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
CA2756833C (en) | 2009-04-09 | 2019-11-19 | Sangamo Biosciences, Inc. | Targeted integration into stem cells |
US8772008B2 (en) | 2009-05-18 | 2014-07-08 | Sangamo Biosciences, Inc. | Methods and compositions for increasing nuclease activity |
WO2010143917A2 (en) | 2009-06-11 | 2010-12-16 | Toolgen Incorporation | Targeted genomic rearrangements using site-specific nucleases |
CA2765488C (en) | 2009-06-30 | 2018-01-02 | Sangamo Biosciences, Inc. | Rapid screening of biologically active nucleases and isolation of nuclease-modified cells |
US20120178647A1 (en) | 2009-08-03 | 2012-07-12 | The General Hospital Corporation | Engineering of zinc finger arrays by context-dependent assembly |
KR102262704B1 (en) | 2009-08-11 | 2021-06-09 | 상가모 테라퓨틱스, 인코포레이티드 | Organisms homozygous for targeted modification |
MY174390A (en) | 2009-10-22 | 2020-04-15 | Sangamo Biosciences Inc | Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis |
US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
AU2010325549B2 (en) | 2009-11-27 | 2017-04-20 | Basf Plant Science Company Gmbh | Optimized endonucleases and uses thereof |
JP5922029B2 (en) | 2009-11-27 | 2016-05-24 | ビーエーエスエフ プラント サイエンス カンパニー ゲーエムベーハー | Chimeric endonuclease and use thereof |
WO2011064751A1 (en) | 2009-11-27 | 2011-06-03 | Basf Plant Science Company Gmbh | Chimeric endonucleases and uses thereof |
PL2510096T5 (en) | 2009-12-10 | 2018-06-29 | Regents Of The University Of Minnesota | Tal effector-mediated dna modification |
US20110203012A1 (en) | 2010-01-21 | 2011-08-18 | Dotson Stanton B | Methods and compositions for use of directed recombination in plant breeding |
EP2615106B1 (en) | 2010-02-08 | 2018-04-25 | Sangamo Therapeutics, Inc. | Engineered cleavage half-domains |
CA2788850C (en) | 2010-02-09 | 2019-06-25 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
US8771985B2 (en) | 2010-04-26 | 2014-07-08 | Sangamo Biosciences, Inc. | Genome editing of a Rosa locus using zinc-finger nucleases |
CA2798988C (en) * | 2010-05-17 | 2020-03-10 | Sangamo Biosciences, Inc. | Tal-effector (tale) dna-binding polypeptides and uses thereof |
EP2392208B1 (en) | 2010-06-07 | 2016-05-04 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins comprising a DNA-binding domain of a Tal effector protein and a non-specific cleavage domain of a restriction nuclease and their use |
WO2011159369A1 (en) | 2010-06-14 | 2011-12-22 | Iowa State University Research Foundation, Inc. | Nuclease activity of tal effector and foki fusion protein |
US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
CA2854819C (en) * | 2011-11-16 | 2022-07-19 | Sangamo Biosciences, Inc. | Modified dna-binding proteins and uses thereof |
-
2011
- 2011-05-17 CA CA2798988A patent/CA2798988C/en active Active
- 2011-05-17 EP EP11783865.6A patent/EP2571512B1/en active Active
- 2011-05-17 JP JP2013511148A patent/JP6208580B2/en active Active
- 2011-05-17 US US13/068,735 patent/US8586526B2/en active Active
- 2011-05-17 KR KR1020127032393A patent/KR101953237B1/en active IP Right Grant
- 2011-05-17 CN CN201180034243.1A patent/CN103025344B/en active Active
- 2011-05-17 EP EP16200664.7A patent/EP3156062A1/en not_active Ceased
- 2011-05-17 AU AU2011256838A patent/AU2011256838B2/en active Active
- 2011-05-17 WO PCT/US2011/000885 patent/WO2011146121A1/en active Application Filing
-
2012
- 2012-11-11 IL IL222961A patent/IL222961B/en active IP Right Grant
-
2013
- 2013-10-28 US US14/065,055 patent/US8912138B2/en active Active
- 2013-10-28 US US14/065,028 patent/US9493750B2/en active Active
- 2013-10-28 US US14/064,991 patent/US9322005B2/en active Active
-
2016
- 2016-07-08 JP JP2016135751A patent/JP2016182143A/en active Pending
- 2016-10-03 US US15/284,164 patent/US9783827B2/en active Active
-
2017
- 2017-09-20 US US15/709,969 patent/US10253333B2/en active Active
-
2019
- 2019-02-12 US US16/274,024 patent/US11661612B2/en active Active
-
2021
- 2021-06-11 US US17/346,020 patent/US20220356493A1/en active Pending
Non-Patent Citations (3)
Title |
---|
BOCH ET AL.: "Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors.", SCIENCE, vol. 326, no. 5959, 11 December 2009 (2009-12-11), pages 1509 - 1512, XP002570745 * |
BOCH ET AL.: "Xanthomonas AvrBs3 Family-Type III Effectors: Discovery and Function.", ANNUAL REVIEW OF PHYTOPATHOLOGY, vol. 48, 10 May 2010 (2010-05-10), pages 419 - 436, XP055070452 * |
See also references of EP2571512A1 * |
Cited By (502)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9017967B2 (en) | 2009-01-12 | 2015-04-28 | Ulla Bonas | Modular DNA-binding domains and methods of use |
US10590175B2 (en) | 2009-01-12 | 2020-03-17 | Ulla Bonas | Modular DNA-binding domains and methods of use |
US9453054B2 (en) | 2009-01-12 | 2016-09-27 | Ulla Bonas | Modular DNA-binding domains and methods of use |
US8420782B2 (en) | 2009-01-12 | 2013-04-16 | Ulla Bonas | Modular DNA-binding domains and methods of use |
US9809628B2 (en) | 2009-01-12 | 2017-11-07 | Ulla Bonas | Modular DNA-binding domains and methods of use |
US11827676B2 (en) | 2009-01-12 | 2023-11-28 | Ulla Bonas | Modular DNA-binding domains and methods of use |
US8470973B2 (en) | 2009-01-12 | 2013-06-25 | Ulla Bonas | Modular DNA-binding domains and methods of use |
US9353378B2 (en) | 2009-01-12 | 2016-05-31 | Ulla Bonas | Modular DNA-binding domains and methods of use |
US11564380B2 (en) | 2009-07-08 | 2023-01-31 | Kymab Limited | Animal models and therapeutic molecules |
US9505827B2 (en) | 2009-07-08 | 2016-11-29 | Kymab Limited | Animal models and therapeutic molecules |
US9434782B2 (en) | 2009-07-08 | 2016-09-06 | Kymab Limited | Animal models and therapeutic molecules |
US9504236B2 (en) | 2009-07-08 | 2016-11-29 | Kymab Limited | Animal models and therapeutic molecules |
US9447177B2 (en) | 2009-07-08 | 2016-09-20 | Kymab Limited | Transgenic mouse homozygous for chimeric IgH locus |
US10064398B2 (en) | 2009-07-08 | 2018-09-04 | Kymab Limited | Animal models and therapeutic molecules |
US11606941B2 (en) | 2009-07-08 | 2023-03-21 | Kymab Limited | Animal models and therapeutic molecules |
US11812731B2 (en) | 2009-07-08 | 2023-11-14 | Kymab Ltd. | Animal models and therapeutic molecules |
US10165763B2 (en) | 2009-07-08 | 2019-01-01 | Kymab Limited | Animal models and therapeutic molecules |
US8450471B2 (en) | 2009-12-10 | 2013-05-28 | Regents Of The University Of Minnesota | TAL effector-mediated DNA modification |
US8586363B2 (en) | 2009-12-10 | 2013-11-19 | Regents Of The University Of Minnesota | TAL effector-mediated DNA modification |
US8697853B2 (en) | 2009-12-10 | 2014-04-15 | Regents Of The University Of Minnesota | TAL effector-mediated DNA modification |
US11274294B2 (en) | 2009-12-10 | 2022-03-15 | Regents Of The University Of Minnesota | TAL effector-mediated DNA modification |
US10400225B2 (en) | 2009-12-10 | 2019-09-03 | Regents Of The University Of Minnesota | TAL effector-mediated DNA modification |
US8440432B2 (en) | 2009-12-10 | 2013-05-14 | Regents Of The University Of Minnesota | Tal effector-mediated DNA modification |
US8440431B2 (en) | 2009-12-10 | 2013-05-14 | Regents Of The University Of Minnesota | TAL effector-mediated DNA modification |
US10619153B2 (en) | 2009-12-10 | 2020-04-14 | Regents Of The University Of Minnesota | TAL effector-mediated DNA modification |
US9758775B2 (en) | 2009-12-10 | 2017-09-12 | Regents Of The University Of Minnesota | TAL effector-mediated DNA modification |
EP2660318A1 (en) * | 2010-02-09 | 2013-11-06 | Sangamo BioSciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
US9255259B2 (en) | 2010-02-09 | 2016-02-09 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
US9970028B2 (en) | 2010-02-09 | 2018-05-15 | Sangamo Therapeutics, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
US9005973B2 (en) | 2010-02-09 | 2015-04-14 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
US8912138B2 (en) | 2010-05-17 | 2014-12-16 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
US9493750B2 (en) | 2010-05-17 | 2016-11-15 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
US9322005B2 (en) | 2010-05-17 | 2016-04-26 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
EP2575439A1 (en) * | 2010-06-07 | 2013-04-10 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins comprising a dna-binding domain of a tal effector protein and a non-specific cleavage domain of a restriction nuclease and their use |
US10858416B2 (en) | 2010-07-21 | 2020-12-08 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a HLA locus |
US8945868B2 (en) | 2010-07-21 | 2015-02-03 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a HLA locus |
US10072062B2 (en) | 2010-07-21 | 2018-09-11 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a HLA locus |
JP2014509195A (en) * | 2011-02-25 | 2014-04-17 | リコンビネティクス・インコーポレイテッド | Genetically modified animal and method for producing the same |
JP2017184744A (en) * | 2011-02-25 | 2017-10-12 | リコンビネティクス・インコーポレイテッドRecombinetics,Inc. | Genetically modified animal and method for making the same |
US10920242B2 (en) | 2011-02-25 | 2021-02-16 | Recombinetics, Inc. | Non-meiotic allele introgression |
US10893667B2 (en) | 2011-02-25 | 2021-01-19 | Recombinetics, Inc. | Non-meiotic allele introgression |
WO2012168124A1 (en) | 2011-06-06 | 2012-12-13 | Bayer Cropscience Nv | Methods and means to modify a plant genome at a preselected site |
EP3461896A3 (en) * | 2011-07-15 | 2019-06-26 | The General Hospital Corporation | Methods of transcription activator like effector assembly |
US11472849B2 (en) | 2011-07-15 | 2022-10-18 | The General Hospital Corporation | Methods of transcription activator like effector assembly |
US10273271B2 (en) | 2011-07-15 | 2019-04-30 | The General Hospital Corporation | Methods of transcription activator like effector assembly |
WO2013026740A2 (en) | 2011-08-22 | 2013-02-28 | Bayer Cropscience Nv | Methods and means to modify a plant genome |
US9670496B2 (en) | 2011-08-22 | 2017-06-06 | Bayer Cropscience N.V. | Methods and means to modify a plant genome |
US10538774B2 (en) | 2011-08-22 | 2020-01-21 | Basf Agricultural Solutions Seed, Us Llc | Methods and means to modify a plant genome |
US11051497B2 (en) | 2011-09-19 | 2021-07-06 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US9963716B2 (en) | 2011-09-26 | 2018-05-08 | Kymab Limited | Chimaeric surrogate light chains (SLC) comprising human VpreB |
US9458205B2 (en) | 2011-11-16 | 2016-10-04 | Sangamo Biosciences, Inc. | Modified DNA-binding proteins and uses thereof |
EP2780460A4 (en) * | 2011-11-16 | 2015-08-26 | Sangamo Biosciences Inc | Modified dna-binding proteins and uses thereof |
US11312937B2 (en) | 2011-11-30 | 2022-04-26 | The Broad Institute, Inc. | Nucleotide-specific recognition sequences for designer TAL effectors |
US10801017B2 (en) | 2011-11-30 | 2020-10-13 | The Broad Institute, Inc. | Nucleotide-specific recognition sequences for designer TAL effectors |
EP2821413B2 (en) † | 2011-11-30 | 2019-10-02 | The Broad Institute, Inc. | Nucleotide-specific recognition sequences for designer tal effectors |
EP2821413B1 (en) | 2011-11-30 | 2016-09-07 | The Broad Institute, Inc. | Nucleotide-specific recognition sequences for designer tal effectors |
EP2785831A4 (en) * | 2011-11-30 | 2015-09-09 | Broad Inst Inc | Nucleotide-specific recognition sequences for designer tal effectors |
CN111893140A (en) * | 2011-12-05 | 2020-11-06 | 菲克特生物科学股份有限公司 | Methods and products for transfecting cells |
EP3835420A1 (en) * | 2011-12-05 | 2021-06-16 | Factor Bioscience Inc. | Methods and products for transfecting cells |
US11708586B2 (en) | 2011-12-05 | 2023-07-25 | Factor Bioscience Inc. | Methods and products for transfecting cells |
US11692203B2 (en) | 2011-12-05 | 2023-07-04 | Factor Bioscience Inc. | Methods and products for transfecting cells |
US11278560B2 (en) | 2011-12-16 | 2022-03-22 | Targetgene Biotechnologies Ltd. | Compositions and methods for modifying a predetermined target nucleic acid sequence |
JP2015500648A (en) * | 2011-12-16 | 2015-01-08 | ターゲットジーン バイオテクノロジーズ リミテッド | Compositions and methods for modifying a given target nucleic acid sequence |
US10220052B2 (en) | 2011-12-16 | 2019-03-05 | Targetgene Biotechnologies Ltd | Compositions and methods for modifying a predetermined target nucleic acid sequence |
US11690866B2 (en) | 2011-12-16 | 2023-07-04 | Targetgene Biotechnologies Ltd. | Compositions and methods for modifying a predetermined target nucleic acid sequence |
US11458157B2 (en) | 2011-12-16 | 2022-10-04 | Targetgene Biotechnologies Ltd. | Compositions and methods for modifying a predetermined target nucleic acid sequence |
CN103987860A (en) * | 2012-01-04 | 2014-08-13 | 清华大学 | Method for specifically recognizing DNA containing 5-methylated cytosine |
WO2013102290A1 (en) * | 2012-01-04 | 2013-07-11 | 清华大学 | Method for specifically recognizing dna containing 5-methylated cytosine |
CN103987860B (en) * | 2012-01-04 | 2017-04-12 | 清华大学 | Method for specifically recognizing DNA containing 5-methylated cytosine |
CN104093855A (en) * | 2012-01-04 | 2014-10-08 | 清华大学 | Specific binding and targeting method for dna-rna heteroduplex |
WO2013102289A1 (en) * | 2012-01-04 | 2013-07-11 | 清华大学 | Specific binding and targeting method for dna-rna heteroduplex |
CN103193871A (en) * | 2012-01-04 | 2013-07-10 | 清华大学 | Method for designing novel TALE (transcription activator like effector) according to protein-DNA compound crystal structure |
WO2013130824A1 (en) | 2012-02-29 | 2013-09-06 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
US11723952B2 (en) | 2012-02-29 | 2023-08-15 | Sangamo Therapeutics, Inc. | Methods and compositions for treating Huntington's Disease |
US9499597B2 (en) | 2012-02-29 | 2016-11-22 | Sangamo Biosciences, Inc. | Methods and compositions for treating Huntington's disease |
US10265377B2 (en) | 2012-02-29 | 2019-04-23 | Sangamo Therapeutics, Inc. | Methods and compositions for treating Huntington's Disease |
US10471123B2 (en) | 2012-02-29 | 2019-11-12 | Sangamo Therapeutics, Inc. | Methods and compositions for treating Huntington's disease |
US10857203B2 (en) | 2012-02-29 | 2020-12-08 | Sangamo Therapeutics, Inc. | Methods and compositions for treating Huntington's disease |
US8841260B2 (en) | 2012-02-29 | 2014-09-23 | Sangamo Biosciences, Inc. | Methods and compositions for treating Huntington's Disease |
WO2013136175A3 (en) * | 2012-03-15 | 2013-11-21 | Cellectis | Repeat variable diresidues for targeting nucleotides |
EP3799878A2 (en) | 2012-03-15 | 2021-04-07 | Cellectis | Repeat variable diresidues for targeting nucleotides |
EP3799878A3 (en) * | 2012-03-15 | 2021-07-14 | Cellectis | Repeat variable diresidues for targeting nucleotides |
EP3415158A3 (en) * | 2012-03-15 | 2019-01-16 | Cellectis | Repeat variable diresidues for targeting nucleotides |
US11778993B2 (en) | 2012-03-15 | 2023-10-10 | Cellectis, S.A. | Repeat variable diresidues for targeting nucleotides |
EP3141259A3 (en) * | 2012-03-15 | 2017-04-19 | Cellectis | Repeat variable diresidues for targeting nucleotides |
EP3415158A2 (en) | 2012-03-15 | 2018-12-19 | Cellectis | Repeat variable diresidues for targeting nucleotides |
WO2013136175A2 (en) | 2012-03-15 | 2013-09-19 | Cellectis | New repeat variable diresidues for targeting nucleotides |
JP7186574B2 (en) | 2012-03-20 | 2022-12-09 | ヴィリニュス・ユニヴァーシティー | RNA-directed DNA cleavage by Cas9-crRNA complex |
JP7113877B2 (en) | 2012-03-20 | 2022-08-05 | ヴィリニュス・ユニヴァーシティー | RNA-directed DNA cleavage by Cas9-crRNA complex |
US11555187B2 (en) | 2012-03-20 | 2023-01-17 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
US10844378B2 (en) | 2012-03-20 | 2020-11-24 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
JP2021019617A (en) * | 2012-03-20 | 2021-02-18 | ヴィリニュス・ユニヴァーシティー | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
JP2019030321A (en) * | 2012-03-20 | 2019-02-28 | ヴィリニュス・ユニヴァーシティー | RNA-directed DNA cleavage by Cas9-crRNA complex |
JP2015510778A (en) * | 2012-03-20 | 2015-04-13 | ヴィリニュス・ユニヴァーシティー | RNA-directed DNA cleavage by Cas9-crRNA complex |
US9924705B2 (en) | 2012-03-28 | 2018-03-27 | Kymab Limited | Animal models and therapeutic molecules |
US11297811B2 (en) | 2012-03-28 | 2022-04-12 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
US9896516B2 (en) | 2012-03-28 | 2018-02-20 | Kymab Limited | Animal models and therapeutic molecules |
US9938357B2 (en) | 2012-03-28 | 2018-04-10 | Kymab Limited | Animal models and therapeutic molecules |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
US10774155B2 (en) | 2012-03-28 | 2020-09-15 | Kymab Limited | Animal models and therapeutic molecules |
US9938358B2 (en) | 2012-03-28 | 2018-04-10 | Kymab Limited | Animal models and therapeutic molecules |
US10745695B2 (en) | 2012-04-04 | 2020-08-18 | Life Technologies Corporation | TAL-effector assembly platform, customized services, kits and assays |
WO2013160230A1 (en) | 2012-04-23 | 2013-10-31 | Bayer Cropscience Nv | Targeted genome engineering in plants |
US11518997B2 (en) | 2012-04-23 | 2022-12-06 | BASF Agricultural Solutions Seed US LLC | Targeted genome engineering in plants |
US10301646B2 (en) | 2012-04-25 | 2019-05-28 | Regeneron Pharmaceuticals, Inc. | Nuclease-mediated targeting with large targeting vectors |
US9834786B2 (en) | 2012-04-25 | 2017-12-05 | Regeneron Pharmaceuticals, Inc. | Nuclease-mediated targeting with large targeting vectors |
US10667501B2 (en) | 2012-05-17 | 2020-06-02 | Kymab Limited | Transgenic non-human vertebrate for the in vivo production of dual specificity immunoglobulins or hypermutated heavy chain only immunoglobulins |
US10669560B2 (en) | 2012-05-25 | 2020-06-02 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11293034B2 (en) | 2012-05-25 | 2022-04-05 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10337029B2 (en) | 2012-05-25 | 2019-07-02 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10513712B2 (en) | 2012-05-25 | 2019-12-24 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10519467B2 (en) | 2012-05-25 | 2019-12-31 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11549127B2 (en) | 2012-05-25 | 2023-01-10 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10487341B2 (en) | 2012-05-25 | 2019-11-26 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10308961B2 (en) | 2012-05-25 | 2019-06-04 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11479794B2 (en) | 2012-05-25 | 2022-10-25 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11473108B2 (en) | 2012-05-25 | 2022-10-18 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10526619B2 (en) | 2012-05-25 | 2020-01-07 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10301651B2 (en) | 2012-05-25 | 2019-05-28 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10533190B2 (en) | 2012-05-25 | 2020-01-14 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11028412B2 (en) | 2012-05-25 | 2021-06-08 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11008589B2 (en) | 2012-05-25 | 2021-05-18 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11008590B2 (en) | 2012-05-25 | 2021-05-18 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10550407B2 (en) | 2012-05-25 | 2020-02-04 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11401532B2 (en) | 2012-05-25 | 2022-08-02 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10266850B2 (en) | 2012-05-25 | 2019-04-23 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10563227B2 (en) | 2012-05-25 | 2020-02-18 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10900054B2 (en) | 2012-05-25 | 2021-01-26 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10443076B2 (en) | 2012-05-25 | 2019-10-15 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10570419B2 (en) | 2012-05-25 | 2020-02-25 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10577631B2 (en) | 2012-05-25 | 2020-03-03 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11634730B2 (en) | 2012-05-25 | 2023-04-25 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10351878B2 (en) | 2012-05-25 | 2019-07-16 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10358658B2 (en) | 2012-05-25 | 2019-07-23 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10358659B2 (en) | 2012-05-25 | 2019-07-23 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11001863B2 (en) | 2012-05-25 | 2021-05-11 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10227611B2 (en) | 2012-05-25 | 2019-03-12 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
EP3241902B1 (en) | 2012-05-25 | 2018-02-28 | The Regents of The University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
US10793878B1 (en) | 2012-05-25 | 2020-10-06 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10597680B2 (en) | 2012-05-25 | 2020-03-24 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11674159B2 (en) | 2012-05-25 | 2023-06-13 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10612045B2 (en) | 2012-05-25 | 2020-04-07 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10428352B2 (en) | 2012-05-25 | 2019-10-01 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11186849B2 (en) | 2012-05-25 | 2021-11-30 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10988782B2 (en) | 2012-05-25 | 2021-04-27 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10626419B2 (en) | 2012-05-25 | 2020-04-21 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10421980B2 (en) | 2012-05-25 | 2019-09-24 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10988780B2 (en) | 2012-05-25 | 2021-04-27 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11242543B2 (en) | 2012-05-25 | 2022-02-08 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10415061B2 (en) | 2012-05-25 | 2019-09-17 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11814645B2 (en) | 2012-05-25 | 2023-11-14 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10000772B2 (en) | 2012-05-25 | 2018-06-19 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11332761B2 (en) | 2012-05-25 | 2022-05-17 | The Regenis of Wie University of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10982230B2 (en) | 2012-05-25 | 2021-04-20 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10774344B1 (en) | 2012-05-25 | 2020-09-15 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10982231B2 (en) | 2012-05-25 | 2021-04-20 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10385360B2 (en) | 2012-05-25 | 2019-08-20 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10640791B2 (en) | 2012-05-25 | 2020-05-05 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10407697B2 (en) | 2012-05-25 | 2019-09-10 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10400253B2 (en) | 2012-05-25 | 2019-09-03 | The Regents Of The University Of California | Methods and compositions or RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10752920B2 (en) | 2012-05-25 | 2020-08-25 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10676759B2 (en) | 2012-05-25 | 2020-06-09 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US11274318B2 (en) | 2012-05-25 | 2022-03-15 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US10113167B2 (en) | 2012-05-25 | 2018-10-30 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
US9890364B2 (en) | 2012-05-29 | 2018-02-13 | The General Hospital Corporation | TAL-Tet1 fusion proteins and methods of use thereof |
US10894950B2 (en) | 2012-05-29 | 2021-01-19 | The General Hospital Corporation | TAL-Tet1 fusion proteins and methods of use thereof |
US11384360B2 (en) | 2012-06-19 | 2022-07-12 | Regents Of The University Of Minnesota | Gene targeting in plants using DNA viruses |
WO2014011817A3 (en) * | 2012-07-11 | 2014-04-17 | The Board Of Regents Of Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas | Genome surgery with paired, permeant endonuclease excision |
US10472396B2 (en) | 2012-07-24 | 2019-11-12 | Cellectis | Modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteins |
WO2014018601A3 (en) * | 2012-07-24 | 2014-06-26 | Cellectis | New modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteins |
EP3494997B1 (en) | 2012-07-25 | 2019-09-18 | The Broad Institute, Inc. | Inducible dna binding proteins and genome perturbation tools and applications thereof |
KR102201867B1 (en) | 2012-09-04 | 2021-01-12 | 더 스크립스 리서치 인스티튜트 | Chimeric polypeptides having targeted binding specificity |
JP7100681B2 (en) | 2012-09-04 | 2022-07-13 | ザ スクリプス リサーチ インスティテュート | Chimeric polypeptide with target binding specificity |
KR20210008437A (en) * | 2012-09-04 | 2021-01-21 | 더 스크립스 리서치 인스티튜트 | Chimeric polypeptides having targeted binding specificity |
JP2020178703A (en) * | 2012-09-04 | 2020-11-05 | ザ スクリプス リサーチ インスティテュート | Chimeric polypeptides having targeted binding specificity |
KR20150070120A (en) * | 2012-09-04 | 2015-06-24 | 더 스크립스 리서치 인스티튜트 | Chimeric polypeptides having targeted binding specificity |
JP7459174B2 (en) | 2012-09-04 | 2024-04-01 | ザ スクリプス リサーチ インスティテュート | Chimeric polypeptides with target binding specificity |
KR102357105B1 (en) | 2012-09-04 | 2022-02-08 | 더 스크립스 리서치 인스티튜트 | Chimeric polypeptides having targeted binding specificity |
JP2015529464A (en) * | 2012-09-07 | 2015-10-08 | ダウ アグロサイエンシィズ エルエルシー | FAD2 performance locus and corresponding target site specific binding protein capable of inducing targeted cleavage |
US10844389B2 (en) | 2012-09-07 | 2020-11-24 | Dow Agrosciences Llc | FAD2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
US9963711B2 (en) | 2012-09-07 | 2018-05-08 | Sangamo Therapeutics, Inc. | FAD2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
EP3431600A1 (en) * | 2012-09-07 | 2019-01-23 | Dow AgroSciences LLC | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
KR20150043539A (en) * | 2012-09-07 | 2015-04-22 | 다우 아그로사이언시즈 엘엘씨 | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
KR102147006B1 (en) * | 2012-09-07 | 2020-08-21 | 다우 아그로사이언시즈 엘엘씨 | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
WO2014039702A2 (en) | 2012-09-07 | 2014-03-13 | Dow Agrosciences Llc | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
RU2656159C2 (en) * | 2012-09-07 | 2018-05-31 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
JP2020096611A (en) * | 2012-09-07 | 2020-06-25 | ダウ アグロサイエンシィズ エルエルシー | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
US10577616B2 (en) | 2012-09-07 | 2020-03-03 | Dow Agrosciences Llc | FAD2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
AU2013312455B2 (en) * | 2012-09-07 | 2018-12-13 | Corteva Agriscience Llc | FAD2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
KR102147005B1 (en) * | 2012-09-07 | 2020-08-21 | 다우 아그로사이언시즈 엘엘씨 | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
EP2892321A4 (en) * | 2012-09-07 | 2016-03-02 | Dow Agrosciences Llc | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
RU2656158C2 (en) * | 2012-09-07 | 2018-05-31 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
AU2013312455A2 (en) * | 2012-09-07 | 2018-12-13 | Corteva Agriscience Llc | FAD2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
JP2020110150A (en) * | 2012-09-07 | 2020-07-27 | ダウ アグロサイエンシィズ エルエルシー | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
JP2015527082A (en) * | 2012-09-07 | 2015-09-17 | ダウ アグロサイエンシィズ エルエルシー | FAD2 performance locus and corresponding target site specific binding protein capable of inducing targeted cleavage |
AU2013312465B2 (en) * | 2012-09-07 | 2018-08-09 | Corteva Agriscience Llc | FAD2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
KR20150043538A (en) * | 2012-09-07 | 2015-04-22 | 다우 아그로사이언시즈 엘엘씨 | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
EP3404099A1 (en) * | 2012-09-07 | 2018-11-21 | Dow AgroSciences LLC | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
EP2893023A4 (en) * | 2012-09-07 | 2016-09-21 | Dow Agrosciences Llc | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
WO2014039692A2 (en) | 2012-09-07 | 2014-03-13 | Dow Agrosciences Llc | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
US9493779B2 (en) | 2012-09-07 | 2016-11-15 | Dow Agrosciences Llc | FAD2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
US11891631B2 (en) | 2012-10-12 | 2024-02-06 | The General Hospital Corporation | Transcription activator-like effector (tale) - lysine-specific demethylase 1 (LSD1) fusion proteins |
CN103772506A (en) * | 2012-10-22 | 2014-05-07 | 北京唯尚立德生物科技有限公司 | Transcription activator like effector-functional group-estrogen receptor function protein and application thereof |
EP3733847B1 (en) | 2012-10-23 | 2022-06-01 | Toolgen Incorporated | Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof |
US10851380B2 (en) | 2012-10-23 | 2020-12-01 | Toolgen Incorporated | Methods for cleaving a target DNA using a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein |
US11576317B2 (en) | 2012-11-01 | 2023-02-14 | Cellectis Sa | Mutant Nicotiana benthamiana plant or cell with reduced XylT and FucT |
CN104769112A (en) * | 2012-11-01 | 2015-07-08 | 菲克特生物科学股份有限公司 | Methods and products for expressing proteins in cells |
US11555198B2 (en) | 2012-11-01 | 2023-01-17 | Cellectis Sa | Method for making nicotiana plants with mutations in XylT and FucT alleles using rare-cutting endonucleases |
WO2014076571A2 (en) | 2012-11-16 | 2014-05-22 | Cellectis | Method for targeted modification of algae genomes |
JP2015535010A (en) * | 2012-11-16 | 2015-12-07 | トランスポサジェン バイオファーマシューティカルズ, インコーポレイテッド | Site-specific enzymes and methods of use |
AU2017221779B2 (en) * | 2012-11-16 | 2019-05-16 | Transposagen Biopharmaceuticals, Inc. | Site-Specific Enzymes and Methods of Use |
EP2920319A4 (en) * | 2012-11-16 | 2016-07-06 | Transposagen Biopharmaceuticals Inc | Site-specific enzymes and methods of use |
US10844361B2 (en) | 2012-11-16 | 2020-11-24 | Poseida Therapeutics, Inc. | Site-specific enzymes and methods of use |
US10415024B2 (en) | 2012-11-16 | 2019-09-17 | Poseida Therapeutics, Inc. | Site-specific enzymes and methods of use |
WO2014078819A2 (en) | 2012-11-16 | 2014-05-22 | Transposagen Biopharmaceuticals, Inc. | Site-specific enzymes and methods of use |
AU2013344375B2 (en) * | 2012-11-16 | 2017-09-14 | Transposagen Biopharmaceuticals, Inc. | Site-specific enzymes and methods of use |
JP2016500254A (en) * | 2012-12-05 | 2016-01-12 | サンガモ バイオサイエンシーズ, インコーポレイテッド | Methods and compositions for the regulation of metabolic diseases |
EP3135765A1 (en) * | 2012-12-06 | 2017-03-01 | Sigma-Aldrich Co. LLC | Crispr-based genome modification and regulation |
EP2928496B1 (en) | 2012-12-06 | 2019-10-09 | Sigma Aldrich Co. LLC | Crispr-based genome modification and regulation |
JP2020120674A (en) * | 2012-12-06 | 2020-08-13 | シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーSigma−Aldrich Co. LLC | Crispr-based genome modification and regulation |
EP3138912B1 (en) | 2012-12-06 | 2018-12-05 | Sigma Aldrich Co. LLC | Crispr-based genome modification and regulation |
EP3138911B1 (en) | 2012-12-06 | 2018-12-05 | Sigma Aldrich Co. LLC | Crispr-based genome modification and regulation |
US10745716B2 (en) | 2012-12-06 | 2020-08-18 | Sigma-Aldrich Co. Llc | CRISPR-based genome modification and regulation |
EP2928496A1 (en) | 2012-12-06 | 2015-10-14 | Sigma Aldrich Co. LLC | Crispr-based genome modification and regulation |
IL267598A (en) * | 2012-12-06 | 2019-08-29 | Sigma Aldrich Co Llc | Crispr-based genome modification and regulation |
CN105142669A (en) * | 2012-12-06 | 2015-12-09 | 西格马-奥尔德里奇有限责任公司 | Crispr-based genome modification and regulation |
EP3363902A1 (en) * | 2012-12-06 | 2018-08-22 | Sigma Aldrich Co. LLC | Crispr-based genome modification and regulation |
EP3360964A1 (en) * | 2012-12-06 | 2018-08-15 | Sigma Aldrich Co. LLC | Crispr-based genome modification and regulation |
JP2021101706A (en) * | 2012-12-06 | 2021-07-15 | シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーSigma−Aldrich Co. LLC | Genome modification and control based on crispr |
US10731181B2 (en) | 2012-12-06 | 2020-08-04 | Sigma, Aldrich Co. LLC | CRISPR-based genome modification and regulation |
JP2019037231A (en) * | 2012-12-06 | 2019-03-14 | シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーSigma−Aldrich Co., LLC | Crispr-based genome modification and regulation |
EP2928496A4 (en) * | 2012-12-06 | 2017-03-01 | Sigma-Aldrich Co. LLC | Crispr-based genome modification and regulation |
EP3138912A1 (en) | 2012-12-06 | 2017-03-08 | Sigma-Aldrich Co. LLC | Crispr-based genome modification and regulation |
EP3138909A1 (en) * | 2012-12-06 | 2017-03-08 | Sigma-Aldrich Co. LLC | Crispr-based genome modification and regulation |
EP3141604A1 (en) * | 2012-12-06 | 2017-03-15 | Sigma-Aldrich Co. LLC | Crispr-based genome modification and regulation |
EP3363902B1 (en) | 2012-12-06 | 2019-11-27 | Sigma Aldrich Co. LLC | Crispr-based genome modification and regulation |
JP2022115994A (en) * | 2012-12-06 | 2022-08-09 | シグマ-アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー | Crispr-based genome modification and regulation |
JP2017192392A (en) * | 2012-12-06 | 2017-10-26 | シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーSigma−Aldrich Co., LLC | Crispr-based genome modification and regulation |
EP2940140B1 (en) | 2012-12-12 | 2019-03-27 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
EP2764103B1 (en) | 2012-12-12 | 2015-08-19 | The Broad Institute, Inc. | Crispr-cas systems and methods for altering expression of gene products |
JP7013406B2 (en) | 2012-12-12 | 2022-02-15 | ザ・ブロード・インスティテュート・インコーポレイテッド | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
JP2022040308A (en) * | 2012-12-12 | 2022-03-10 | ザ・ブロード・インスティテュート・インコーポレイテッド | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
JP2021166513A (en) * | 2012-12-12 | 2021-10-21 | ザ・ブロード・インスティテュート・インコーポレイテッド | CRISPR-Cas COMPONENT SYSTEM, METHOD AND COMPOSITION FOR SEQUENCE MANIPULATION |
US9822372B2 (en) | 2012-12-12 | 2017-11-21 | The Broad Institute Inc. | CRISPR-Cas component systems, methods and compositions for sequence manipulation |
EP2825654B1 (en) | 2012-12-12 | 2017-04-26 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
US9840713B2 (en) | 2012-12-12 | 2017-12-12 | The Broad Institute Inc. | CRISPR-Cas component systems, methods and compositions for sequence manipulation |
JP7090775B2 (en) | 2012-12-12 | 2022-06-24 | ザ・ブロード・インスティテュート・インコーポレイテッド | CRISPR-Cas systems and methods for altering expression of gene products |
JP2019103511A (en) * | 2012-12-12 | 2019-06-27 | ザ・ブロード・インスティテュート・インコーポレイテッド | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
JP2019103510A (en) * | 2012-12-12 | 2019-06-27 | ザ・ブロード・インスティテュート・インコーポレイテッド | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
US10930367B2 (en) | 2012-12-12 | 2021-02-23 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for Cas enzymes or CRISPR-Cas systems for target sequences and conveying results thereof |
US11041173B2 (en) | 2012-12-12 | 2021-06-22 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
EP2764103A2 (en) | 2012-12-12 | 2014-08-13 | The Broad Institute, Inc. | Crispr-cas systems and methods for altering expression of gene products |
US8993233B2 (en) | 2012-12-12 | 2015-03-31 | The Broad Institute Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
US8999641B2 (en) | 2012-12-12 | 2015-04-07 | The Broad Institute Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
EP2784162B1 (en) | 2012-12-12 | 2015-04-08 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
JP2019103513A (en) * | 2012-12-12 | 2019-06-27 | ザ・ブロード・インスティテュート・インコーポレイテッド | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
EP2898075A1 (en) | 2012-12-12 | 2015-07-29 | The Broad Institute, Inc. | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
JP2019115348A (en) * | 2012-12-12 | 2019-07-18 | ザ・ブロード・インスティテュート・インコーポレイテッ | Crispr-cas systems and methods for altering expression of gene products |
JP7228059B2 (en) | 2012-12-12 | 2023-02-22 | ザ・ブロード・インスティテュート・インコーポレイテッド | Delivery, engineering and optimization of systems, methods and compositions for sequence engineering and therapeutic applications |
EP2921557B1 (en) | 2012-12-12 | 2016-07-13 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
EP2931897B1 (en) | 2012-12-12 | 2017-11-01 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
JP2021104055A (en) * | 2012-12-12 | 2021-07-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | Crispr-cas systems and methods for altering expression of gene products |
EP2896697B1 (en) | 2012-12-12 | 2015-09-02 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
EP2931898B1 (en) | 2012-12-12 | 2016-03-09 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
EP3064585B1 (en) | 2012-12-12 | 2020-02-05 | The Broad Institute, Inc. | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
EP2931897A2 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
JP2016504026A (en) * | 2012-12-12 | 2016-02-12 | ザ・ブロード・インスティテュート・インコーポレイテッド | Engineering systems, methods and optimization guide compositions for sequence manipulation |
JP2016501531A (en) * | 2012-12-12 | 2016-01-21 | ザ・ブロード・インスティテュート・インコーポレイテッド | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
EP2931898A2 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
JP2016500262A (en) * | 2012-12-12 | 2016-01-12 | ザ・ブロード・インスティテュート・インコーポレイテッ | CRISPR-Cas system and method for altering expression of gene products |
JP7269990B2 (en) | 2012-12-12 | 2023-05-09 | ザ・ブロード・インスティテュート・インコーポレイテッド | CRISPR-Cas Component Systems, Methods and Compositions for Sequence Engineering |
EP3252160B1 (en) | 2012-12-12 | 2020-10-28 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
US11535863B2 (en) | 2012-12-17 | 2022-12-27 | President And Fellows Of Harvard College | RNA-guided human genome engineering |
US11365429B2 (en) | 2012-12-17 | 2022-06-21 | President And Fellows Of Harvard College | RNA-guided human genome engineering |
US11236359B2 (en) | 2012-12-17 | 2022-02-01 | President And Fellows Of Harvard College | RNA-guided human genome engineering |
US11512325B2 (en) | 2012-12-17 | 2022-11-29 | President And Fellows Of Harvard College | RNA-guided human genome engineering |
JP2016501036A (en) * | 2012-12-17 | 2016-01-18 | プレジデント アンド フェローズ オブ ハーバード カレッジ | RNA-induced human genome modification |
US9260723B2 (en) | 2012-12-17 | 2016-02-16 | President And Fellows Of Harvard College | RNA-guided human genome engineering |
JP2021048882A (en) * | 2012-12-17 | 2021-04-01 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Rna-guided human genome engineering |
US10273501B2 (en) | 2012-12-17 | 2019-04-30 | President And Fellows Of Harvard College | RNA-guided human genome engineering |
US11359211B2 (en) | 2012-12-17 | 2022-06-14 | President And Fellows Of Harvard College | RNA-guided human genome engineering |
US9970024B2 (en) | 2012-12-17 | 2018-05-15 | President And Fellows Of Harvard College | RNA-guided human genome engineering |
US10435708B2 (en) | 2012-12-17 | 2019-10-08 | President And Fellows Of Harvard College | RNA-guided human genome engineering |
US10717990B2 (en) | 2012-12-17 | 2020-07-21 | President And Fellows Of Harvard College | RNA-guided human genome engineering |
US10513698B2 (en) | 2012-12-21 | 2019-12-24 | Cellectis | Potatoes with reduced cold-induced sweetening |
US10676749B2 (en) | 2013-02-07 | 2020-06-09 | The General Hospital Corporation | Tale transcriptional activators |
US10731167B2 (en) | 2013-02-07 | 2020-08-04 | The General Hospital Corporation | Tale transcriptional activators |
US10329582B2 (en) | 2013-02-20 | 2019-06-25 | Regeneron Pharmaceuticals, Inc. | Genetic modification of rats |
US10894965B2 (en) | 2013-02-20 | 2021-01-19 | Regeneron Pharmaceuticals, Inc. | Genetic modification of rats |
US9783780B2 (en) | 2013-02-27 | 2017-10-10 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt | Gene editing in the oocyte by CAS9 nucleases |
US10214723B2 (en) | 2013-02-27 | 2019-02-26 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt | Gene editing in the oocyte by Cas9 nucleases |
EP2922393A1 (en) | 2013-02-27 | 2015-09-30 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Gene editing in the oocyte by cas9 nucleases |
WO2014144155A1 (en) * | 2013-03-15 | 2014-09-18 | Regents Of The University Of Minnesota | Engineering plant genomes using crispr/cas systems |
CN105209624A (en) * | 2013-03-15 | 2015-12-30 | 明尼苏达大学董事会 | Engineering plant genomes using CRISPR/Cas systems |
AU2014227831B2 (en) * | 2013-03-15 | 2020-01-30 | Regents Of The University Of Minnesota | Engineering plant genomes using CRISPR/Cas systems |
US10113162B2 (en) | 2013-03-15 | 2018-10-30 | Cellectis | Modifying soybean oil composition through targeted knockout of the FAD2-1A/1B genes |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US11297810B2 (en) | 2013-03-18 | 2022-04-12 | Kymab Limited | Animal models and therapeutic molecules |
US10226033B2 (en) | 2013-03-18 | 2019-03-12 | Kymab Limited | Animal models and therapeutic molecules |
WO2014161821A1 (en) | 2013-04-02 | 2014-10-09 | Bayer Cropscience Nv | Targeted genome engineering in eukaryotes |
CN105008536A (en) * | 2013-04-16 | 2015-10-28 | 深圳华大基因科技服务有限公司 | Isolated oligonucleotide and use thereof |
US10385359B2 (en) | 2013-04-16 | 2019-08-20 | Regeneron Pharmaceuticals, Inc. | Targeted modification of rat genome |
WO2014169810A1 (en) * | 2013-04-16 | 2014-10-23 | 深圳华大基因科技服务有限公司 | Isolated oligonucleotide and use thereof |
US10975390B2 (en) | 2013-04-16 | 2021-04-13 | Regeneron Pharmaceuticals, Inc. | Targeted modification of rat genome |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US10730930B2 (en) | 2013-05-02 | 2020-08-04 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US11820810B2 (en) | 2013-05-02 | 2023-11-21 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
EP3597755A1 (en) * | 2013-06-17 | 2020-01-22 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components |
JP2016521995A (en) * | 2013-06-17 | 2016-07-28 | ザ・ブロード・インスティテュート・インコーポレイテッド | Delivery, use and therapeutic applications of CRISPR-Cas systems and compositions for targeting disorders and diseases using viral components |
US11008588B2 (en) | 2013-06-17 | 2021-05-18 | The Broad Institute, Inc. | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
US10577630B2 (en) | 2013-06-17 | 2020-03-03 | The Broad Institute, Inc. | Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy |
US10781444B2 (en) | 2013-06-17 | 2020-09-22 | The Broad Institute, Inc. | Functional genomics using CRISPR-Cas systems, compositions, methods, screens and applications thereof |
US10946108B2 (en) | 2013-06-17 | 2021-03-16 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for targeting disorders and diseases using viral components |
US11597949B2 (en) | 2013-06-17 | 2023-03-07 | The Broad Institute, Inc. | Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation |
US10711285B2 (en) | 2013-06-17 | 2020-07-14 | The Broad Institute, Inc. | Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation |
FR3008424A1 (en) * | 2013-07-09 | 2015-01-16 | Centre Nat Rech Scient | METHOD OF TARGETED MODIFICATION OF GENOME FOR THE GENERATION OF ANIMAL ORGANISM |
US10006011B2 (en) | 2013-08-09 | 2018-06-26 | Hiroshima University | Polypeptide containing DNA-binding domain |
US10030235B2 (en) | 2013-08-09 | 2018-07-24 | Hiroshima University | Polypeptide containing DNA-binding domain |
US11359186B2 (en) | 2013-08-09 | 2022-06-14 | Hiroshima University | Polypeptide containing DNA-binding domain |
US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
EP3699293A1 (en) * | 2013-08-22 | 2020-08-26 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (tale) domains and uses thereof |
US9528124B2 (en) | 2013-08-27 | 2016-12-27 | Recombinetics, Inc. | Efficient non-meiotic allele introgression |
US10959414B2 (en) | 2013-08-27 | 2021-03-30 | Recombinetics, Inc. | Efficient non-meiotic allele introgression |
WO2015030881A1 (en) * | 2013-08-27 | 2015-03-05 | Recombinetics, Inc. | Efficient non-meiotic allele introgression |
CN111471719A (en) * | 2013-08-27 | 2020-07-31 | 重组股份有限公司 | Efficient non-meiotic allele introgression |
US11477969B2 (en) | 2013-08-27 | 2022-10-25 | Recombinetics, Inc. | Efficient non-meiotic allele introgression in livestock |
WO2015033343A1 (en) | 2013-09-03 | 2015-03-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions and methods for expressing recombinant polypeptides |
EP2877571B1 (en) | 2013-09-18 | 2018-05-30 | Kymab Limited | Methods, cells and organisms |
US11920128B2 (en) | 2013-09-18 | 2024-03-05 | Kymab Limited | Methods, cells and organisms |
WO2015040402A1 (en) | 2013-09-18 | 2015-03-26 | Kymab Limited | Methods. cells & organisms |
US10149462B2 (en) | 2013-10-01 | 2018-12-11 | Kymab Limited | Animal models and therapeutic molecules |
US11399522B2 (en) | 2013-10-01 | 2022-08-02 | Kymab Limited | Animal models and therapeutic molecules |
US9476884B2 (en) | 2013-10-04 | 2016-10-25 | University Of Massachusetts | Hybridization- independent labeling of repetitive DNA sequence in human chromosomes |
US10767156B2 (en) | 2013-10-24 | 2020-09-08 | Yeda Research And Development Co., Ltd. | Polynucleotides encoding BREX system polypeptides and methods of using same |
US10779518B2 (en) | 2013-10-25 | 2020-09-22 | Livestock Improvement Corporation Limited | Genetic markers and uses therefor |
US11149267B2 (en) | 2013-10-28 | 2021-10-19 | The Broad Institute, Inc. | Functional genomics using CRISPR-Cas systems, compositions, methods, screens and applications thereof |
US10640788B2 (en) | 2013-11-07 | 2020-05-05 | Editas Medicine, Inc. | CRISPR-related methods and compositions with governing gRNAs |
US9834791B2 (en) | 2013-11-07 | 2017-12-05 | Editas Medicine, Inc. | CRISPR-related methods and compositions with governing gRNAS |
US11390887B2 (en) | 2013-11-07 | 2022-07-19 | Editas Medicine, Inc. | CRISPR-related methods and compositions with governing gRNAS |
US10190137B2 (en) | 2013-11-07 | 2019-01-29 | Editas Medicine, Inc. | CRISPR-related methods and compositions with governing gRNAS |
US10369201B2 (en) | 2013-11-11 | 2019-08-06 | Sangamo Therapeutics, Inc. | Methods and compositions for treating Huntington's disease |
WO2015073867A1 (en) * | 2013-11-15 | 2015-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Engineering neural stem cells using homologous recombination |
US9951353B2 (en) | 2013-11-15 | 2018-04-24 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Engineering neural stem cells using homologous recombination |
US20160264999A1 (en) * | 2013-11-15 | 2016-09-15 | The United States of America, as represented by the Secretary, Department of Health & Human | Engineering neural stem cells using homologous recombination |
US10208317B2 (en) | 2013-12-11 | 2019-02-19 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a mouse embryonic stem cell genome |
US9228208B2 (en) | 2013-12-11 | 2016-01-05 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
US9546384B2 (en) | 2013-12-11 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a mouse genome |
US11820997B2 (en) | 2013-12-11 | 2023-11-21 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
US10711280B2 (en) | 2013-12-11 | 2020-07-14 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a mouse ES cell genome |
US10377998B2 (en) | 2013-12-12 | 2019-08-13 | The Broad Institute, Inc. | CRISPR-CAS systems and methods for altering expression of gene products, structural information and inducible modular CAS enzymes |
US10550372B2 (en) | 2013-12-12 | 2020-02-04 | The Broad Institute, Inc. | Systems, methods and compositions for sequence manipulation with optimized functional CRISPR-Cas systems |
US10851357B2 (en) | 2013-12-12 | 2020-12-01 | The Broad Institute, Inc. | Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders |
US11407985B2 (en) | 2013-12-12 | 2022-08-09 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for genome editing |
US11597919B2 (en) | 2013-12-12 | 2023-03-07 | The Broad Institute Inc. | Systems, methods and compositions for sequence manipulation with optimized functional CRISPR-Cas systems |
US11155795B2 (en) | 2013-12-12 | 2021-10-26 | The Broad Institute, Inc. | CRISPR-Cas systems, crystal structure and uses thereof |
US11149259B2 (en) | 2013-12-12 | 2021-10-19 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products, structural information and inducible modular Cas enzymes |
US11591581B2 (en) | 2013-12-12 | 2023-02-28 | The Broad Institute, Inc. | Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders |
US11028388B2 (en) | 2014-03-05 | 2021-06-08 | Editas Medicine, Inc. | CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa |
US11339437B2 (en) | 2014-03-10 | 2022-05-24 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
US9938521B2 (en) | 2014-03-10 | 2018-04-10 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10) |
US11141493B2 (en) | 2014-03-10 | 2021-10-12 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
US10253312B2 (en) | 2014-03-10 | 2019-04-09 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating Leber's Congenital Amaurosis 10 (LCA10) |
US11268086B2 (en) | 2014-03-10 | 2022-03-08 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating Leber's Congenital Amaurosis 10 (LCA10) |
US11242525B2 (en) | 2014-03-26 | 2022-02-08 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating sickle cell disease |
US9522936B2 (en) | 2014-04-24 | 2016-12-20 | Sangamo Biosciences, Inc. | Engineered transcription activator like effector (TALE) proteins |
WO2015169314A1 (en) | 2014-05-07 | 2015-11-12 | Universitätsklinikum Hamburg-Eppendorf (UKE) | Tal-effector nuclease for targeted knockout of the hiv co-receptor ccr5 |
EP3140398B1 (en) | 2014-05-07 | 2019-08-28 | Advanced Gene & Cell Technologies Llc (Agct Llc) | Tal-effector nuclease for targeted knockout of the hiv co-receptor ccr5 |
KR20170002542A (en) * | 2014-05-07 | 2017-01-06 | 어드밴스드 진 앤드 셀 테크놀로지스 엘엘씨 (에이쥐씨티 엘엘씨) | Tal-effector nuclease for targeted knockout of the hiv co-receptor ccr5 |
EA036375B1 (en) * | 2014-05-07 | 2020-11-02 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ЭйДжиСиТи" | Tal-effector nuclease for targeted knockout of the hiv co-receptor ccr5 |
KR102324460B1 (en) | 2014-05-07 | 2021-11-09 | 어드밴스드 진 앤드 셀 테크놀로지스 엘엘씨 (에이쥐씨티 엘엘씨) | Tal-effector nuclease for targeted knockout of the hiv co-receptor ccr5 |
DE102014106327A1 (en) | 2014-05-07 | 2015-11-12 | Universitätsklinikum Hamburg-Eppendorf (UKE) | TAL-Effektornuklease for targeted knockout of the HIV co-receptor CCR5 |
US10301637B2 (en) | 2014-06-20 | 2019-05-28 | Cellectis | Potatoes with reduced granule-bound starch synthase |
WO2016005985A2 (en) | 2014-07-09 | 2016-01-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method for reprogramming cells |
WO2016038616A1 (en) | 2014-09-14 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Nmda receptor antagonists for treating gaucher disease |
US11697828B2 (en) | 2014-11-21 | 2023-07-11 | Regeneran Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification using paired guide RNAs |
US10457960B2 (en) | 2014-11-21 | 2019-10-29 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification using paired guide RNAs |
US10696986B2 (en) | 2014-12-12 | 2020-06-30 | The Board Institute, Inc. | Protected guide RNAS (PGRNAS) |
US11624078B2 (en) | 2014-12-12 | 2023-04-11 | The Broad Institute, Inc. | Protected guide RNAS (pgRNAS) |
US11241505B2 (en) | 2015-02-13 | 2022-02-08 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
WO2016135507A1 (en) * | 2015-02-27 | 2016-09-01 | University Of Edinburgh | Nucleic acid editing systems |
CN104694539A (en) * | 2015-03-09 | 2015-06-10 | 上海市同济医院 | Method for establishing plasmid capable of knocking out mouse CRAMP gene by use of TALEN technique |
EP4218771A1 (en) | 2015-03-27 | 2023-08-02 | Yeda Research and Development Co. Ltd | Methods of treating motor neuron diseases |
US11180793B2 (en) | 2015-04-24 | 2021-11-23 | Editas Medicine, Inc. | Evaluation of Cas9 molecule/guide RNA molecule complexes |
US11473082B2 (en) | 2015-06-17 | 2022-10-18 | Poseida Therapeutics, Inc. | Compositions and methods for directing proteins to specific loci in the genome |
US10876100B2 (en) | 2015-06-18 | 2020-12-29 | The Broad Institute, Inc. | Crispr enzyme mutations reducing off-target effects |
US11578312B2 (en) | 2015-06-18 | 2023-02-14 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of CAS9 orthologs and variants for sequence manipulation |
US10494621B2 (en) | 2015-06-18 | 2019-12-03 | The Broad Institute, Inc. | Crispr enzyme mutations reducing off-target effects |
WO2016203088A1 (en) * | 2015-06-19 | 2016-12-22 | Biopraxis Research Aie | Nucleic acid molecule, fusion protein and method for altering the genetic material of a cell |
WO2017009842A2 (en) | 2015-07-16 | 2017-01-19 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
EP3943098A2 (en) | 2015-07-16 | 2022-01-26 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
EP3744340A2 (en) | 2015-07-16 | 2020-12-02 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
US10837024B2 (en) | 2015-09-17 | 2020-11-17 | Cellectis | Modifying messenger RNA stability in plant transformations |
WO2017118985A1 (en) | 2016-01-06 | 2017-07-13 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating malignant, autoimmune and inflammatory diseases |
WO2017125931A1 (en) | 2016-01-21 | 2017-07-27 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Parthenocarpic plants and methods of producing same |
WO2017130205A1 (en) | 2016-01-31 | 2017-08-03 | Hadasit Medical Research Services And Development Ltd. | Autosomal-identical pluripotent stem cell populations having non-identical sex chromosomal composition and uses thereof |
US10550402B2 (en) | 2016-02-02 | 2020-02-04 | Cellectis | Modifying soybean oil composition through targeted knockout of the FAD3A/B/C genes |
WO2017138008A2 (en) | 2016-02-14 | 2017-08-17 | Yeda Research And Development Co. Ltd. | Methods of modulating protein exocytosis and uses of same in therapy |
WO2017153982A1 (en) | 2016-03-06 | 2017-09-14 | Yeda Research And Development Co. Ltd. | Method for modulating myelination |
US11512311B2 (en) | 2016-03-25 | 2022-11-29 | Editas Medicine, Inc. | Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency |
US11761018B2 (en) | 2016-05-26 | 2023-09-19 | Nunhems B.V. | Seedless fruit producing plants |
US11174493B2 (en) | 2016-05-26 | 2021-11-16 | Nunhems B.V. | Seedless fruit producing plants |
US10266851B2 (en) | 2016-06-02 | 2019-04-23 | Sigma-Aldrich Co. Llc | Using programmable DNA binding proteins to enhance targeted genome modification |
US11566263B2 (en) | 2016-08-02 | 2023-01-31 | Editas Medicine, Inc. | Compositions and methods for treating CEP290 associated disease |
US10363321B2 (en) | 2016-08-17 | 2019-07-30 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
US10369233B2 (en) | 2016-08-17 | 2019-08-06 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
US10894092B2 (en) | 2016-08-17 | 2021-01-19 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
US10137206B2 (en) | 2016-08-17 | 2018-11-27 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
US10576167B2 (en) | 2016-08-17 | 2020-03-03 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
US10350304B2 (en) | 2016-08-17 | 2019-07-16 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
US10888627B2 (en) | 2016-08-17 | 2021-01-12 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
US11904023B2 (en) | 2016-08-17 | 2024-02-20 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
WO2018033929A1 (en) | 2016-08-18 | 2018-02-22 | Yeda Research And Development Co. Ltd. | Diagnostic and therapeutic uses of exosomes |
US11845965B2 (en) | 2016-08-24 | 2023-12-19 | Sangamo Therapeutics, Inc. | Regulation of gene expression using engineered nucleases |
US11312972B2 (en) | 2016-11-16 | 2022-04-26 | Cellectis | Methods for altering amino acid content in plants through frameshift mutations |
WO2018096547A1 (en) | 2016-11-28 | 2018-05-31 | Yeda Research And Development Co. Ltd. | Isolated polynucleotides and polypeptides and methods of using same for expressing an expression product of interest |
WO2018122771A1 (en) | 2016-12-29 | 2018-07-05 | Ukko Inc. | Methods for identifying and de-epitoping allergenic polypeptides |
WO2018129021A1 (en) * | 2017-01-06 | 2018-07-12 | The Johns Hopkins University | Modular, inducible repressors for the control of gene expression |
WO2018142416A1 (en) | 2017-02-06 | 2018-08-09 | Yeda Research And Development Co. Ltd. | Isolated cells genetically modified to express a disarm system having an anti-phage activity and methods of producing same |
US11851690B2 (en) | 2017-03-14 | 2023-12-26 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
WO2018189360A1 (en) | 2017-04-13 | 2018-10-18 | Cellectis | New sequence specific reagents targeting ccr5 in primary hematopoietic cells |
US11479782B2 (en) | 2017-04-25 | 2022-10-25 | Cellectis | Alfalfa with reduced lignin composition |
WO2018207178A1 (en) | 2017-05-07 | 2018-11-15 | Yeda Research And Development Co. Ltd. | Methods of treating psychiatric stress disorders |
EP3821888A1 (en) | 2017-05-07 | 2021-05-19 | Yeda Research and Development Co. Ltd | Lxr agonists for treating psychiatric stress disorders |
US11963982B2 (en) | 2017-05-10 | 2024-04-23 | Editas Medicine, Inc. | CRISPR/RNA-guided nuclease systems and methods |
WO2019021284A1 (en) | 2017-07-24 | 2019-01-31 | Yeda Research And Development Co. Ltd. | Combination therapy for the treatment of cancer |
US11897920B2 (en) | 2017-08-04 | 2024-02-13 | Peking University | Tale RVD specifically recognizing DNA base modified by methylation and application thereof |
EP3663310A4 (en) * | 2017-08-04 | 2021-08-11 | Peking University | Tale rvd specifically recognizing dna base modified by methylation and application thereof |
US11624077B2 (en) | 2017-08-08 | 2023-04-11 | Peking University | Gene knockout method |
WO2019038771A1 (en) | 2017-08-23 | 2019-02-28 | Technion Research & Development Foundation Limited | Compositions and methods for improving alcohol tolerance in yeast |
WO2019097514A1 (en) | 2017-11-14 | 2019-05-23 | Yeda Research And Development Co. Ltd. | Hematopoietic stem cells with improved properties |
EP3501268A1 (en) | 2017-12-22 | 2019-06-26 | Kws Saat Se | Regeneration of plants in the presence of histone deacetylase inhibitors |
WO2019122360A1 (en) | 2017-12-22 | 2019-06-27 | Kws Saat Se | Regeneration of plants in the presence of histone deacetylase inhibitors |
US11700805B2 (en) | 2017-12-22 | 2023-07-18 | KWS SAAT SE & Co. KGaA | Regeneration of plants in the presence of histone deacetylase inhibitors |
WO2019134884A1 (en) | 2018-01-03 | 2019-07-11 | Kws Saat Se | Regeneration of genetically modified plants |
EP4234701A2 (en) | 2018-01-03 | 2023-08-30 | Basf Se | Regeneration of genetically modified plants |
EP3508581A1 (en) | 2018-01-03 | 2019-07-10 | Kws Saat Se | Regeneration of genetically modified plants |
WO2019145964A1 (en) | 2018-01-29 | 2019-08-01 | Yeda Research And Development Co. Ltd. | Combination of a mek inhibitor and a cdk4/6 inhibitor for the treatment of sarcoma |
WO2019183123A1 (en) | 2018-03-19 | 2019-09-26 | Regeneron Pharmaceuticals, Inc. | Transcription modulation in animals using crispr/cas systems |
EP3545756A1 (en) | 2018-03-28 | 2019-10-02 | KWS SAAT SE & Co. KGaA | Regeneration of plants in the presence of inhibitors of the histone methyltransferase ezh2 |
WO2019185849A1 (en) | 2018-03-28 | 2019-10-03 | KWS SAAT SE & Co. KGaA | Regeneration of plants in the presence of inhibitors of the histone methyltransferase ezh2 |
EP3567111A1 (en) | 2018-05-09 | 2019-11-13 | KWS SAAT SE & Co. KGaA | Gene for resistance to a pathogen of the genus heterodera |
WO2019238908A1 (en) | 2018-06-15 | 2019-12-19 | KWS SAAT SE & Co. KGaA | Methods for enhancing genome engineering efficiency |
WO2019238832A1 (en) | 2018-06-15 | 2019-12-19 | Nunhems B.V. | Seedless watermelon plants comprising modifications in an abc transporter gene |
WO2019238909A1 (en) | 2018-06-15 | 2019-12-19 | KWS SAAT SE & Co. KGaA | Methods for improving genome engineering and regeneration in plant |
WO2019238911A1 (en) | 2018-06-15 | 2019-12-19 | KWS SAAT SE & Co. KGaA | Methods for improving genome engineering and regeneration in plant ii |
EP3814524A4 (en) * | 2018-06-27 | 2022-04-27 | Altius Institute For Biomedical Sciences | Gapped and tunable repeat units for use in genome editing and gene regulation compositions |
WO2020008412A1 (en) | 2018-07-04 | 2020-01-09 | Ukko Inc. | Methods of de-epitoping wheat proteins and use of same for the treatment of celiac disease |
EP3623379A1 (en) | 2018-09-11 | 2020-03-18 | KWS SAAT SE & Co. KGaA | Beet necrotic yellow vein virus (bnyvv)-resistance modifying gene |
WO2020053313A1 (en) | 2018-09-11 | 2020-03-19 | KWS SAAT SE & Co. KGaA | Beet necrotic yellow vein virus (bnyvv)-resistance modifying gene |
WO2020089892A1 (en) | 2018-10-28 | 2020-05-07 | Yeda Research And Development Co. Ltd. | Prevention of age related clonal hematopoiesis and diseases associated therewith |
WO2020157573A1 (en) | 2019-01-29 | 2020-08-06 | The University Of Warwick | Methods for enhancing genome engineering efficiency |
WO2020178822A1 (en) | 2019-03-05 | 2020-09-10 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Genome-edited birds |
EP3708651A1 (en) | 2019-03-12 | 2020-09-16 | KWS SAAT SE & Co. KGaA | Improving plant regeneration |
WO2020182971A1 (en) | 2019-03-12 | 2020-09-17 | KWS SAAT SE & Co. KGaA | Improving plant regeneration |
EP4317950A2 (en) | 2019-03-18 | 2024-02-07 | Regeneron Pharmaceuticals, Inc. | Crispr/cas screening platform to identify genetic modifiers of tau seeding or aggregation |
WO2020190932A1 (en) | 2019-03-18 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Crispr/cas screening platform to identify genetic modifiers of tau seeding or aggregation |
WO2020190927A1 (en) | 2019-03-18 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Crispr/cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation |
JP7356739B2 (en) | 2019-04-09 | 2023-10-05 | 国立研究開発法人科学技術振興機構 | Nucleic acid binding protein |
WO2020209332A1 (en) * | 2019-04-09 | 2020-10-15 | 国立研究開発法人科学技術振興機構 | Nucleic acid binding protein |
JPWO2020209332A1 (en) * | 2019-04-09 | 2021-12-02 | 国立研究開発法人科学技術振興機構 | Nucleic acid binding protein |
WO2020252340A1 (en) | 2019-06-14 | 2020-12-17 | Regeneron Pharmaceuticals, Inc. | Models of tauopathy |
WO2020260682A1 (en) | 2019-06-28 | 2020-12-30 | KWS SAAT SE & Co. KGaA | Enhanced plant regeneration and transformation by using grf1 booster gene |
EP3757219A1 (en) | 2019-06-28 | 2020-12-30 | KWS SAAT SE & Co. KGaA | Enhanced plant regeneration and transformation by using grf1 booster gene |
WO2021001784A1 (en) | 2019-07-04 | 2021-01-07 | Ukko Inc. | De-epitoped alpha gliadin and use of same for the management of celiac disease and gluten sensitivity |
WO2021009763A1 (en) | 2019-07-16 | 2021-01-21 | Yeda Research And Development Co. Ltd. | Methods of treating pain |
US10611722B1 (en) | 2019-07-30 | 2020-04-07 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
US10556855B1 (en) | 2019-07-30 | 2020-02-11 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
US11814333B2 (en) | 2019-07-30 | 2023-11-14 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
US10752576B1 (en) | 2019-07-30 | 2020-08-25 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
US11242311B2 (en) | 2019-07-30 | 2022-02-08 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
WO2021050940A1 (en) | 2019-09-13 | 2021-03-18 | Regeneron Pharmaceuticals, Inc. | Transcription modulation in animals using crispr/cas systems delivered by lipid nanoparticles |
WO2021069684A1 (en) * | 2019-10-11 | 2021-04-15 | Basf Plant Science Company Gmbh | Increase in corn transformation efficacy by the n-terminus of a tale |
WO2021084540A1 (en) | 2019-10-30 | 2021-05-06 | Yeda Research And Development Co. Ltd. | Inhibitors of mmej pathway for prevention and treatment of pre-myeloid and myeloid malignancies |
WO2021093943A1 (en) | 2019-11-12 | 2021-05-20 | KWS SAAT SE & Co. KGaA | Gene for resistance to a pathogen of the genus heterodera |
WO2021108363A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-mediated upregulation of humanized ttr allele |
WO2021130752A1 (en) | 2019-12-22 | 2021-07-01 | Yeda Research And Development Co. Ltd. | Systems and methods for identifying cells that have undergone genome editing |
WO2021152587A1 (en) | 2020-01-30 | 2021-08-05 | Yeda Research And Development Co. Ltd. | Treating acute liver disease with tlr-mik inhibitors |
WO2021178556A1 (en) | 2020-03-04 | 2021-09-10 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for sensitization of tumor cells to immune therapy |
WO2021195079A1 (en) | 2020-03-23 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use |
WO2022074646A1 (en) | 2020-10-05 | 2022-04-14 | Protalix Ltd. | Dicer-like knock-out plant cells |
WO2022079719A1 (en) | 2020-10-15 | 2022-04-21 | Yeda Research And Development Co. Ltd. | Method of treating myeloid malignancies |
WO2022115498A1 (en) | 2020-11-26 | 2022-06-02 | Ukko Inc. | Modified high molecular weight glutenin subunit and uses thereof |
WO2022120022A1 (en) | 2020-12-02 | 2022-06-09 | Regeneron Pharmaceuticals, Inc. | Crispr sam biosensor cell lines and methods of use thereof |
WO2022130384A1 (en) | 2020-12-17 | 2022-06-23 | Yeda Research And Development Co. Ltd. | Controlling ubiquitination of mlkl for treatment of disease |
WO2022130388A2 (en) | 2020-12-18 | 2022-06-23 | Yeda Research And Development Co. Ltd. | Compositions for use in the treatment of chd2 haploinsufficiency and methods of identifying same |
EP4019638A1 (en) | 2020-12-22 | 2022-06-29 | KWS SAAT SE & Co. KGaA | Promoting regeneration and transformation in beta vulgaris |
EP4019639A1 (en) | 2020-12-22 | 2022-06-29 | KWS SAAT SE & Co. KGaA | Promoting regeneration and transformation in beta vulgaris |
WO2022136535A1 (en) | 2020-12-22 | 2022-06-30 | KWS SAAT SE & Co. KGaA | Promoting regeneration and transformation in beta vulgaris |
WO2022136557A1 (en) | 2020-12-22 | 2022-06-30 | KWS SAAT SE & Co. KGaA | Promoting regeneration and transformation in plants |
WO2022239001A1 (en) | 2021-05-10 | 2022-11-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Pharmaceutical compositions for treating neurological conditions |
WO2022264132A1 (en) | 2021-06-13 | 2022-12-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method for reprogramming human cells |
EP4130028A1 (en) | 2021-08-03 | 2023-02-08 | Rhazes Therapeutics Ltd | Engineered tcr complex and methods of using same |
WO2023012584A2 (en) | 2021-08-03 | 2023-02-09 | Genicity Limited | Engineered tcr complex and methods of using same |
US11970711B2 (en) | 2021-09-21 | 2024-04-30 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
WO2023062636A1 (en) | 2021-10-14 | 2023-04-20 | Weedout Ltd. | Methods of weed control |
WO2023077053A2 (en) | 2021-10-28 | 2023-05-04 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-related methods and compositions for knocking out c5 |
WO2023108047A1 (en) | 2021-12-08 | 2023-06-15 | Regeneron Pharmaceuticals, Inc. | Mutant myocilin disease model and uses thereof |
WO2023240282A1 (en) | 2022-06-10 | 2023-12-14 | Umoja Biopharma, Inc. | Engineered stem cells and uses thereof |
WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
Also Published As
Publication number | Publication date |
---|---|
CN103025344B (en) | 2016-06-29 |
JP6208580B2 (en) | 2017-10-04 |
US20140134741A1 (en) | 2014-05-15 |
JP2013529083A (en) | 2013-07-18 |
EP3156062A1 (en) | 2017-04-19 |
AU2011256838A1 (en) | 2012-12-06 |
US20190169640A1 (en) | 2019-06-06 |
AU2011256838B2 (en) | 2014-10-09 |
US20140134723A1 (en) | 2014-05-15 |
US20140134740A1 (en) | 2014-05-15 |
US20110301073A1 (en) | 2011-12-08 |
IL222961A0 (en) | 2013-02-03 |
KR101953237B1 (en) | 2019-02-28 |
US9783827B2 (en) | 2017-10-10 |
US9322005B2 (en) | 2016-04-26 |
EP2571512A4 (en) | 2013-11-20 |
CA2798988A1 (en) | 2011-11-24 |
CA2798988C (en) | 2020-03-10 |
EP2571512B1 (en) | 2017-08-23 |
US20220356493A1 (en) | 2022-11-10 |
IL222961B (en) | 2018-08-30 |
US11661612B2 (en) | 2023-05-30 |
US8586526B2 (en) | 2013-11-19 |
US20170016030A1 (en) | 2017-01-19 |
JP2016182143A (en) | 2016-10-20 |
US20180010152A1 (en) | 2018-01-11 |
US9493750B2 (en) | 2016-11-15 |
US8912138B2 (en) | 2014-12-16 |
CN103025344A (en) | 2013-04-03 |
EP2571512A1 (en) | 2013-03-27 |
KR20130111219A (en) | 2013-10-10 |
US10253333B2 (en) | 2019-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220356493A1 (en) | Dna-binding proteins and uses thereof | |
AU2012340213B2 (en) | Modified DNA-binding proteins and uses thereof | |
CA2901676C (en) | Methods and compositions for enhancing nuclease-mediated gene disruption | |
CA2910427C (en) | Delivery methods and compositions for nuclease-mediated genome engineering | |
WO2015164748A1 (en) | Engineered transcription activator like effector (tale) proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180034243.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11783865 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2798988 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 222961 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2013511148 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2011783865 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011783865 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2011256838 Country of ref document: AU Date of ref document: 20110517 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20127032393 Country of ref document: KR Kind code of ref document: A |